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Soybean allergy affects approximately 0.4% of children worldwide. At least 16 proteins 
in soybean bind IgE from some soybean allergic subjects. Although the relative 
allergenic importance and abundance of individual proteins in soybean varieties is not 
understood, the allergenicity assessment guideline for the safety of genetically modified 
(GM) food crops (Codex, 2003) includes assessing potential increases in expression of 
endogenous allergens in an allergenic crop like soybeans that might be due to insertion of 
the new DNA. The studies described in this dissertation included comparison of binding 
of IgE from individual soybean allergic subjects to proteins in three transgenic soybean 
lines, their respective near-isogenic and other commercial lines. The results indicated no 
evidence that the transgenic soybean lines present an increased risk for soybean allergic 
subjects especially since those with soybean allergy should avoid all soybeans. 
Furthermore, based on the observed variation among commercial lines, it is not clear that 
similar tests are useful to evaluate food safety for typical GM varieties. 
Soybean products are widely used in food because of their functionality, nutritional 
properties and low cost. Some soybean ingredients are processed either by heat treatment 
or enzymatic hydrolysis to attain desirable functional properties or in some cases to 
reduce the allergenicity. However, few studies have investigated the effect various 
processing conditions have on allergenicity of soybean products and their efficacy in 
 
 
reducing allergenicity of soybean. Additional studies described in this dissertation 
evaluated potential changes in IgE binding to soybean proteins that are heat-treated under 
conditions that mimic some commercial processing or undergo enzyme hydrolysis. 
Results indicated that majority of thermal treatment conditions utilized in making 
soybean products will not affect their allergenicity and hydrolysis of soybean proteins by 
different enzymes does not make them less allergenic compared to the untreated proteins 
and may increase their allergenicity.
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CHAPTER 1: LITERATURE REVIEW 
SOYBEAN 
 Soybean (Glycine max), a crop native to China and Southeast Asia, has a high 
nutritional value due to the high concentration of oil (18-25%) and protein (38-50%) and 
is a popular food all over the world (Muller et al., 1998). Production and consumption of 
soy products in western countries have increased dramatically in the last decade. In Asian 
countries soybean is processed into various fermented and non-fermented food stuffs 
such as soy sauce, miso, natto, yogurts, kinako, protein crisp, desserts, baby food, and soy 
milk which is further processed into tofu, aburage and yuba. The use of soybean-based 
food in western countries has gained popularity recently because of the health benefits of 
soybean. In western countries relatively unprocessed soybeans are mainly used in soy 
milk, tofu, soy sprouts and edamame, while soy protein products that are textured are 
used in soy and tofu burgers, soy sausages, chicken nuggets, soy ice cream, yogurt and 
various other products (Hammond and Jez, 2011). In the US, the area planted with 
soybeans is second only to corn. Globally 38% of the total soybean crop is grown in US, 
followed by Brazil (25%), Argentina (19%), China (7%), India (3%), Canada (2%), and 
Paraguay (2%) (Singh et al., 2008). In a recent survey approximately 33% of Americans 
recalled consuming soybean products at least once a month (Michelfelder, 2009). Soy 
protein formulas are generally introduced into the diet early in life particularly for infants 
with an intolerance or allergy to cow’s milk. Soybean based products are also used as the 
primary protein source for those with several other disorders such as lactose intolerance 
and severe gastroenteritis in infants (Businco et al., 1992). 
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Mature soybean seed contains approximately 35% protein, 31% carbohydrates, 
17% fat, 5% mineral and 12% moisture (L'Hocine and Boye, 2007). Soybean protein 
contains adequate amounts of essential amino acids; histidine, isoleucine, leucine, lysine, 
phenylalanine, tyrosine, threonine, tryptophan and valine. However, the combined 
amount of lysine and methionine (sulfur containing amino acid) falls below the 
recommended daily intake for a balanced diet. Soybean is particularly high in lysine, 
which is a limiting amino acid in rice, wheat or corn (Erdman and Fordyce, 1989). 
Several health benefits have been reported to be associated with consumption of soybean. 
For example, consumption of soybean has been reported to lower plasma cholesterol 
(Anthony et al., 1996), prevent cancer (Kennedy, 1998), improve bone mineral density 
(Kreijkamp-Kaspers et al., 2004) and provide protection against bowel and kidney 
disease (Friedman and Brandon, 2001). These health benefits are attributed to the 
presence of isoflavones, saponins, proteins, and peptides in soybean (Friedman and 
Brandon, 2001; Michelfelder, 2009; Xiao, 2008). The Food and Drug Administration 
(FDA) has authorized the use on food labeling of health claims on the association 
between soy protein and a reduced risk of coronary heart disease 
(http://www.fda.gov/food/labelingnutrition/labelclaims/healthclaimsmeetingsignificantsci
entificagreementssa/ucm074740.htm 
Although soybean is well utilized by human, it has a low nutritional value 
compared to milk, which is attributed to the presence of anti-nutritional factors in 
soybean including inhibitors of digestive enzymes and lectins and its low content of the 
essential amino acid L-methionine. The low methionine content of soy protein is 
particularly important since it is chemically modified during food processing and storage, 
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further reducing nutritional quality (Friedman and Brandon, 2001). Also protein-bound 
methionine in some plant foods is poorly utilized. To overcome this problem, several 
soybean lines are being investigated as options to increase the methionine-rich proteins 
(Friedman and Brandon, 2001). Protease inhibitors present in raw soybean can bind to 
proteolytic digestive enzyme thereby reducing the intestinal digestive process. Two major 
types of protease inhibitors are found in soybean including Kunitz inhibitor and 
Bowman-Birk inhibitor. Kunitz trypsin inhibitor is heat labile and has a molecular weight 
of approximately 20 kDa. It has a strong inhibitory effect against trypsin and weak action 
against chymotrypsin. Bowman-Birk inhibitor is a heat stable inhibitor with a molecular 
weight of approximately 8 kDa and can inhibit both trypsin and chymotrypsin strongly 
(DiPietro and Liener, 1989). Although heat treatment can inactivate these inhibitors, 
commercially available soybean products have been shown to contain approximately 5-
20% of trypsin inhibitor activity found in raw soy (Erdman and Fordyce, 1989). Despite 
their anti-nutritional effects, soybean protease inhibitor particularly Bowman-Birk 
inhibitor has been reported to have anti-carcinogenic and anti-inflammatory properties 
(Kennedy, 1998). Other important anti-nutritional factors found in soybean are lectins or 
plant agglutinins. These are carbohydrate-binding proteins that have hemagglutinating 
properties. They are present in several legume species including soybean and can exert 
anti-nutritional effects and cause growth depression in agriculturally important species 
(Etzler, 1985).  
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SOYBEAN ALLERGY 
Soybean is one of the eight allergenic foods or groups of foods (peanuts, soybeans, tree 
nuts, milk, egg, fish, crustaceans, and wheat) that are thought to cause nearly 90% of 
food-allergic reactions in the US (Goodman et al., 2005). Soybean allergy affects 
approximately 0.4% of children worldwide (Savage et al., 2010). The prevalence and 
incidence of soy allergy in the general population is unknown and is likely to be 
dependent on local dietary habit and exposure (Sicherer et al., 2000). The prevalence is 
considered to be higher in Asian countries compared to Europe and US and it has been 
reported to be the fifth most common food allergen causing anaphylaxis in Japan (Ito et 
al., 2011). Several reports suggest wide discrepancies in prevalence of soybean allergy. A 
study including a large cohort of atopic children, where soybean was fed early in life for 
up to several months, showed that soy allergy is not common in children with atopic 
disorders and also rare in children fed soy early in life (Bruno et al., 1997). In another 
study designed to determine the prevalence of soy allergy in 704 atopic children in Italy, 
out of 131 soy skin prick positive children, only 6% showed positive oral challenge with 
soybean, representing 1.1% of the atopic children (Magnolfi et al., 1996). Soybean 
allergy has also been reported to occur in a minority of young children with cow’s milk 
allergy (CMA). Zeiger et al. (1999) found that 14% of IgE mediated cow’s milk allergic 
children also have soy allergy based on double blind placebo controlled food challenge 
(DBPCFC), open challenge, and history of anaphylactic reaction to soy. Most children 
with soy allergy tend to outgrow their allergy later in life. It has been shown that the 
median age at which tolerance develops is around 10 years (Savage et al., 2010). The rate 
of soy allergy resolution depends on soy specific IgE levels and children with higher soy 
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specific IgE levels tend to have persistent soy allergy (Savage et al., 2010). Although soy 
allergy is considered an early onset disease, the disease can occur later in life, which may 
be due to cross-reactivity with peanut or birch pollen (Savage et al., 2010). In a study by 
Mittag et al. (2004) soybean allergy has been shown to be prevalent in adult patients 
allergic to birch pollen, and the allergy is due to cross-reactivity or shared IgE binding of 
the soybean allergen Gly m 4 with the birch pollen allergen Bet v 1. Unlike mild oro-
pharyngeal symptoms in patients with pollen related food allergy, patients with marked 
allergies to birch pollen showed systemic reactions in DBPCFC to soybean (Mittag et al., 
2004).  
Clinical manifestations of soy allergy range from severe enterocolitis to atopic 
eczema and immediate IgE-mediated systemic multi-system reactions (Sicherer et al., 
2000). While still a common allergen, life threatening reactions to soy are quite rare and 
much lower in prevalence than severe reactions to peanut (Cantani and Lucenti, 1997). A 
recent study was conducted by Rolinck-Werninghaus et al. (2012), where oral food 
challenge was performed in 869 children using cow’s milk, egg, wheat and soy. In 
contrast to 4 and 14% of milk- and egg-allergic children respectively who showed severe 
reaction at the first dose (3 mg), most of the severe reactions to soy in soy-sensitized 
children occurred at larger doses (>1.1 gram) (Rolinck-Werninghaus et al., 2012). 
Nevertheless, a few cases of anaphylactic reactions including food dependent exercise 
induced anaphylaxis have been reported due to consumption of soybean (Adachi et al., 
2009; David, 1984; Foucard and Malmheden Yman, 1999; Magnolfi et al., 1996; Moroz 
and Yang, 1980; Senna et al., 1998; Taramarcaz et al., 2001).  
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SOYBEAN ALLERGENS 
At least 16 soybean proteins with molecular weights ranging from 14 kDa to 70 kDa have 
been shown to bind IgE from sera of patients with atopic dermatitis (Ogawa et al., 1991). 
Soybean Gly m Bd 30K was identified as a major allergenic component of soybean seed 
protein with 65% of soy-sensitive patients with atopic dermatitis showing specific IgE 
binding (Ogawa et al., 1993; Helm et al., 1998). Gly m Bd 30K is a 34-kDa oil body 
associated cysteine protease from soybean, also known as soybean vacuolar protein P34 
(Ogawa et al., 1993; Kalinski et al., 1992). It is a monomeric insoluble glycoprotein of 
257 amino acids and is often found attached by a disulfide bond to the 7S globulin 
proteins of soybeans (Wilson et al., 2005). This protein accounts for 5% of total seed 
cotyledon protein of soybean. It accumulates during seed maturation and is processed to a 
32 kDa protein by removal of its amino terminus on the fourth through sixth days of 
seedling growth (Herman et al., 1990; Ogawa et al., 1993). B-cell epitope mapping with 
overlapping peptides of P34 identified five immuno-dominant IgE binding linear 
epitopes; while conformational epitopes have not been identified (Helm et al., 1998). 
Soybean allergen Gly m Bd 28K is a minor soybean glycoprotein component shown to be 
recognized by 25% of soybean allergic subject. It has a molecular mass of 26 kDa and an 
iso-electric point of 6.1 (Ogawa et al., 2000; Tsuji et al., 1997; Tsuji et al., 2001). The 
glycan moiety of this glycoprotein is similar to that of other glycoprotein allergens 
including bromelain, horseradish peroxidase, ascorbate oxidase and Gly m Bd 30K (Tsuji 
et al., 1997). The glycan at Asn 20 was demonstrated to bind IgE (Hiemori et al., 2000). 
A C-terminal peptide fragment of Gly m Bd 28 K, a 23 kDa glycoprotein, has also been 
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shown to bind IgE from soybean sensitive patients, primarily due to the glycan moiety 
(Hiemori et al., 2004).  
Soybean glycinin (Gly m 6) and β-conglycinin (Gly m 5), the major seed storage 
proteins of soybean, have been implicated as the major allergens in soybean (Holzhauser 
et al., 2009; Ito et al., 2011). Soybean glycinin is a hexameric protein of approximately 
350 kDa and composed of six non-identical subunits (Adachi et al., 2003). The subunit 
composition of soybean glycinin varies according to cultivar (Mori et al., 1981). Five 
major kinds of subunits have been identified in glycinin; A1aB1b, A2B1a, A1bB2, 
A3B4, and A5A4B3 (Adachi et al., 2003). Each of these subunits is composed of an 
acidic chain of 37-42 kDa, pI=4.2-4.8 (A1a, A1b, A2, A3, A4, A5) and a basic chain of 
17-20 kDa, pI=8-8.5 (B1a, B1b, B2, B3, B4) linked by a single disulfide bond 
(Petruccelli and Anon, 1995a; Sathe et al., 1987; Maruyama et al., 2003). An early study 
by Pedersen and Djurtoft (1989) indicated that the acidic glycinin chain is mainly 
responsible for IgE binding with sera from soy allergic patients. However, IgE binding to 
the basic chain of glycinin has also been reported (Helm et al., 2000a). In a recent study, 
36% of study subjects with positive DBPCFC and with history of anaphylaxis to soy had 
specific IgE to glycinin (Holzhauser et al., 2009). A recent Japanese study found that 
58% of children with severe allergic reactions to soybean (n=33) exhibited IgE binding to 
Gly m 6 (Ito et al., 2011). Eleven linear epitopes have been identified in glycinin by B-
cell epitope mapping among which, four are immuno-dominant (Helm et al., 2000b). The 
IgE binding epitopes of the acidic chain of glycinin were shown to be identical to that of 
major peanut allergen Ara h 3 in other studies (Beardslee et al., 2000; Xiang et al., 2002).  
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Soybean β-conglycinin (Gly m 5) is a trimeric protein of approximately 150-200 
kDa, composed of different combinations of three subunits; α (67 kDa), α’(71 kDa) and β 
(50 kDa). All of the monomers include a single asparagine-linked glycosylation site and 
these are usually glycosylated by addition of a polymannose or complex glycan 
(Maruyama et al., 2003). In a study by Ogawa et al. (1995), the α subunit of β-
conlgycinin (Gly m Bd 60k) was shown to be recognized by IgE from 25% of sera from 
soybean sensitive patients with atopic dermatitis. Although both the α’ and β subunits are 
homologous to the α subunit, no IgE binding was seen to either of these subunits (Ogawa 
et al., 1995). However, another study used IgE immunoblot analysis with soybean-
allergic patient sera and showed that the α’ and β subunits of β-conglycinin can also be 
recognized by IgE and are therefore likely allergens (Krishnan et al., 2009). Another 
recent study by Holzhauser et al. (2009) also showed all three subunits of β-conglycinin 
may be bound by IgE from subjects who were allergic to soybean as demonstrated by 
DBPCFC. In a recent Japanease study, 67% of children with severe allergic reactions to 
soybean (n=33) showed IgE reactivity against β-conglycinin (Ito et al., 2011). β-
conglycinin has also been identified as the soybean allergen responsible for food 
dependent exercise induced anaphylaxis induced during consumption of tofu (Adachi et 
al., 2009).  
Soybean profilin (Gly m 3) is a 14 kDa protein from soybean. This protein has 
been isolated and identified by PCR based c-DNA cloning and has been shown to bind 
IgE from 69% of soybean sensitive patient sera (Rihs et al., 1999). Only the full length 
profilin and not profilin fragments showed IgE binding indicating the importance of 
conformational epitopes in IgE binding to this protein. Cross-reactivity of soybean 
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recombinant Gly m 3 (rGly m 3) with the birch pollen profilin allergen Bet v 2, has also 
been shown (Mittag et al., 2004; Rihs et al., 1999). However, soybean profilin has not 
been demonstrated to elicit clinical food allergy. The Bet v 1 homologous PR-10 protein 
of soybean, Gly m 4 is another important soybean allergen. This protein was first 
described by Crowell et al. (1992) as a stress induced protein in soybean also known as 
SAM 22 (starvation associated message 22). It is a 16 kDa protein, which shows a 53% 
sequence identity with the major birch pollen aeroallergen, Bet v 1; 58% with the major 
hazelnut food allergen Cor a 1.0401; 53% with the major apple food allergen Mal d 1; 
and 54% with the major cherry food allergen Pru a v (Crowell et al., 1992; Kleine-Tebbe 
et al., 2002). The study by Kleine-Tebbe et al. (2002), using sera from patients with 
severe oropharyngeal and anaphylactic reactions to a soy-containing nutritional 
supplement drink showed high IgE levels to rSAM 22 indicating that this soybean protein 
was responsible for the severe adverse reaction to this soybean product. Both rSAM22 
and rBet v 1 fully inhibited IgE binding to soy protein isolate in Enzyme Allergosorbent 
tests (EAST) and immunoblotting inhibition assays. Additionally rSAM22 induced 
mediator release from basophils of patients with birch pollen allergy indicating cross-
reactivity between soybean SAM 22 (or Gly m 4) and the birch pollen allergen Bet v1 
(Kleine-Tebbe et al., 2002). Another study by Mittag et al. (2004) found that 71% of 
patients allergic to birch pollen with high titers of Bet v 1–specific IgE were sensitized to 
Gly m 4, further confirming cross-reactivity between Gly m 4 and Bet v 1 (Mittag et al., 
2004). A recent study reported that soybean-dependent pollen-food cross-reaction in 
children due to ingestion of soy milk was likely due to the presence of high 
concentrations of Gly m 4 in moderately processed soy milk (Kosma et al., 2011). The 2S 
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albumin from peanut, Ara h 2, is one of the major food allergens in one of the most 
allergenic food crops. Some investigators speculate that 2S albumins are likely to be 
major allergens in other legumes.  However, a study using 23 soybean allergic patients 
sera demonstrated that the two isolated 2S albumins of soybean (AL 1 and AL 3) are 
minor allergens at best, based on serum IgE binding (Lin et al., 2006) 
At least five IgE binding proteins have been identified in soybean lecithin (P7, 
P12, P57, P39 and STI), which is widely used as emulsifier in processed food (Xiang et 
al., 2008). Out of the five IgE binding proteins, P39 soybean allergen has been well 
characterized. It is a hydrophobic protein associated with the matrix of the protein bodies 
and possesses four conserved cysteine residues (Gu et al., 2001; Xiang et al., 2008). 
Several aeroallergens have also been identified in soybean that can cause sensitization by 
inhalation. This includes Kunitz soybean trypsin inhibitor (KSTI) from soybean flour. 
The KSTI is a 20 kDa protein with a pI of 4.5 and has been shown to be recognized by 
sera from 68% of bakers suffering from workplace-related respiratory symptoms and 
sensitized to soybean (Baur et al., 1996; Quirce et al., 2002). The KSTI has also been 
reported to be a minor soybean allergen responsible for causing allergic reaction after 
ingestion of soybean-containing products (Moroz and Yang, 1980; Burks et al., 1994). 
Several soybean hull allergens such as Gly m 1.0101 (Gly m 1A), Gly m 1.0102 (Gly m 
1B), and Gly m 2 have also been identified as aeroallergens in soybean. These were 
reportedly responsible for very common airway allergies around the shipping port in 
Barcelona, Spain (Codina et al., 1997, 1999). 
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GENETICALLY MODIFIED SOYBEANS AND THEIR ALLERGENICITY 
ASSESSMENT 
 Recombinant DNA technology allows for the transfer of gene from one species into 
another, bypassing biological barriers for recombination and genetic exchange 
(Cockburn, 2002). Different methods are used for the introduction of DNA into plants 
including electroporation, particle bombardment and infection with modified 
recombinant vectors such as Agrobacterium tumefaciens (Goodman et al., 2005). The 
introduced gene produces an additional protein that confers the trait of interest in 
resistance to virus, fungi and to improve nutritional quality (Cockburn, 2002). The 
potential of GM crops is manifold. Transgenic technology has not only reduced 
environmental degradation by decreasing the use of pesticides, but also has the potential 
to increase crop yield thereby fight global hunger (Tester and Langridge, 2010). Plants 
have also been developed by introduction of genes encoding industrial and 
pharmaceutical proteins thereby reducing production costs compared to microbial 
fermentation or purification from the natural sources (Goodman et al., 2005). The first 
commercial GM crop introduced in US was the FLAVR SAVR tomato in 1994 that had 
delayed ripening characteristics (Kok and Kuiper, 2003). Several other GM crops that 
underwent regulatory evaluation during 1994-1996 include herbicide-tolerant soybean, 
insect-resistant and herbicide-tolerant cotton, insect-resistant and herbicide-tolerant 
maize, insect-resistant potato, virus-resistant papaya and virus-resistant squash (Goodman 
et al., 2005). In 2007, GM crop production covered 143 million hectors of land in 23 
countries. GM soybean occupied 50% of global biotech crop area in 2007 followed by 
maize (31%), cotton (13%), and canola (5%) (Holst-Jensen, 2009; Magaña-Gómez and 
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de la Barca, 2008). United States (50%) holds the major share of GM crop area followed 
by Argentina (17%), Brazil (13%), India (6%), Canada (6%), and China (3%) (Qaim, 
2009). The production of GM crops in European countries is much lower than those 
listed above. Spain is the only country that grows GM crops on a significant scale. 
Several GM crops that have been developed in the past few years have never been 
commercialized. Many are awaiting regulatory approval or have been withdrawn from 
the market because of consumer acceptance or marketing problems. Examples include 
insect resistant Bt eggplant, Bt cauliflower and Bt cabbage in India and golden rice (rice 
containing pro-vitamin A) in Asian countries (Qaim, 2009).  
Approximately 90% of soybeans grown in the US are now GM cultivars 
(http://www.gmocompass.org/eng/agri_biotechnology/gmo_planting/506.usa_cultivation
_gm_plants_2009.html). Most genetic modification in soybean is targeted to increase the 
yield such as crop varieties that resist pest and disease and tolerant to herbicides rather 
than improving nutritional or quality parameters (Sten et al., 2004). Herbicide tolerant 
soybean is the dominant GM soybean crop and accounts for 70% of global soybean 
production. It is currently grown in United States, Argentina, Brazil, and other South 
American countries (Qaim, 2009). One of the most widely grown herbicide tolerant GM 
soybean varieties is the Roundup Ready soybean that is resistant to glyphosate, the active 
ingredient in Roundup agricultural herbicides. This GM soybean is produced by 
introduction of the glyphosate-tolerant CP4 EPSPS coding sequence, derived from the 
common soil bacterium Agrobacterium sp. strain CP4, into the soybean genome 
(Gizzarelli et al., 2006). 
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 Although GM technology provides several benefits, there is opposition to the 
development and use of GM crops particularly in European and some Asian countries. 
Several issues are being debated regarding GM crops. Potential issues include economic 
issues, environmental impact, ethical and social considerations and public confidence in 
regulatory procedures. However, the major concerns are food safety and environmental 
risk. The potential human health risks due to the use of GM food crops include toxicity, 
allergenicity, instability of the inserted gene, and negative effects on nutrition (Qaim, 
2009; Magaña-Gómez and Calderon de la Barca, 2008). Therefore GM crops are 
subjected to rigorous safety evaluation before they could be approved by regulators for 
market release. The purpose of this assessment is to avoid transferring a gene encoding a 
major allergenic protein or toxin into a food crop to ensure the safety of the food for 
human consumption (Goodman et al., 2005). Since 1990, several national and 
international organizations [International Food Biotechnology Council (IFBC) and the 
International Life Sciences Institute (ILSI), the Organization for Economic Cooperation 
and Development (OECD), the Food and Agricultural Organization (FAO), the World 
Health Organization (WHO)] and several biotechnology industries have been working to 
put forward strategies for safety assessment of GM food crops (Martens, 2000). In the 
US, three principal agencies regulate GM crops; the Food and Drug Administration 
(FDA), the Animal and Plant Health Inspection Service (APHIS) of the US Department 
of Agriculture (USDA), and the Environmental Protection Agency (EPA). In Europe, an 
independent agency, the European Food Safety Authority (EFSA), funded by the 
European community is responsible for assessing the safety of GM crops and to 
communicate their findings within the European community (Goodman and Hefle, 2005).   
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The guidelines for safety assessment of GM food crops were first outlined in the 
1992 FDA Federal register. Soon after, the iFBC-ILSI drafted recommendations in 1996 
and the FAO/WHO followed in 2001 with some modification. These earlier 
recommendations were based on a stepwise decision tree approach. The current 
recommended guidelines for safety evaluation of GM proteins are outlined in the Codex 
Alimentarius Commission Guidelines, Alinorm 3/34 (2003), which recommends a weight 
of evidence approach rather than a specific decision tree approach for safety assessment 
of GM crops (Goodman et al., 2005; Goodman et al., 2008). Guidelines from the US, 
Japan and the European Union (through EFSA), have adopted requirements that are 
generally consistent with Codex (Goodman et al., 2008). In spite of all efforts made to 
ensure the safety of GM foods before their release into the market for human 
consumption, there have been isolated cases in which novel foods that were not approved 
for a specified use ended up in the market. For example, the case of Starlink® corn, a 
GM corn variety engineered to express the Cry 9 C gene from Bacillus thuringiensis 
providing resistance from the European corn borer. This GM crop was approved for use 
in animal feed and non-food industrial uses, but not for human consumption in the US. 
The US EPA did not approve the Cry 9 C protein for human consumption because of an 
assumed higher potential ability of the protein to cause allergic reactions due to stability 
of the protein in pepsin at acidic pH. However, despite this restriction, Starlink corn 
ended up in the processed food chain and resulted in significant food chain disruptions 
and added costs to remove the grain and seeds from the agricultural and food system (Lin 
et al., 2003). 
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 Food allergy is an important public health issue that affects approximately 6% of 
children and 3-4% of adults in US (Riascos et al., 2010). Approximately 90,000 
individual cases of food-induced anaphylaxis reactions require emergency room 
treatment per year in the US, and there may be 150–200 food allergy related deaths per 
year (Clark et al., 2011; Goodman et al., 2005). The assessment of potential allergenicity 
of GM crops is important since protecting individuals with food allergy from accidental 
exposure to an allergen is very important from a food safety point of view (Goodman et 
al., 2008). The focus should be to ensure that the allergenicity of the GM variety is not 
greater than that of the traditionally produced crop (Goodman et al., 2005). There are four 
possible ways in which a novel protein may increase the risk of allergenicity; by being an 
allergen itself, by cross-reacting with a known allergen, by acting as a de-novo allergen 
not exposed previously to the human or by increasing the endogenous allergenicity of the 
target allergic plant population. However, the primary risk is introduction of a known 
allergen or a cross-reacting allergen (Deraman and Kimber, 2009).  For example, early in 
the development of a nutritionally enhanced GM soybean by introduction of Brazil nut 
2S albumin, testing discovered that the 2S albumin is the major allergen in the Brazil nut 
(Nordlee et al., 1996). Continued development and commercial release of that product 
would have introduced a major risk for individuals allergic to Brazil nuts as soybeans are 
used in many processed foods. However, due to the results of the safety study by Nordlee 
et al., (1996), Pioneer Hi-Bred, the developer, stopped all development of this transgenic 
line.  
 The Codex Alimentarius Guidelines, Alinorm 3/34 (2003) outline the current 
recommended procedures for allergenicity assessment of a new protein(s) produced in the 
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GM event. The guidelines involve evaluation of the source of the gene for allergenicity, 
protein sequence comparison to known allergens, evaluation of stability of the protein to 
digestion, and when indicated based on the allergenicity of the source of the gene or high 
identity to a known allergen, serum IgE testing would be required. In addition, there 
would be additional concerns and probably a demand for further undefined testing if the 
protein was stable to digestion by pepsin or if it was abundant in the food grade materials 
(Goodman et al. 2008). The Codex guidelines also recommend evaluating the plant for 
potential changes in the overall allergenicity as measured by various antigen-specific 
serum IgE tests of the food materials from the GM plant; compared to the near isogenic 
event, or to other varieties that are genetically similar; if the GM plant species is one that 
is known to be a common source of food allergy (Goodman et al., 2008). The purpose is 
to evaluate any unintended effect the genetic modification may have on the plant by 
modulating directly or indirectly the level of accumulation of endogenous allergens 
thereby increasing the allergic potential of the GM crop compared to the non-GM 
counterpart (Rouquie et al., 2010). Several studies have been done to evaluate 
endogenous allergenicity of various GM soybean varieties. A study conducted by Burks 
and Fuchs (1995) compared the endogenous allergenicity of glyphosate tolerant and 
commercial soybean varieties by IgE immunoblotting using a pool of sera from five 
soybean allergic patients. No differences in IgE binding were observed between the GM 
soybean and the commercial or parental soybean lines (Burks and Fuchs, 1995). Another 
study by Gizzarelli et al. (2006) compared the same GM soybean variety to a wild type 
variety by IgE immunoblotting and enzyme linked immunosorbent assay (ELISA) using 
a pool of sera from 10 soybean allergic subjects. No quantitative or qualitative 
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differences were found in the IgE recognition of the GM soybean compared to the wild 
type soybean. The same study also used a Balb/c mouse model to identify any differences 
in the GM and wild type soybean. The levels of IgE and IgG1 antibodies produced by 
GM soybean sensitized mice were found to be comparable to those obtained from the 
wild type soybean sensitized mice (Gizzarelli et al., 2006). Another recent study was 
conducted using 2-dimensional gel electrophoresis (2D PAGE) to separate proteins based 
on isoelectric point and molecular mass followed by quantitative measurement of spot 
densities between the GM and non-GM soybean lines. Comparisons were made only of 
spots identified as the endogenous allergenic proteins with spot identities confirmed by 
MALDI-TOF to compare the endogenous allergenicity of an herbicide tolerant GM 
soybean with a non-GM near-isogenic counterpart and three commercial soybean lines. 
No biologically significant differences in the level of endogenous allergens in the GM 
soybean were found (Rouquie et al., 2010).  
An important consideration for studies attempting to evaluate potential 
differences in the endogenous allergenicity of varieties of a crop is the clear fact that no 
limits of acceptable variance in allergen content are established. Differences in 
expression of proteins in plants could be due to genetic variations (e.g. gene mutations) or 
variation produced by epigenetic mechanisms and the latter is influenced by the 
environment where the plants are grown (Jaenisch and Bird, 2003; Ruebelt et al., 2006). 
Variation in the post translational modification of proteins has also been shown to occur 
among plant varieties (Campbell et al., 2011). A study by Conde Hernández et al., (2002) 
investigating the allergenicity of 16 cultivars of olive trees using olive pollen sensitized 
subjects found a difference in allergenicity among cultivars by skin prick test and specific 
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IgE determination, which can be attributed to factors such as eco-environment and crop 
management (Conde Hernandez et al., 2002).  In the case of soybean, Yaklich et al. 
(1999) indicated that P34 is highly conserved in soybean varieties. Sera from soybean 
sensitized human and a monoclonal antibody against P34 were used in immunoassays 
that found no difference in the expression and level of P34 in several soybean cultivars 
representing the public cultivars released between 1947 and 1988 in North America 
(Yaklich et al., 1999). Consistent with this, another study reported finding no differences 
in P34 allergen distribution among 16 soybean genotypes (Xu et al., 2007). However, 
several other studies have found differences in the expression or concentration of proteins 
including allergenic proteins among soybean varieties. Quantitative variation in soybean 
glycinin and β-conglycinin, two major allergens and storage proteins of soybean, has 
been observed among high protein soybean lines indicating that genomic differences are 
responsible for the synthesis of different quantities of subunits and polypeptides of these 
two proteins in different soybean lines (Yaklich, 2001). In a study by Codina et al. 
(2003), 10 soybean varieties were investigated for differences in the content of hull 
allergens responsible for causing respiratory allergy from dust near loading docks using 
21 subjects sensitized to soybean hull. It was found that the allergen content (Gly m 1 and 
Gly m 2) of some varieties were lower as determined by in vitro tests. However, this 
lower allergen content would not reflect clinical sensitivity since all 10 varieties showed 
similar wheal and flare skin test reactions in soybean sensitized subjects (Codina et al., 
2003). In another recent study, the distribution of three major soybean allergens (Gly m 
Bd 60K, Gly m Bd 30K and Gly m Bd 28K) were compared among 16 soybean 
genotypes (including wild and cultivated genotypes) by separating allergens by 2D 
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PAGE and subsequently identifying by LC-MS/MS. Considerable heterogeneity in the 
distribution of the α subunit of β-conglycinin was found among these 16 soybean 
genotypes (Xu et al., 2007).  
Based on published differences in allergen and protein content among varieties of 
a single crop such as soybeans, it is clear further data are necessary to establish the 
natural variability of allergen levels from non-GM food varieties that are currently 
commercially available and consumed by non-allergic individuals. That data can then be 
used to establish a range of acceptability for later evaluation of the allergen content and 
differences when considering a specific GM and non-GM comparator. Studies on the 
natural variation in allergen levels among crop varieties grown in different environments 
are essential to conclude that significant differences occur in the endogenous allergen 
content produced by genetic modification as well as providing information on the level of 
allergens currently consumed (Goodman et al., 2008; Rouquie et al., 2010). 
SOYBEAN PROCESSING 
Good nutritional qualities and physiochemical properties have led to the application of 
soy proteins in a diversity of processed food products. Approximately 60% of processed 
foods are estimated to contain ingredients derived from soybean (Hou and Chang, 2004). 
Soybean proteins are used in food in various forms including relatively unprocessed soy 
flour, soy protein isolates (SPI), soy protein concentrates (SPC) and various texturized 
products (Friedman and Brandon, 2001). In the mid-1990s world production of soy flour 
was estimated to be 2,300,000 metric tons, SPC was 150,000 metric tons and SPI was 
200,000 metric tons (Lusas and Riaz, 1995). Soy flour contains approximately 40-50% 
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protein and is prepared from soybeans after dehulling and milling, either as active full fat 
soy flour, enzyme inactive full fat flour, or defatted soy flour. Defatted soy flour is 
produced through hexane extraction of the oils. Soy flour is the least refined form of soy 
protein (Singh et al., 1995; Hammond and Jez; Lusas and Riaz, 1995). Soy protein 
concentrates, which contains approximately 70% protein, is prepared from defatted 
soybean flakes or flour after either extraction with aqueous ethyl alcohol (60-80%), 
extraction with water at the isolelectric point of soy protein (pH 4.5) or denaturing the 
protein with moist heat before extraction with water. The SPC has a reduced flavor level 
compared to soy flour since the processes used to prepare the concentrate remove some 
of flavor constituents (Singh et al., 2008). Soy protein isolate is the most refined form of 
soy protein containing approximately 90% protein and is prepared by precipitating 
protein from an alkaline extract (NaOH, pH 7-8.5) of defatted soybean flakes or flour 
with hydrochloric acid or phosphoric acid at pH 4.5 (Lusas and Riaz, 1995; Wolf, 1970). 
The 11S globulin (60%) and 7S globulin (30%) proteins together are the main 
components of SPI (Lusas and Riaz, 1995; Renkema et al., 2000). Texturized soy protein 
is produced by thermoplastic extrusion of flours, grits, and protein concentrates under 
heat and pressure to form chips, chunks, flakes, and a variety of other shapes used as 
meat substitutes or analogs. The texturization process can denature soy protein, inactivate 
trypsin inhibitors present in soybean as well as help in controlling bitter flavor (Singh et 
al., 2008; Lusas, 1996).  
The functionality of soybean proteins is an important attribute that makes them a 
popular choice to be used in food applications. For example, the gel forming property of 
soy proteins is one of the most important functional properties, particularly for food such 
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as Tofu (Hou and Chang, 2004). Soybean proteins are used in various baked products to 
provide specific functional properties such as improved texture, moisture, fat retention 
and emulsification. When heated, proteins in SPI denature and form a matrix that can 
bind substantial quantities of water, so they may be used as an egg or milk replacer in 
baked products. Similarly the hydrophilic nature of soy protein is responsible for 
enhancing the viscosity and moistness in baked products. Soy flour and isolates can 
improve the dough strength and elasticity of yeast-leavened products (Klein et al., 1995). 
Defatted soy flour is the most widely used ingredient in bakery products as a partial 
replacement for dry milk. The flour has high fat and water absorption capacity, and when 
incorporated at 2-4% can improve the water holding capacity and sheeting properties of 
sweet dough. Up to 0.5% (flour-weight basis) of enzyme active soy flour and 3% of 
defatted soy flour are permitted in standardized bakery foods. Soy flour may be 
incorporated at up to 12% with wheat flour to improve the protein quantity and quality of 
bread. Enzyme active soy flour with lipoxidase activity can bleach the carotenoid 
pigments in dough thereby producing whiter breadcrumbs. Soy flour can also be used at a 
level of 5-20% in cookies to improve their nutritional values and extend the self-life 
without changing their sensory qualities (Riaz, 1999; Singh et al., 2008). 
Soy proteins in processed meat products can act as an emulsifier. While SPI is the 
most effective soy protein product used for this purpose, soybean flour and SPC can 
provide the desired texture in coarsely chopped meats including meat patties, sausages, 
meatballs, chili, Salisbury steaks, pizza topping, and meat sauces. About 3.5% of soy 
flour and SPC and 2% SPI can be used in cooked or fresh sausage. Up to 8% of these soy 
protein ingredients can be used in chili con carne and about 12% in spaghetti with meat 
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balls or Salisbury steak. Various SPI are used in dairy products because of their fine 
particle size and dispensability. Soybean proteins are also used in soups, gravies and 
sauces, confections, imitation nut meats, coffee creamer, ice cream, low fat spreads, 
chocolate products and yogurts (Lusas and Riaz, 1995; Singh et al., 2008).  
Food and food ingredients are subjected to a wide variety of processing treatments 
in order to improve sensory quality, to remove or inactivate toxins, microbes and anti-
nutritional factors and to modify their properties to suit the end use (improve 
functionality and digestibility). Several thermal and non-thermal processing methods are 
applied during food manufacture. Thermal processing includes application of moist or 
dry heat and non-thermal processing methods include fermentation, germination, enzyme 
hydrolysis and ultra-filtration to name just a few of the various unit operations commonly 
used in food production (Thomas et al., 2007). Heat treatment of soybean is commonly 
used in the manufacture of products such as soy milk, tofu, texturized soy proteins and 
fermented soy products such as Tempeh. Soy milk is traditionally heated to 93-100
o
C for 
30 min to destroy anti-nutritional factors and to improve flavor (Kwok et al., 2002; 
Golbitz, 1995; Kowk and Niranjan, 1995). It has been shown that heating soy milk at a 
temperature higher than 90
o
C increases the dispersion stability of soy milk protein and 
soy milk emulsions. The increased stability is due to the denaturation of glycinin and β-
conglycinin present in soymilk and subsequent formation of soluble aggregates due to 
disulfide bonding (Shimoyamada et al., 2008). Heat processing may also improve the 
functionality of soybean proteins for use as food ingredients (Sorgentini et al. 1995).  
Enzymatic hydrolysis of food proteins is a biochemical procedure that is used to impart 
certain functionalities to food as well as in preparing hypoallergenic food (Lusas and 
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Riaz, 1995; L’Hocine and Boye, 2007). The reduced solubility of soybean proteins at 
acidic pH (close to the iso-electric point (4.5) of major seed storage proteins glycinin and 
β-conglycinin) limits their use as functional ingredients in moderately acidic foods such 
as citric beverages and salad dressings. The hydrolysis of soybean proteins with proteases 
can increase the protein solubility thereby providing functional properties that depends on 
protein solubility such as foaming and emulsifying properties (Molina Ortiz and Wagner, 
2002). Several investigators have used various protease enzymes to treat soybean proteins 
to improve their solubility and to achieve the desirable functionality. Calderon de la 
Barca, et al. (2000) treated defatted soybean flour with the enzyme, chymotrypsin, to 
improve protein solubility, emulsifying and foaming properties. In another study, SPI was 
treated with enzymes such as Alcalase, α-chymotrypsin, trypsin, liquozyme and rennet to 
improve its solubility, emulsifying capacity and its ability to undergo thermal aggregation 
(Kim et al., 1990). SPI has also been treated with enzymes such as papain and bromelain 
to improve its solubility and foaming properties (Molina Ortiz et al., 2000). A 
combination of heat and enzymatic treatment has also been used to improve the 
functional properties of soybean proteins. Molina Ortiz and Wagner (2002) heat-treated 
SPI at 90
o
C for 30 min followed by treatment with the enzyme bromelain. An 
improvement in solubility and foaming property was observed under this combination 
treatment (Molina Ortiz and Wagner, 2002). In another study, selective hydrolysis of 
soybean β-conglycinin and glycinin was achieved by treatment with a combination of 
heat and enzymes such as papain and pepsin. It was observed that selective hydrolysis 
altered functional properties such as the viscosity, emulsifying activity, whippability, and 
gel forming ability of soybean protein. A study by Tsumura et al. (2005) indicates that 
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SPI foaming properties are improved by selective hydrolysis of glycinin and β-
conglycinin. High pressure treatment has recently been used to improve the emulsifying 
and gelation properties of soybean proteins (Molina et al., 2001; Wang et al., 2008). A 
combination of heat and high pressure has been shown to alter the textural property of 
gels formed by SPI, 7S and 11S globulin (Molina and Ledward, 2003). 
EFFECT OF FOOD PROCESSING ON ALLERGENICITY  
Various processing steps applied during food manufacture can alter the allergenicity of 
food. Changes could be due to inactivation or destruction of epitope structures, formation 
of new epitopes, or improved access of previously hidden epitopes (Paschke and Besler, 
2002). However, processing methods may not affect the allergenicity of all allergens in a 
similar manner (Paschke and Besler, 2002). Understanding the impact of food processing 
and food structure on allergenic potential is crucial in managing allergen risks in the food 
chain. Our current knowledge of the impact of food processing on allergen structure 
indicates that it is hard to predict how different allergens respond to various food 
processing treatments. Several studies have indicated a wide variation in the allergenicity 
of processed food products. In a study to investigate the allergenicity of 20 peanut 
products, 15 processed peanut products were found to be allergenic by the RAST 
inhibition assay using peanut allergic patient sera indicating that the various processing 
treatments (shelling, blanching, dry roasting, oil roasting, toasting, grinding, defatting) 
used in preparation of those products have negligible effects on allergenicity (Nordlee et 
al., 1981). A market-based study with 8 different soybean products involving various 
processing treatments (soy flour, roasted soybean, SPI, soy grit, soy milk, defatted soy 
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flour, SPC) and IgE binding using seven soybean allergic patient sera showed highly 
variable results. None of the processes resulted in the abolition of IgE binding and 
roasted soybean showed enhanced IgE binding to a 20 kDa band with sera from two 
patients (Herian et al., 1990). In another study, commercially available soy flour, soy 
milk, two infant formula milk products (hydrolyzed and unhydrolyzed) and texturized 
soy protein products were tested for serum IgE binding using sera from nine soy allergic 
individuals. The infant formula soy milk did not show any IgE binding; however, IgE 
binding was observed for the other soy milk with all nine soy allergic sera. Texturized 
soy protein (produced by heating, mechanical pressure and acid treatment (pH 4.5) of soy 
protein) showed IgE binding with seven out of nine sera tested (Franck et al., 2002). 
Based on the findings of these studies it can be concluded that since commercially 
available food products undergo complex industrial processing steps involving a 
combination of heat, enzymatic treatment and texturization, it is difficult to interpret the 
effect the individual processing steps can have on the allergenicity of proteins/allergens 
by these kinds of studies. Certain allergens are frequently labile to common food 
processing technologies while others are not. For example, IgE binding to cross-reactive 
Bet v1 related food allergens in general are lost by processing as the epitopes of these 
allergens are primarily conformational and the allergens are easily denatured. The 
prolamine super family proteins including 2S albumins and non-specific lipid transfer 
proteins are quite stable to denaturation due to conserved cysteine residues, which form 
intra-chain disulfide bonds (Mills et al., 2009).  
Various thermal processes applied during food manufacture may lead to alteration 
of protein conformation and reduction of IgE binding to conformational epitopes. 
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Additionally some processes can lead to the creation of new epitopes. For example, the 
formation of glycation adducts by the Maillard reaction (covalent cross-linking between 
lysine residues of protein with reducing sugars present in food) can lead to the formation 
of new immunologically reactive structures (Paschke, 2009; Paschke and Besler, 2002). 
The heat induced denaturation and alteration of conformational epitopes can explain the 
loss of 90% of the immuno-reactivity of the heat labile birch-pollen-related allergens of 
hazelnuts such as Cor a1.04 and Cor a 2 (Hansen et al., 2003), whereas the absence of 
conformational epitopes can explain IgE binding to the lipid transfer protein of maize 
after thermal treatment at 100
o
C for 160 min (Pastorello et al., 2003). In the case of 
peanut allergy, it has been observed that the cooking method can influence the 
allergenicity of peanut proteins. A study conducted by Beyer et al., (2001) indicated that 
frying (5 min for Valencia peanuts and 10 min for Florunner) and boiling (100
o
C for 20 
min) peanut resulted in the reduction in IgE reactivity to the major peanut allergens Ara h 
1, Ara h 2 and Ara h 3, whereas roasting (170
o
C, 20 min) resulted in increased reactivity 
to the same allergens. This could explain the apparent lower prevalence of peanut allergy 
in China where fried or boiled peanuts are primarily consumed compared to the US 
where peanut is usually consumed after roasting (Beyer et al., 2001). A study by Maleki 
et al. (2000) showed that proteins from roasted peanuts bound IgE from peanut allergic 
subjects at an approximately 90-fold higher level compared to raw peanut, which they 
attributed to protein modification by the Maillard reaction. In another study, boiling 
peanuts in water (100
o
C, 30 min) reduced the median IgE binding by 1.5- to 2-fold 
compared to raw or roasted peanuts. This decrease was attributed to the loss of soluble 
proteins in the water used for boiling the peanuts (Mondoulet et al., 2005). For other 
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legume allergens such as lentil, chickpea and lupine, the reduction of IgE binding to 
proteins has been observed by prolonged autoclaving, whereas little modification in IgE 
binding has been observed by boiling (Alvarez-Alvarez et al., 2005; Cuadrado et al., 
2009). A few studies have investigated the effect of heat processing on the allergenicity 
of soy flour or on individual soybean proteins. In a study by Shibasaki et al. (1980) 
soybean glycinin, -conglycinin and 2S globulin were heat treated at 80oC, 100oC and 
autoclaved at 120
o
C for 30 min prior to testing IgE binding by RAST and RAST 
inhibition using five soy allergic sera. A reduction in IgE binding to glycinin and -
conglycinin and a slight increase in IgE binding to 2S globulin was observed under these 
heat treatment conditions (Shibasaki et al., 1980). In another study where soy flour 
extract, purified 11S globulin and 7S globulin fractions of soybean were heat treated at 
37
o
C for 1 hour, 56
o
C for 1 hour and 100
o
C for 5 min, 20 min and 60 min, no differences 
in IgE or IgG binding compared to control samples were observed using a pool of 
soybean allergic patient sera (Burks et al., 1992). In another study by Muller et al. (1998), 
three of six patients used in the study showed specific IgE against cooked soybean extract 
(100
o
C for 2 hours) by the enzyme allergosorbent test (EAST) while the other three sera 
failed to bind. The protein extract of raw soybean had a reduced inhibitory capacity of 
approximately 40% for inhibition of IgE binding to the heated soybean proteins by EAST 
inhibition assay using a pool of soybean allergic sera (Muller et al., 1998). IgE from the 
same serum pool recognized six protein bands from heat-treated soybean with strongest 
binding to a 39 kDa band (Muller et al., 1998).  
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 Enzymatic hydrolysis can lead to the alteration of allergenicity in two different 
ways. The enzyme used for hydrolysis could itself be a potent allergen. Further 
enzymatic hydrolysis of food proteins can lead to loss of epitope structure thereby 
reducing allergenicity (Paschke and Besler, 2002). The prerequisites for removal of 
allergenicity are sufficient contact between the allergenic epitope and the enzyme and 
sufficient control of undesirable side effects that may affect sensory quality or 
functionality (De Angelis et al., 2010). However, the enzymatic hydrolysis of protein 
does not always lead to a reduction in allergenicity. The initial breakdown of proteins can 
expose new antigenic epitopes, which can result in increased allergenicity. With the 
progress of hydrolysis however, proteins are broken down to a greater degree resulting in 
lessening of their allergenic properties (Nagodawithana, et al., 2010). Porcine trypsin and 
chymotrypsin are frequently used to prepare hypoallergenic formulas, as well as other 
enzymes of bacterial and fungal origin. These enzymes cleave proteins at different sites 
due to favored binding in the catalytic sites and depending on the exposure of those sites. 
Thus digestion often leads to residues of peptides of different lengths with more or less 
residual IgE binding capacity (Fritsche, 2003). Sequential hydrolysis with the enzymes 
Alcalase and flavourzyme were shown to reduce IgE binding to lentil and chickpea 
protein hydrolysates (Cabanillas et al., 2010; Clemente et al., 1999). Alcalase, pepsin and 
trypsin have also been used to hydrolyze and reduce the immunoreactivity of pea protein 
extract (Szymkiewicz and Jedrychowski, 2005). Protease, elastase and trypsin have been 
shown to eliminate IgE binding to hazelnut proteins (Wigotzki et al., 2000). A few 
studies have focused on the use of enzymatic hydrolysis on reduction of the allergenicity 
of soybean proteins. Tsumura et al. (1999) hydrolyzed SPI using a commercially 
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available Bacillus sp. protease. Degradation of the soybean allergens Gly m Bd 30K and 
Gly m Bd 28K was observed using an alkaline protease, porleather FG-F (Tsumura et al., 
1999). A reduction in IgE binding with serum from soybean sensitive subjects was also 
observed using the same protease (Tsumura et al., 1999). In another study, soybean 11S 
globulins were hydrolyzed by sequential treatment with the enzymes, pepsin and 
chymotrypsin. Although a reduction of IgE binding was observed after this treatment, it 
was not completely eliminated (Lee et al., 2007). In a study by Van Boxtel et al. (2008), 
the effects of heating and pepsin digestion on the IgE binding to Ara h 3 of peanut and 
glycinins of soybean were investigated. Both proteins were found to be relatively stable 
to denaturation, having denaturation temperatures ranging from 70 to 92
o
C. However, the 
IgE binding capacity of both allergens was shown to be markedly degraded within 10 min 
of peptic digestion as no IgE binding was observed with any samples (van Boxtel et al., 
2008). 
Evaluation of the allergenicity of food proteins, rather than simply IgE binding to 
soluble proteins, must be done following processing to understand food safety. The 
conditions used to extract proteins from both raw and processed foods is an important 
determinant for appropriate interpretation of effects of the processing on the allergenicity 
of a given food material. The inefficient extraction of proteins from processed food 
products can happen due to matrix effects including impaired solubility of denatured 
proteins from other constituents, cross-linking through glycation and binding of 
hydrophobic proteins to the food matrix. Some of the studies reporting reduced 
allergenicity of various foods do not seem to control for possible poor extraction of 
allergenic proteins and most use water-soluble extraction methods followed by antibody 
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detection. A study conducted by Poms et al. (2004) utilized different temperature and 
time combinations for dry and oil roasting of peanuts. They found that elevated roasting 
temperatures resulted in a greater influence on the solubility of peanut proteins with a 
reduction in protein yield of 50-75% from dry roasted peanuts and 75-80% from oil 
roasted peanuts. Their study demonstrated that the extraction efficiency of the allergenic 
proteins varied by using a variety of extraction buffers (Poms et al., 2004). Quite often it 
is necessary to optimize sample extraction in order to ensure that an analytical result 
represents the true impact of a process on allergenic activity. Normally the allergic 
subject would consume a whole food material and not an aqueous extract, so the tests to 
measure the impact of processing on allergens must reflect likely true exposure to the 
proteins that cause allergy (Poms et al., 2004).    
Physio-chemical methods such as SDS-PAGE and peptide profiling can be used 
to assess the degree of hydrolysis after heat and enzymatic processing of allergenic 
proteins. However, immunological methods are more suitable to determine the 
allergenicity of the resulting peptides or proteins obtained (Fritsche, 2003). In vitro IgE 
binding tests such as radioallergosorbent test (RAST), RAST inhibition test, 
immunoelectrophoresis methods and ELISA are commonly used to evaluate any 
reduction in allergenicity obtained after heat or enzymatic hydrolysis (Host and Halken, 
2004). In vitro tests are often quick, inexpensive and without a threat to human or animal 
subjects. However, certain limitations of in vitro immunological methods include 
alteration of three dimensional structures, destruction of epitopes by the adsorption of 
allergens to solid matrix, susceptibility of the results to interference by the presence of 
IgG of similar specificity as IgE and a lack of correlation between positive IgE binding 
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results with expression of clinical symptoms due to several factors such as presence of 
cross-reactive carbohydrate determinants, low affinity binding, one IgE binding epitope 
and poor spatial orientation of epitopes (Kaul et al., 2007; Ladics et al., 2008). Functional 
assays such as basophil histamine release, skin prick tests, patch tests and challenge tests 
would evaluate the biological consequence of any IgE binding detected by in vitro 
immunological methods and thereby help in providing a true picture of any reduction in 
allergenicity achieved by various processing treatments (Host and Halken, 2004; L’ 
Hocine and Boye, 2007). Several in vitro functional assays can be used to measure the 
biological activity of allergens. They are based on in vitro activation of basophils 
sensitized with IgE and measurement of release of histamine and/or sulphidoleukotriene 
or expression of basophil surface activation markers CD63 or CD 203c when exposed to 
the allergen or allergen-containing material. Specific mediators can be measured by 
ELISA based methods or by flow cytometry to investigate the up regulation of activation 
markers on the basophil surface (Crockard and Ennis, 2001; Ebo, 2009; Poulsen, 2001). 
The CD63 protein is a member of the transmembrane-4 super family that is expressed on 
basophils, mast cells, macrophages, and platelets. In resting basophils, it is attached to the 
intracytoplamic granules. Activation of basophils with IgE and allergen leads to 
expression of the CD63 on the surface of basophils. The CD203c protein is expressed 
only on IgE-bearing basophils, mast cells, and their progenitors. Similar to CD63, they 
are up-regulated on the surface of mast cells and basophils by activation with allergen or 
anti-IgE (Hamilton and Franklin Adkinson, 2004). Mediator release assays with basophils 
can be performed either by incubating heparinized whole blood from an allergic 
individual with allergen or after stripping endogenous IgE from basophils of non-allergic 
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donors prior to incubating with serum IgE from appropriately allergic donors, followed 
by stimulating with allergen (Hamilton and Franklin Adkinson, 2004; Kleine Budde et 
al., 2001). The primary advantage of using the stripped basophil assays rather than fresh 
basophils isolated from specifically allergic donors is that serum IgE from donors around 
the world or serum collected 10 years before may be used with IgE-stripped basophils, 
whereas basophils from allergic donors must be used within 24 hrs of drawing blood 
samples (Kleine Budde et al., 2001; Poulsen, 2001). The disadvantage is that additional 
controls are needed to demonstrate that the stripped basophils are not activated by non-
allergen related signaling. Another option for evaluating the biological activity of 
allergens is by measuring the release of β-hexosaminidase (present within granules in 
basophils and released along with histamine during an allergic reaction) from humanized 
RBL (rat basophilic leukemia) cells that have been sensitized by addition of appropriately 
allergic sera. Three versions of hRBL cells have been generated by transforming a rat 
basophil line with human genes expressing α, β and γ chain (RBL SX-38) or only the α-
chain (RBL-30/25 and hEIa-2B12) of human Fc epsilon RI receptors (Dibbern et al., 
2003; Vogel et al., 2005; Ladics et al., 2008). These cells have been shown to be useful in 
exploring IgE- allergen interactions using sera from peanut specific subjects and peanut 
extract or peanut allergens Ara h 2 and Ara h 1 (Dibbern et al., 2003). Some of the 
limitations of using a humanized RBL assay are lack of consistency, reduced IgE binding 
capacity over time and a tendency of being effective only with sera containing high 
concentrations of allergen specific IgE (Ladics et al., 2008; Palmer et al., 2005).   
The best way to determine the biological activity of an allergen is by challenging 
food allergic patients with their specific food allergen in a double-blind, placebo-
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controlled food challenge (DBPCFC). DBPCFC is considered the gold standard for 
diagnosis of allergy. However, the possibility of a severe anaphylactic reaction occurring 
during a food challenge limits the use of this method as a routine way for allergenicity 
assessment. Other limitations of using this method are the involvement of ethical issues 
in using human subjects, the challenges are time consuming, labor intensive, costly and a 
uniform challenge protocol (minimum dose, maximum dose, assessment of symptoms 
and challenge vehicle) is still lacking. In addition, the low prevalence of allergy to any 
one allergen makes a coordinated and timely test of reactivity for any but the most 
common allergenic foods impossible to perform. Also these tests need to be conducted in 
well-equipped hospitals or other healthcare settings to take appropriate measures in case 
severe anaphylactic reactions occur (Asero et al., 2007; Bindslev-Jensen, 2001; Sicherer 
and Sampson, 2006; Taylor et al., 2004).  
The use of animal models, such as a rodent model, may be an alternative way of 
evaluating the potential allergenicity of processed food products or novel food proteins. 
Some advantages of using a rodent model are that they have a well characterized immune 
system, tests would not risk the health or life of human subjects, both exposure and 
challenges may be carefully controlled. The question is whether the rodent model would 
accurately predict the response of the allergic human subject. Rodents can be sensitized 
by oral, intra-peritoneal, dermal or sub-cutaneous routes, with or without the use of 
adjuvants (Ladics et al., 2008). However, tests of rodent models for allergenic risk 
assessment have not been demonstrated to accurately predict the sensitizing potential or 
active allergenicity of dietary proteins when purified proteins are used (Ladics et al., 
2008). Tests with whole, highly allergenic foods have demonstrated similar responses to 
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those of allergic humans in the type and severity of the immunological responses, but the 
responses seem to be variable and strain-dependent. There are additional limitations for 
some allergenic foods because of the bulkiness and nutritional content of the whole food 
limits the amount of protein of interest that is administered during the challenge when 
they are fed to rodents (Constable et al., 2007; Ladics et al., 2008). 
The major portion of this dissertation focuses on the evaluation of potential 
changes in the endogenous allergenicity of three newly developed transgenic soybean 
lines using serum samples from soybean sensitized patients by in vitro IgE immunoblot 
and inhibition ELISA to evaluate potential risks to soybean allergic individuals from the 
GM products. Further the effect of heat processing and enzymatic hydrolysis on the 
allergenicity of endogenous soybean proteins was evaluated by in vitro IgE binding tests 
as well as a mediator release assay using hRBL cell lines with soybean sensitive patient 
sera to find out whether any of these processes have the potential to increase or decrease 
the allergenicity of soybean proteins.  
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CHAPTER 2: THE EFFECT OF GENETIC MODIFICATION ON SOYBEAN 
ALLERGENICITY 
 
 
INTRODUCTION 
Soybean is one of the eight allergenic foods or groups of foods (peanuts, soybeans, tree 
nuts, milk, egg, fish, crustaceans, and wheat) that are thought to cause nearly 90% of 
food-allergic reactions in the US (Goodman et al., 2005). Soybean allergy affects 
approximately 0.4% of children worldwide (Savage et al., 2010). The prevalence and 
incidence of soy allergy is likely to be dependent on local dietary habits and exposure 
(Sicherer et al., 2000). At least 16 IgE binding proteins of molecular weights ranging 
from 14 kDa to 70 kDa has been identified in soybean and the major seed storage 
proteins are likely to be the major allergens (Ballmer-Weber et al., 2007; Holzhauser et 
al., 2009; Ogawa et al., 1991; Ogawa et al., 1993).  
Approximately 90% of soybeans grown in the USA are now genetically modified 
(GM)(http://www.gmocompass.org/eng/agri_biotechnology/gmo_planting/506.usa_cultiv
ation_gm_plants_2009.html). Most of the genetic modifications in the current collection 
of transgenic soybeans are targeted to herbicide resistance or insect protection and to 
improve agricultural efficiencies (Sten et al., 2004). All newly developed transgenic crop 
lines need to undergo a rigorous safety evaluation before regulatory approval. The safety 
evaluation of transgenic food crops described in the Codex Alimentarius Guidelines 
(Codex, 2003) includes assessment of the potential allergenicity to reduce potential risks 
of transferring a gene that codes for an allergenic protein. The risk of allergic reactions to 
a specific food produced from a transgenic organism that included an allergen from 
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another source (e.g. peanut or wheat) into a different food crop (e.g. rice) would be 
increased; but more importantly those with allergies to the transferred protein would be at 
great risk because they would not avoid foods that normally do not cause their reactions 
(Goodman et al., 2005; Goodman et al., 2008). Not only is the safety of the protein 
expressed by the introduction of the new gene inserted into transgenic crop is evaluated, 
but potential unintended changes in the transgenic crop due to gene insertion are also 
evaluated. Those include possible disruption of endogenous genes as well as altered 
expression of endogenous genes. Further, if the inserted gene encodes an enzyme, the 
possibility that it will increase or decrease key metabolites or produce a novel metabolite 
with potential health consequences is evaluated. Possible changes in the endogenous 
levels of allergens expressed in the food fractions of the transgenic plant are measured if 
that species is a known source of food allergy, e.g. soybean (Barros et al.; Cellini et al., 
2004). Therefore the Codex Alimentarius Guidelines, Alinorm 3/34 (2003), and many 
countries including the U.S., Japan, the European Union (through EFSA) that have 
adopted requirements that are generally consistent with the Codex recommend evaluating 
a transgenic plant for potential changes in the overall allergenicity by comparing them to 
a near-isoline or other genetically similar lines (Goodman et al., 2008). Although explicit 
procedures for such an evaluation are not provided, the comparison is generally 
performed by measuring and comparing antigen-specific serum IgE binding to proteins in 
the food material from the transgenic plant; compared to a near-isoline and/or to other 
lines that are genetically similar by immunoblot and ELISA procedure using sera from 
donors allergic to soybeans (Goodman and Leach, 2004; Goodman et al., 2008; Hoff et 
al., 2007). Proteomic techniques such as two dimensional poly-acrylamide gel 
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electrophoresis (2D-PAGE) have also been used to compare the protein/allergen 
expression profile of transgenic and non-transgenic soybean seeds (Brandao et al., 2010; 
Rouquie et al., 2010). However, in vitro IgE binding studies with allergic sera could give 
a more complete answer to the question of whether there are differences in the expression 
of allergenic proteins as a combination of tests with native, denatured and reduced 
extracts, and tested with sera from a number of specifically allergic subjects. It is highly 
likely that different allergic subjects can exhibit markedly different IgE recognition 
patterns and some allergic subjects may exhibit IgE binding to a minor protein(s) that 
may be differentially expressed in some lines. In addition, their IgE may recognize some 
isoforms of allergens and not others due to one or a few amino acid differences between 
isoforms. Yet it is also important to remember that not all proteins identified by IgE 
binding are capable of eliciting an allergic response. Some may express only one epitope, 
others may have very low affinity binding and still others have specific carbohydrate 
determinants (CCD) that are not likely to cause an allergic reaction (Goodman et al., 
2008; Hoff et al., 2007). If the protein is expressed in a crop that is always cooked, it is 
also important to understand whether the epitopes are conformational structures that 
might be destroyed by heating.   
In studies described in this chapter, potential changes in the endogenous 
allergenicity of three transgenic soybean lines were evaluated by comparing them to their 
near-isolines and other commercial soybean lines by using sera from soybean sensitive 
patients. One study (study 1) was sponsored by BASF (Research Triangle Park, NC, 
USA) and two studies (study 2 and 3) were sponsored by Bayer CropScience AG 
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(Monheim am Rhein, Germany). Rather than focusing on a few proteins as probable 
major allergens, these studies were designed to test for any antigen-specific IgE binding 
using direct binding from individual soybean allergic subjects using 1D-immunoblots for 
qualitative assessment of possible differences between soybean extracts. Gels were run 
under both reducing and non-reducing conditions to differentiate IgE recognition of 
conformational and linear epitopes. Further inhibition ELISA was conducted for 
evaluating any quantitative differences in IgE binding potential between the soybean 
lines, which allows for the evaluation of aggregate IgE binding differences. In addition, 
blots with proteins separated by 2D-PAGE were carried out, which allows for separation 
of proteins both according to their molecular weight and isoelectic point (pI) and 
therefore increases the possibility of finding differences in IgE binding patterns (Lilley et 
al., 2002). Minor changes in post-translational processing including differential C-
terminal proteolysis, modified carbohydrate structures, differential phosphorylation will 
result in slight differences in migration.   
It is also important to consider that consumption of soybean food products does 
not pose a risk of allergy except to those who are already sensitized (Goodman et al., 
2008). Non-allergic consumers can consume soybeans ad libitum, without risk. Further, 
those with allergy to soybeans are at risk if they consume soybeans and they therefore 
should avoid eating any soybean to avoid the risk of allergic reactions. The results of 
these studies provide some data regarding the natural variation of soybean allergen 
content. If there are even modest differences in the allergen content of various soybean 
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varieties, there is no practical risk consequence as those with soybean allergy should be 
avoiding consumption of all soybean foods. 
MATERIALS AND METHODS 
Human sera 
Soybean allergic and control sera from historical clinical samples collected for research 
purposes were used in the studies described in this chapter. Additional samples procured 
from PlasmaLab International, a U.S. FDA approved facility, were also used in these 
studies. The University of Nebraska Institutional Review Board has approved the use of 
these samples in these studies (reviewed and approved for the Goodman laboratory). The 
allergic patients utilized in Study 1 had soybean specific IgE levels ranging from 0.8 to 
47 kU/L (Appendix A), those utilized in Study 2 had a soybean specific IgE level ranging 
from 3-71.6 kU/L (Appendix C) and those used in Study 3 had a soybean specific IgE 
level ranging from 1.12-71.6 kU/L (Appendix E) as measured by either the 
ImmunoCAP® (Phadia, Uppsala, Sweden, recently purchased by Thermo Scientific) or 
the IMMULITE® system (Siemens AG, Erlangen, Germany). Most of the soybean 
allergic subjects also had history of allergic reactions to peanut and significant peanut 
specific IgE levels ranging from 1.94 to 100 kU/L as assayed by ImmunoCAP® or 
IMMULITE®. Three of the six control subjects utilized in these studies had reported 
allergies to other legumes such as lupine and pea, one had no allergic symptoms and two 
subjects had asthma. However, none of the control subjects reported soybean specific 
symptoms (Appendices B, D and F).  
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Test proteins and extracts 
Nearly identical methods were used for all the three serum studies. For brevity, the assay 
descriptions that are identical are described together, although the studies were performed 
at different times. Transgenic lines were the only GM line used in this study. All other  
soybean lines (near-isolines and commercial lines) were non-transgenic. The transgenic 
line used in Study 1 was BPS-CV127-9 /3411-T (referred to as transgenic line I in this 
chapter). It is an herbicide-tolerant soybean tolerant to the imidazolinone class of 
agricultural herbicides. The near-isoline used in Study 1 was 3410-I and the three 
commercial soybean lines used in this study were 3415-M/MON8001, 3416-C/CD217 and 
Conquista (referred to as commercial lines 1, 2 and 3 respectively in this chapter). For 
Study 2, the transgenic line A5547-127 soybean, also known as LibertyLink
®
 soybean 
(referred to as transgenic line II in this chapter) was used, which is tolerant to the 
glufosinate ammonium class of agricultural herbicide and in Study 3 transgenic line FG72 
(referred to as transgenic line III in this chapter), another herbicide tolerant transgenic line 
was used. The near-isoline used was A5547 for Study 2 and Jack for study 3. The three 
commercial lines utilized in Studies 2 and 3 were Stine 2686-6, Stine 2788 and Stine 
3000-0 (referred to as commercial lines 4, 5 and 6 respectively in this chapter). 
 For one dimensional poly-acrylamide gel electrophoresis (1D-PAGE) and 
immunoblots, full fat flour of all three transgenic soybean lines (transgenic line I, II and 
III), their near-isolines (near isogenic lines) and similar use commercial soybean lines 
were extracted at room temperature for 2 hours at a 1:10 w/v ratio with 1X PBS (11.9mM 
phosphate, 137mM sodium chloride, 2.7mM potassium chloride, pH 7.4) containing 
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protease inhibitor (ThermoScientific, Rockford, IL, USA, Cat # 78415). The extracts were 
clarified by centrifugation using an Eppendorf centrifuge (model 5810R) at 18514 g for 30 
min, and then filtered by gravity through Whatman 2V filter papers. The soluble protein 
content of the extracts were determined by the Lowry method using a DC protein assay kit 
(BioRad, Hercules, CA, USA, Cat # 500-0113, reagent A, Cat # 500-0114, reagent B). 
Bovine serum albumin (BioRad, Hercules, CA, USA, Cat # L9704881) was used as a 
standard, with the absorbance read at 750 nm. Three control samples (navy bean, peanut 
and corn) utilized in the immunoblot along with the soybean samples were also extracted 
and tested for protein content as indicated above. For 2D-PAGE immunoblots, soybean 
samples were extracted by a trichloroacetic acid (TCA)/acetone precipitation method 
modified from Natarajan et al. (2005). A powdered sample of 0.1 g of full-fat soybean 
powder was mixed with 1 mL of cold acetone (Fisher Scientific Rockford, IL, USA, Cat # 
FL-08-0704, stored at −20oC for at least 1 hour and used cold) containing 10% TCA 
solution (Sigma Aldrich, St. Louis, MO, USA, Cat # T0699-100ML) and 2% 2-
mercaptoethanol (BioRad, Hercules, CA, USA, Cat #161-0710), and stored at −20oC 
overnight. The mixture was centrifuged at 10,000  x g for 30 min at 4
o
C. The supernatant 
was discarded and the pellet was washed with cold acetone by vortexing and then 
centrifuged at 10,000 g for 10 min at 4
o
C, which was repeated twice. The protein pellet 
was dried in a chemical fume hood for 30 min to fully eliminate the acetone. The dried 
pellet was then dissolved in 1.5 ml of 8 M urea (Invitrogen, Carlsbad, CA, USA, Cat 
#15505-035) and 2% CHAPS (Invitrogen, Carlsbad, CA, USA, Cat # ZC10003) by 
vortexing a few times and then mixing on a rotary shaker at room temperature for 1 hour. 
The solution was then centrifuged at 10,000 x g for 30 min to remove any undissolved 
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particles. The soluble protein content of the samples was determined by the Bradford 
assay (BioRad, Hercules, CA, USA, Cat # 500-0205) using bovine serum albumin as a 
standard, with the absorbance read at 595 nm.   
SDS-PAGE and Immunoblotting 
  For 1D-PAGE, the soybean and control extracts were diluted in Laemmli SDS-
sample buffer (Boston BioProducts, Ashland, MA, Cat # BP-111NR) to a protein content 
of 10 µg per well except the peanut extract was loaded at 2 µg per well. Samples were 
separated under both reducing (2-mercaptoethanol and heating at ~ 95°C for 5 minutes) 
and non-reducing conditions using Novex 10-20% tris-glycine gels (Invitrogen, Carlsbad, 
CA, USA, Cat # EC61355). A 4µl sample of pre-stained Precision Plus molecular weight 
marker proteins (BioRad, Hercules, CA, USA, Cat # 161-0374) was run in one lane on 
each gel. Electrophoresis was performed with a constant 125 Vdc for 105 min. Following 
separation, proteins in the gels were fixed with 7% acetic acid, 40% methanol for one 
hour, then stained for a minimum of 6 hours in Colloidal Brilliant blue G250 (Sigma, St 
Louis, MO, USA, Cat # B2025). Background staining was reduced by submerging gels for 
one minute in 10% acetic acid, 25% methanol and followed by multiple changes of 25% 
aqueous methanol. Images were captured using white light in a Kodak Gel Logic 440 
Image Station. 
 For 2D-PAGE, a Bio Rad PROTEAN IEF Cell (BioRad Hercules, CA, USA, Cat 
# 165-4001) was used for the first dimensional separation of the proteins based to their 
isoelectric points. Samples of two of the three transgenic soybeans, near-isoline controls 
and two sets of commercial lines were prepared as describe above. The samples 
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representing 25 µg of TCA/Acetone precipitated protein were diluted to a final volume of 
125 µl with IEF sample buffer [8M urea, 2% CHAPS, 50 mM DTT (Fisher Bioreagents, 
Pittsburg, PA, USA, Cat # BP172-5) and 0.5% ampholyte (BioRad, Hercules, CA, USA, 
Cat # 163-1112)] and then applied to individual troughs of the IEF focusing tray (BioRad, 
Hercules, CA, USA, Cat # 165-4030). Individual 3-10 non-linear IEF strips (BioRad, 
Hercules, CA, USA, Cat # 163-2002) were placed into the trough of each sample well gel 
side down and the strips were then covered with 1 ml of mineral oil (BioRad, Hercules, 
CA, USA, Cat # 163-2129). Active rehydration was performed at 50 Vdc for 12 hours to 
equilibrate the strips and initiate protein migration followed by 250 Vdc run for 15 min, 
4000 vdc ramping for 2 hours and finally a 4000 Vdc limit step was used until 30,000 
integrated volt-hours was reached. The protein focusing pattern was retained by holding at 
500 Vdc. Following IEF, the strips were equilibrated for 15 min with 1 ml of dithiothreitol 
(DTT) equilibration buffer (6 M urea, 2% SDS, 0.375 M Tris-HCl, pH 8.8, 20% glycerol, 
130 mM DTT) and then 15 min in 1 ml of iodoacetamide equilibration buffer (6 M urea, 
2% SDS, 0.375 M Tris-HCl, pH 8.8, 20% glycerol, 135 mM iodoacetamide) for reduction 
and acetylation. Separation in the second dimension was accomplished by placing each 
strip in the 7 cm well of NuPAGE® Novex 4-12% Bis-Tris ZOOM® Gels (Invitrogen, 
Carlsbad, CA, USA, Cat # NP0330BOX), sealing the well with 0.5% agarose (Invitrogen, 
Carlsbad, CA, USA, Cat # 15510-019) as well as loading 4 µl of pre-stained Precision 
Plus molecular weight marker proteins onto the small well and then separating proteins 
with constant 150 Vdc for 60 min. Representative gels were stained with Coomassie Blue 
as described earlier. 
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   For immunoblotting, the separated proteins from the second-dimension gels were 
electro-transferred to polyvinylidene difluoride (PVDF) membranes (Invitrogen, Carlsbad, 
CA, USA, Cat. # LC3675) at 25 Vdc for 90 min. Protein transfer was confirmed by 
staining with Ponceau S. The membranes were then rinsed in deionized water followed by   
blocking with 5% non-fat dry milk (NFDM) in PBS containing 0.05% Tween 20 (PBST) 
in sealed plastic bags for at least one hour. Individual human sera were diluted 
appropriately (1:10 or 1:20 v:v), in 2.5% NFDM in PBST and allowed to block for 1 hour 
in a polypropylene tube at room temperature before adding to the blocked membrane in 
the plastic bag for overnight incubation at room temperature. Unbound antibody was 
removed from the membranes by washing four times for 5 min each with fresh PBST. 
Bound IgE was detected using mouse monoclonal horse radish peroxidase (HRP) 
conjugated anti-human IgE (SouthernBiotech, Birmingham, AL: clone B3102E8 Cat # 
9160-05), diluted 1:1000 with 2.5% NFDM in PBST. The unbound secondary antibodies 
were removed by washing the membranes four times with fresh PBST. Detection was 
achieved using Supersignal West Dura Extended Duration chemiluminescent substrate 
(Pierce, Rockford, IL, USA, Cat # 34076) and emitted light was captured using the Kodak 
Gel Logic 440 image station with multiple exposures. A nitrocellulose membrane 
(Invitrogen, Carlsbad, CA, USA, Cat # 645239) spotted with diluted purified IgE, then 
blocked with 5% NFDM in PBST and incubated with the secondary antibody and 
substrate similarly to the immunoblots was exposed along with the immunoblots to help 
evaluate signal strength across samples.  
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IgE ELISA  
IgE ELISA was performed in Study 1 and 3. For each study, an equal protein pool of 
the transgenic, near-isoline and three commercial lines were used to coat ELISA plates as 
a solid phase antigen. For Study 1, equal volumes of six sera (714, 716, 719, 721, RG 
LEG 118 and 297) and one-half volumes of two sera (715 and RE LEG 103) were pooled 
and a pool of six non-soybean allergic human samples (Appendix B) was used as the 
negative control. For Study 3, samples of sera CC 10, 9735-RE and 20197-BH were added 
in equal volumes and serum of subject 19392-CS was added at one-quarter volume. A 
pool of 4 non-soybean allergic human samples was used as the negative control. Sera of 
subjects chosen for the pool were previously characterized and selected for diverse 
qualitative protein IgE binding patterns by 1D-immunoblotting and were adjusted in 
volume based on direct IgE binding to soybean in the direct ELISA to provide a relative 
balanced pool where no individual dominated soybean-specific IgE binding. For the 
inhibition ELISA, a standard inhibition curve was generated using the same soybean pool 
as the inhibitor that was used to coat the plates, but with six different concentrations of 
protein used in replicate sample wells with a fixed volume of pooled soy allergic sera. 
Similar inhibition curves were produced for each individual soybean line extract using 
equivalent concentrations of protein from individual soybean samples to generate line-
specific inhibition curves. For inhibition, the wells of a microtiter plate were coated with 
100 µl of the soybean pool diluted with pH 10 carbonate-bicarbonate buffer (10 µg 
protein/ml) and incubated overnight at 4
o
C. The plate was washed four times with 300 µl 
of PBST and then blocked with 100 µl of 1% BSA in PBST for 1 hour at 37
o
C. For direct 
binding ELISA, individual soybean allergic sera and control sera were diluted 1:20 (v:v) 
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with 1% BSA in PBS and allowed to incubate in tubes with the blocking buffer at room 
temperature for 1 hour to absorb any BSA-specific IgE. After one hour, 100 µl of the 
diluted sera was added to triplicate wells and incubated at 37
o
C for 2 hours prior to 
washing and detection. For inhibition ELISA, serially diluted soybean extracts were added 
to and mixed with diluted serum pool (1:5 v:v) in micro-centrifuge tubes to achieve final 
concentrations of inhibitor at: 0, 0.04, 0.2, 1, 5, 25 or 125 µg soybean protein per 100 µl 
solution (per well). These were held at room temperature for two hours to allow IgE 
binding to soluble soybean inhibitor proteins before adding the mixture to pre-determined 
wells of the ELISA plate. Duplicate dilution series were prepared for each soybean sample 
(standard pool and each soybean line). After rinsing the blocked wells once with PBST, 
100 µl of pooled soy allergic sera and sera-inhibitor mixture samples from duplicate 
dilutions were added to the wells. Control wells that did not receive diluted soybean serum 
included wells without serum and positive (e.g. peanut coated wells with peanut serum) 
and negative control serum samples (soybean coated wells, received sera from those 
without soybean allergy) added to three replicate wells, respectively. The plates were then 
incubated at 37
o
C for 2 hours to allow IgE binding. For both the direct and inhibition 
ELISA, the wells after sera incubation were washed four times with 300 µl of PBST and 
incubated with 100 µl of 1:5000 dilution of HRP conjugated mouse monoclonal 
antihuman IgE in blocking solution for 1 hour at 37
o
C. After another wash step, 100 µl of 
3,3′,5,5′-tetramethylbenzidine (TMB) substrate (Sigma-Aldrich, St. Louis, MO, USA, Cat 
# T0440) was added to each well and incubated for 20 min in the dark. The reactions were 
stopped after 20 min by adding 100 µl of 1 N sulfuric acid to the wells. The absorbance 
values were measured at 450 nm using a BioTek PowerWave XS2 microplate reader 
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(Winooski, VT, USA). The inhibition ELISA experiments were repeated two more times 
on different days for a total of 3 replicates per study. 
Statistical analysis 
For each study the data of dose of inhibitor and absorbance reading of each well were 
compiled and calculations completed using Microsoft Office Excel 2007 (Microsoft, 
Seattle, WA, USA). Individual inhibition lines were constructed for each standard and 
sample set. The soybean concentration inhibitor dose that resulted in 50% inhibition of 
maximum binding values (EC50) were calculated for comparison of relative IgE binding 
values by using a logistic response model to fit the inhibition values for each replicate of 
each soybean sample (standard pool and five lines) using regression analysis. In 
determining the relative concentration of IgE binding proteins in the extracts, the mean 
EC50 values and standard deviations were calculated from the three replicate values for 
each soybean sample (standard pool and each line). In order to compare samples from 
individual soybean lines with respect to EC50 values, an unbalanced one-way ANOVA 
was carried out on the means for individual lines (omitting the standard pool). Three 
types of lines (transgenic, near-isoline and commercial) were compared in the ANOVA, 
and the Error Mean Square was calculated as the variation among the commercial lines. 
This Error variance can be interpreted as an estimate of variation in a reference 
population of conventional lines. The transgenic lines were compared to the near-isolines 
and also to the mean of the commercial lines, using this measure of variability as error. 
The GLM Procedure of SAS (version 9.1) was used for the analysis, and a 95% level 
(p<0.05) was chosen for significance.   
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RESULTS 
Samples 
All powdered soybean flour samples were extracted as described in the Materials and 
Methods. The average protein content of the sample extracts ranged from 7.4 mg/ml to 
17.8 mg/ml for PBS extracted samples and from 8.1 mg/ml to 11.6 mg/ml for 
TCA/acetone precipitated samples. With 1D-PAGE, no obvious qualitative differences in 
protein expression among the transgenic, near-isoline and the commercial lines were 
found in Coomassie stained gels for proteins separated under either reducing or non-
reducing conditions for any of the three transgenic soybean lines (Figures 1A, 1B and 
1C). However, some minor intensity differences were observed in specific band between 
individual soybean lines. Similarly with the 2D-PAGE, only minor qualitative differences 
in protein expression were observed among the transgenic, near-isoline and the 
commercial lines as demonstrated by Coomassie staining of protein (Figures 2A, 2B). 
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Figure 1A. 1D-PAGE gel of soybean and control extracts under reducing and non-
reducing conditions for transgenic line I. Proteins separated were stained with Brilliant 
Blue G-colloidal stain following electrophoresis.   
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Figure 1B. 1D PAGE gel of soybean and control extracts under reducing and non-
reducing conditions for transgenic soybean line II. Proteins separated were stained 
with Brilliant Blue G-colloidal stain following electrophoresis. 
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Figure 1C. 1D PAGE gel of soybean and control extracts under reducing and non-
reducing conditions for transgenic soybean line III. Proteins separated were stained 
with Brilliant Blue G-colloidal stain following electrophoresis.  
 
 
10
15
20
25
37
50
75
100
150 
250
5
2
1      2     3     4     5      6    7     8     9    10  11   12   13
MW (kDa)
Reduced
10
15
20
25
37
50
75
100
150 
250
5
2
1      2      3     4     5      6     7     8      9    10   11   12   13
MW (kDa)
Non-reduced
67 
 
 
Figure 2A.  2D-PAGE gel of transgenic soybean line I, near-isoline and two 
commercial lines. 25 µg of protein were separated first according to their isoelectric 
points and then according to their size. Proteins separated were stained with Brilliant 
Blue G-colloidal stain following electrophoresis. 
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Figure 2B.  2D PAGE gel of transgenic soybean line II, its near isoline and two 
commercial lines. 25 µg of protein were separated first according to their isoelectric 
points and then according to their size. Proteins separated were stained with Brilliant 
Blue G-colloidal stain following electrophoresis. 
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Qualitative comparison of IgE binding by 1D-immunoblot 
Protein samples of extracts of the three transgenic soybean lines, their near-isolines and 
the commercial lines supplied by study sponsors were separated by 1D-PAGE and 
subsequently transferred to PVDF membranes for immunoblotting. Control IgE dot blots 
were incubated with the same diluted anti-IgE and exposed along with the immunoblots 
to provide an indication of the relative exposure time and sensitivity. Figure 3 shows the 
IgE binding pattern of nine individual serum samples with transgenic soybean line I, 
near-isoline and other commercial lines. As described here, the IgE binding patterns 
differ between the reducing and non-reducing conditions for some of the subjects. 
Immunoblotting with serum 715 provides a good illustration of the difference in binding 
patterns under reducing and non-reducing conditions (Figure 3). Importantly for every 
subject there was from one to a few dominant IgE binding bands; however, typically 
there were also a few minor, less intense bands. No clear differences were noted in IgE 
binding to proteins of the transgenic soybean line I (lane 2) compared to the near-isoline 
(lane 1) using sera from nine soybean allergic subjects. Qualitatively, IgE binding to 
commercial soybean lines 1 (lane 3) and 2 (lane 4) did show a few differences, although 
primarily in relative band intensities (e.g. serum 714, reducing condition). In four out of 
nine sera, a minor IgE binding band was only visible in one commercial line (commercial 
line 2) under reducing condition (the low MW band in lane 4 with sera 719, 721, 716, 
714). Further a clear IgE binding band was visible at approximately 60 kDa in the 
transgenic (lane 2), near-isoline (lane 1) and commercial line 3 (lane 5) but not in 
commercial line 1 and 2 (lane 3 and 4) under both reducing and non-reducing condition 
for sera RG LEG 118.   
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Figure 3. IgE immunoblots of transgenic soybean line I, near-isoline and commercial line 1, 2 and 3 separated by reducing and 
non-reducing SDS PAGE with nine soybean allergic sera. Lane 1, near-isoline; Lane 2, transgenic line I; Lane 3, commercial line 
1; Lane 4, commercial line 2; Lane 5, commercial line 3; Lane 6, empty; Lane 7, navy bean; Lane 8, empty; Lane 9, peanut; Lane 10, 
empty; Lane 11, corn; Lane 12, molecular weight marker (reduced) and empty (non-reduced); Lane 13; molecular weight marker 
(non-reduced).  
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Figure 4. IgE immunoblot of transgenic soybean line II, near-isoline and commercial lines 4, 5 and 6 separated by reducing 
and non-reducing SDS PAGE with 9 soybean allergic sera. Lane 1, near-isoline; Lane 2, transgenic line II; Lane 3, commercial line 
4; Lane 4, commercial line 5; Lane 5, commercial line 6; Lane 6, empty; Lane 7, molecular weight marker; Lane 8, empty; Lane 9, 
navy bean; Lane 10, empty; Lane 11, peanut; Lane 12, empty; Lane 13, corn. 
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Figure 5. IgE immunoblot of transgenic soybean line III, near-isoline and commercial lines 4, 5 and 6 separated by reducing 
and non-reducing SDS PAGE with 8 soybean allergic sera. Lane 1, transgenic line III; Lane 2, near-isoline; Lane 3, commercial 
line 4; Lane 4, commercial line 5; Lane 5, commercial line 6; Lane 6, empty; Lane 7, molecular weight marker; Lane 8, empty; Lane 
9, navy bean; Lane 10, empty; Lane 11, peanut; Lane 12, empty; Lane 13, corn.
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Figure 4 shows the immunoblots of transgenic soybean line II, its near-isoline and three 
commercial lines (4, 5 and 6) with nine individual soybean allergic serum samples. 
Similar to transgenic line I, the IgE binding patterns differed in the apparent molecular 
masses between reducing and non-reducing gels (e.g. serum 22206-DL, reducing gels 
showed two major bands at 35 and 40 compared to four or five bands from 16 to 120 kDa 
in non-reducing gels). This would be expected for some bound proteins contain intra- or 
inter-peptide disulfide bonds, or comprise of two or more subunits that were joined by a 
disulfide bridge. For example, glycinin includes a basic and an acid subunit joined by a 
single disulfide bond. Running the gels under reducing condition results in separation of 
those subunits and some subjects would be expected to bind IgE to one or both subunits 
migrating at lower molecular weight (MW) than in non-reducing gels. The patterns of 
IgE binding did not differ noticeably between the transgenic (lane 2), near-isoline (lane 
1) and non-transgenic commercial lines (lane 3, 4 and 5), but for subjects that also had 
notable IgE binding to bands at approximately 30-35 kDa in navy bean (lane 9), an 
additional high intensity band was evident 40 kDa in reducing and 37 kDa and 70 kDa in 
non-reducing gels (likely cross-reactive carbohydrate (CCD) epitope) for the commercial 
line 4 (Figure 4, lane 3, serum samples 18534-LN, 17006-RM, 22329-JE, 22206-DL, 
20770-MH, 9735-RE).  
With the transgenic line III, the IgE binding pattern differed remarkably between 
some subjects (Figure 5). The IgE from subject CC10 showed a single dominant band at 
about 15 kDa, which is likely to represent Gly m 4, the Bet v 1 homologue in soybeans. 
In addition, in the non-reducing blot, there is a significant signal at 75 kDa only in 
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commercial line 4 (lane 3). That pattern is markedly different than the pattern for subject 
19392-CS, which appears to have the highest level of binding and the most diverse band 
pattern. No clear differences were noted in IgE binding to proteins of the transgenic 
soybean line III (lane 1) compared to its non-transgenic counterpart (lane 2) using sera 
from eight soybean allergic subjects tested here (Figure 5). However, commercial line 4 
did show differences in IgE binding mostly under the non-reducing condition, which was 
observed in five out of eight sera tested (Figure 5, lane 3, serum CC 08, CC 04, CC 03, 
CC 10, CC 15). All of these sera that showed intense binding to the high molecular 
weight protein in commercial soybean line 4 also showed IgE binding to navy bean 
extract (lane 9) at a position that likely represents the lectin phytohemagluttinin (PHA) 
and may involve CCD binding. 
Qualitative comparison of IgE binding by 2D-immunoblot 
Protein samples of extracts of transgenic soybean line I and II, their near-isolines and two 
commercial lines (2 and 3 for transgenic line I, 4 and 5 for transgenic line II) were 
separated by 2D-PAGE and subsequently transferred to PVDF membrane for 
immunoblotting with individual soybean allergic sera (Figures 6, 7, 8, 9). The individual 
serum samples are indicated in the Figures and the spots showing IgE binding have been 
circled and numbered. IgE binding was observed to a number of spots for all of the four 
soybean samples with all individual soybean allergic sera. For the transgenic soybean line 
I (Figures 6, 7), the IgE binding patterns were similar for the transgenic and near-isoline 
for all the subjects. Commercial line 3 also showed similar IgE binding patterns as the 
transgenic and near-isoline for all the subjects. However, commercial line 2 showed some 
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additional IgE binding spots or absence of some common spots compared to the other 
three soybean lines with four out of eight soybean allergic sera (Spot # 18 and 19 in 
Figure 6A, Spot # 22 and 23 in Figure 6B, Spot # 21 and absence of spot 20 in Figure 6C 
and spot # 17 and 19 and absence of spot 4 in Figure 6D). For the transgenic soybean line 
II (Figures 8, 9), a number of differences were observed in the 2D IgE binding pattern 
among the four lines with some serum samples. For example, with serum 18534-LN 
(Figure 8B) an extra IgE binding spot (spot #7) was observed only with the near-isoline. 
Similarly with six out of ten serum samples including 20770-MH (Figure 8A, spot # 6), 
18534-LN (Figure 8B, spot # 6), 22329-JE (Figure 8D, spot # 5), 17006-RM (Figure 9F, 
spot # 5), 22206-DL (Figure 9G, spot # 4), 9735-RE (Figure 9H, spot # 4), IgE binding to 
commercial line 4 included strong binding to an acidic spot at approximately 45 kDa that 
was not present in the other three extracts. The same sera showed IgE binding to bands at 
approximately 30-35 kDa with navy bean (Figure 4, lane 9) in 1D-immunoblots, which is 
likely due to CCD binding. In addition, with serum 20197-BH (Figure 8C), two 
associated light spots were present in the transgenic soybean while not visible in the near-
isoline (spot #11). However, these spots were present in both of the commercial lines, 
which also showed several differences with the same serum compared to the transgenic 
and the near-isoline. For example, the absence of spot # 1 and presence of two low-
intensity additional spots (Spot # 14 and 15) in commercial line 4 and 5 (Figure 8C). 
With serum from subject 22329-JE (Figure 8D), an apparent IgE binding spot was only 
visible in the transgenic line (spot # 2) while not visible in the three non-transgenic 
soybean lines. The serum from the same subject also demonstrated intense IgE binding to 
the likely CCD epitope in commercial line 4 (Spot # 5). 
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Figure 6. 2D-PAGE immunoblots of transgenic soybean line I, near-isoline and 
commercial lines 2 and 3 using individual soy allergic sera RG LEG 103 (figure 6A), 
19392-CS (figure 6B), 714 (Figure 6C) and 297 (Figure 6D). Figure demonstrates 
additional spots that were only visible in commercial line 2 (Spot # 18 and 19 in Figure 
6A, Spot # 22 and 23 in Figure 6B, Spot # 21 and absence of spot 20 in Figure 6C and 
spot # 17 and 19 and absence of spot 4 in Figure 6D). 
 
 
 
 
MW (KDa)
MW (KDa)
10
15
20
25
37
50
75
100
150
250
PI = 3 PI = 10Commercial 3
1
2
3
4
5
6
7
8 9
10
ng IgE/spot102 101 1          10-1 10-2   10-3
PI = 3 PI = 10Commercial 2
1
2
3 4
519
7
8 9 10
18
6
PI = 3 PI = 10Isoline
1
23 4
56
7
8 9 10
10
15
20
25
37
50
75
100
150
250
PI = 3 PI = 10Transgenic
1
23 4
56
7
8 9 10
A (RG LEG 103)
Commercial 3
5
MW (KDa)
MW (KDa)
10
15
20
25
37
50
75
100
150
250
PI = 3 PI = 10
1
2
3
ng IgE/spot102 101 1        10-1 10-2   10-3
10
15
20
25
37
50
75
100
150
250
TransgenicPI = 3 PI = 10
1
2
3
5
1
2
3
5
IsolinePI = 3 PI = 10
PI = 3 PI = 10
1
2
3
5
22
23
Commercial 2
B (19392-CS)
MW (KDa)
MW (KDa)
ng IgE/spot102 101 1        10-1 10-2   10-3
PI = 3 PI = 10Isoline
8 12
1020
13
10
15
20
25
37
50
75
100
150
250
PI = 3 PI = 10Transgenic
8 12
1020
13
10
15
20
25
37
50
75
100
150
250
PI = 3 PI = 10Commercial 3
8
12
1020
13
PI = 3 PI = 10Commercial 2
8 12
10
13
21
C (714)
MW (KDa)
MW (KDa)
ng IgE/spot102 101 1        10-1 10-2   10-3
10
15
20
25
37
50
75
100
150
250
PI = 3 PI = 10Transgenic
1
2
5
7
8
1013
4
PI = 3 PI = 10Isoline
1
2
5
7
8
1013
4
PI = 3 PI = 10Commercial 2
1
2
5
7
8 1013
19
17
10
15
20
25
37
50
75
100
150
250
PI = 3 PI = 10Commercial 3
1
2
5
7
8
1013
4
D (297)
77 
 
 
Figure 7. 2D-PAGE immunoblots of transgenic soybean line I, near-isoline and 
commercial lines 2 and 3 using individual soy allergic sera RG LEG 105 (figure 7E), 
715 (figure 7F), 716 (Figure 7G) and 721 (Figure 7H).  
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Figure 8. 2D-PAGE immunoblots of transgenic soybean line II, near-isoline and 
commercial lines 4 and 5 using individual soy allergic sera 20770-MH (Figure 8A), 
18534-LN (Figure 8B), 20197-BH (Figure 8C) and 22329-JE (Figure 8D). Figure 
demonstrates additional IgE binding spot at approximately 45 kDa for commercial line 4 
(Figure 8A, spot # 6; Figure 8B, spot # 6; Figure 8D, spot # 5). 
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Figure 9. 2D-PAGE immunoblots of transgenic soybean line II, near-isoline and 
commercial lines 4 and 5 using individual soy allergic sera 19392-CS (Figure 9E), 
117006-RM (Figure 9F), 22206-DL (Figure 8G) and 9735-RE (Figure 9H). Figure 
demonstrates additional IgE binding spot at approximately 45 kDa for commercial line 4  
(Figure 9F, spot # 5; Figure 9G, spot # 4; Figure 9H, spot # 4).  
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IgE inhibition ELISA assay 
In order to select soybean allergic sera for IgE inhibition, each individual serum sample 
was tested for IgE binding to non-denatured soybean proteins using direct binding to 
pooled soybean extract (pool of the transgenic, isoline and commercial lines) by ELISA 
(results not shown). Based on the direct ELISA results a serum pool was made, which 
was utilized in the inhibition ELISA to provide standard inhibition curves. The means 
across replicates for inhibition are plotted in Figure 10 for transgenic soybean line I and 
Figure 11 for transgenic soybean line III. The study sponsor did not want an ELISA 
inhibition assay for transgenic soybean line II. The fit of the linear regression lines was 
accurate for each replicate of each sample with r
2
 ≥ 0.96 for each regression (data not 
shown). For the study with transgenic soybean line I, commercial line 3 had slightly more 
inhibiting capacity at all concentrations than all other soybean lines (Figure 10). For the 
transgenic soybean line III, the most noticeable difference between samples in the graph 
is the decrease in inhibition at high inhibitor concentrations for commercial line 4 and to 
a lesser extent for the standard pool (Figure 11). The inhibition values between soybean 
lines are so close that it is nearly impossible to distinguish the other individual points and 
lines. 
 The mean EC50 and standard deviation for transgenic soybean line I, near-isoline 
and commercial lines 1, 2 and 3 are shown in Table 1. From Table 1 data there is less 
than a two-fold difference in the EC50 values across the soybean lines, with observed 
potency being greatest for commercial line 3 (EC50 = 3.11 µg/well) and least for 
commercial line 1 (EC50 = 5.39 µg/well). The EC50 values of the transgenic line I and 
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near-isoline were similar (4.31 vs. 4.68 µg/well, respectively; p = 0.846) and fall within 
the range for commercial lines. For the transgenic soybean line III (Table 2), differences 
in the mean EC50 values among the 5 soybean samples were not statistically significant 
when compared to intra-assay error (F = 2.07; P = 0.177). Similarly, genetic variance 
among EC50s for the commercial lines was estimated to be 0 when compared to intra-
assay variance (F = 0.21; P = 0.814). There was less than a two-fold difference in the 
EC50 values across the soybean lines, with observed potency tending to be higher for the 
commercial lines 4, 5 and 6 (EC50 = 0.67, 0.69, 0.75 µg/well respectively) and least for 
the transgenic line III and its non-transgenic counterpart (EC50 = 0.96, 0.88 µg/well 
respectively). The EC50 values of transgenic soybean line III and its near-isoline were 
similar (0.96 vs. 0.88 µg/well, respectively, t = 0.73; P = 0.489). It should be noted that 
the similarity of EC50 values does not reflect the differences seen at higher inhibitor 
concentrations where the results for the commercial line 4 are different from the other 
four samples. 
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Figure 10. Inhibition ELISA IgE binding curves with transgenic soybean I, near-
isoline and commercial lines 1, 2 and 3 compared to a pooled standard soybean 
extract. 
 
 
Figure 11. Inhibition ELISA IgE binding curves with transgenic soybean III, near-
isoline and commercial lines 4, 5 and 6 compared to a pooled standard soybean 
extract. 
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Table 1. IgE Inhibition ELISA EC50 values of transgenic soybean line I, near-isoline and 
commercial lines 1, 2 and 3: Average of 3 Assays. 
 
Sample EC50 (µg/well) Std Dev 
Pooled Soy 
Standard 
3.86 0.45 
Transgenic I 4.68 0.7 
Near-isoline 4.31 0.11 
Commercial 1 5.39 * 0.27 
Commercial 2 4.76 0.35 
Commercial 3 3.11 
@
 0.19 
 
*Significantly different from the Standard Pool, Dunnett, p<0.05 
@ Significantly different than all other soybean lines, Tukey, p<0.05 
 
Table 2. IgE Inhibition ELISA EC50 values of transgenic soybean line III, near-isoline 
and commercial lines 4, 5 and 6: Average of 3 Assays. 
Sample EC50 (µg/well) Std Dev 
Pooled Soy 
Standard 
0.693 0.197 
Near-isoline 0.877 0.320 
Transgenic III 0.969 0.414 
Commercial 4 0.665 0.232 
Commercial 5 0.746 0.140 
Commercial 6 0.693 0.064 
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DISCUSSION 
The Codex Alimentarius Commission guideline for safety assessment of foods derived 
from recombinant-DNA plants (CAC/GL 46-2003, as described in Foods Derived from 
Modern Biotechnology, 2009), states that the composition of the GM plant including key 
toxicants and (endogenous) allergens, whose toxic potency and level may be significant 
to health, should be compared to the composition of the conventional counterpart, 
harvested under similar conditions. If clear differences are found between the transgenic 
and comparator lines, further evaluation of the biological significance of the differences 
would likely be required. It is well known that soybean can cause adverse reactions in 
humans who are allergic to soybeans, and that soybean allergy is much more common in 
infants and young children compared to adults (Savage et al., 2010; Sicherer et al., 2000). 
While common, severe reactions are relatively rare (Sicherer, 2011; Imamura et al., 2008; 
Sicherer and Sampson, 2010; Rolinck-Werninghaus et al., 2012). Several allergenic 
proteins have been recognized in soybean primarily based on their reactivity to IgE 
antibodies from soybean sensitive patients, however, the major seed storage proteins 
(conglycinins and glycinins) seem to be the most important food allergens (Herian et al., 
1990; Holzhauser et al., 2009; Ogawa et al., 1991; Ito et al., 2011). In the current studies, 
potential changes in endogenous allergenicity (IgE binding) of three unrelated transgenic 
soybean lines were evaluated by comparing them to their non-transgenic, near isogenic 
counterpart (near-isoline) as well as other commercial lines of soybeans. Qualitative 
comparison was performed by separating soybean proteins by 1D- and 2D-immunoblots 
and quantitative comparison was done by inhibition ELISA. For 2D-immunoblots, no 
attempt was made to measure the spots quantitatively as such a comparison would require 
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multiple 2D-PAGE blots for each sample to control for technical variance, which was not 
possible due to limited volumes of appropriately sensitized serum donors and the great 
difficulty in recruiting new donors. From the results of the qualitative and quantitative 
analysis of all three transgenic soybean lines, no significant differences in IgE binding, 
which is used as a measure of potential allergenicity, were observed between the 
transgenic soybean lines and their near-isoline comparators. The only clear difference 
found by the qualitative analysis was a low intensity spot in 2D-immunoblot of 
transgenic soybean line II using serum sample 22329-JE (Figure 8D spot # 2). This spot 
was not present in other soybean lines tested with the same serum. This unique spot was a 
minor IgE-binding spot with a low intensity compared to other IgE binding spots found in 
2D-immunoblot with the same sera. This minor difference should not be considered 
biologically significant regarding the allergenicity of transgenic soybean line II, for the 
following reasons: The intensity of this IgE-binding spot is close to the limit of detection, 
compared to the standard IgE dilution; the IgE spot is minor compared to other IgE 
binding spots observed with this serum; finally this difference is observed with only one 
of ten sera tested by immunoblotting. There were no significant differences in IgE 
binding, as measured by ELISA-inhibition, between any of the transgenic soybean lines 
and their corresponding near-isogenic lines.  
The most important finding from these studies was the variation that was 
observed among the non-transgenic commercial lines (both qualitative and quantitative) 
that are already present in market. In the first study with transgenic soybean line I and 
commercial lines 1, 2 and 3, commercial line 2 showed a minor IgE binding band in ID-
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immunoblots with four out of nine sera used (Figure 3). The same commercial line also 
showed differences in IgE binding spot patterns in 2D-immunoblot with four out of eight 
sera used (Figure 6). Furthermore, commercial lines 1 and 2 showed absence of a 50 kDa 
IgE binding band in the 1D-PAGE immunoblot with one soybean allergic serum, which 
was present in the other three soybean lines (Figure 3, serum RG LEG 118). Similarly in 
the study comparing the transgenic soybean line II and the commercial lines 4, 5 and 6, it 
was the commercial line 4 that showed an extra, strong IgE binding band under both 
reducing and non-reducing 1D-immunoblots as well as a corresponding size spot in 2D-
immunoblots from using six out of ten sera (Figure 4, 8, 9). IgE binding to this extra band 
and spot may be due to the presence of a CCD epitope on a protein in commercial line 4 
compared to the other soybeans. However, this hypothesis is merely implied by the 
correlation between the appearance of the extra soybean band and the presence of binding 
to the phytohemagglutinin (PHA) sized bands in the navy bean extract. The CCD 
presence was not verified by mass spectrometry. Further, commercial line 4 also showed 
a downward inhibition trend when used at higher concentrations in the ELISA inhibition 
(Figure 11). This trend might be due to low affinity binding of IgE to high molecular 
weight proteins in commercial line 4, as the IgE bound to soluble inhibitor would be 
expected to release over time at 37°C during incubation with the plate. If the released IgE 
bound to a solid phase antigen, the binding would go up during the longer exposure.  
Taking into account the variation in IgE binding to the soybean commercial lines used in 
these studies it is logical to first establish how much natural variability exists in allergen 
levels from a broad selection of non-transgenic soybean lines consumed by non-soybean-
allergic individuals, before measuring and comparing allergen levels in transgenic lines to 
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their near-isogenic comparator. Without this data, the measurement of allergen levels in 
transgenic lines will not provide an accurate comparison for evaluating crop safety. It is 
important to consider that the amount of allergen required for sensitization is not known. 
It is likely to differ markedly between individuals and between routes of sensitization. 
Other factors are also thought to contribute to sensitization. Thus the consideration 
should be whether the level of allergen should be measured to judge possible differences 
in risk for elicitation of an allergic response. However, it is clear from studies that there 
are significant differences in natural endogenous allergen content of many crops. It is also 
clear that individuals allergic to a given food crop must avoid food derived from that crop 
and that raw material selection does not hinge on the concentration of endogenous 
allergens.  
Differences in expression of proteins in plants could be due to genetic variations 
(e.g. gene mutations), variation produced by epigenetic mechanisms or by environmental 
factors that modulate gene expression, such as exposure to drought or pathogens 
(Jaenisch and Bird, 2003; Ruebelt et al., 2006). Several studies have substantiated the 
effect that the environment and genetics can have on the proteomic profile of plant seeds 
and how it can affect the GM safety assessment data (Batista and Oliveira; Ruebelt et al., 
2006; Zolla et al., 2008). Variation in post translational modification of proteins has also 
been shown to occur among plant varieties (Campbell et al., 2011). Therefore 
information on the natural variability in allergenic protein expression and also the effects 
of processing on the conformation and IgE binding to the proteins are critical in 
designing and correctly interpreting potential biologically relevant changes in 
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endogenous allergens between transgenic and non-transgenic plant varieties (Ruebelt et 
al., 2006).  
In conclusion, considering the natural variation in allergen content observed and 
based on the qualitative and quantitative results in the studies described in this chapter, 
the serum IgE binding pattern to proteins of three transgenic soybean lines evaluated here 
were not substantially different from the IgE binding to proteins in other non-transgenic 
soybean lines. Therefore, these transgenic soybean lines should be considered as safe as 
the non-transgenic soybean lines. The natural variation of allergens has not been 
systematically studied in diverse commercial soybean lines and a limit of acceptable 
variation has not been established. Studies on natural variation in allergens among 
soybean lines grown in different environments are essential to be able to set acceptability 
limits for transgenic crop lines. Furthermore, the importance of these kinds of studies 
should be re-evaluated considering the fact that soybean food products do not pose a risk 
of allergy except for those who are already sensitized to soybean. There are no practical 
risk consequences to large increases in soybean allergen expression, including 3 or more 
fold increases, as those with soybean allergy should be avoiding consumption of all 
soybean foods. 
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APPENDIX A: SOYBEAN ALLERGIC HUMAN SERA USED FOR 
EVALUATING TRANSGENIC SOYBEAN LINE I 
 
Serum # 
Reported food allergies and 
symptoms of past reactions 
Total IgE 
kU/L 
Soy-specific IgE 
(ImmunoCAP
*
 or 
IMMULITE
#
) kU/L 
297 soybean and peanut: anaphylaxis nd soy: 0.8
#
; peanut: 70
#
  
714 soybean: symptoms not specified 
nd 
soy: 15.9
#
; peanut: 
22
#
 
715 soybean: oral, dermal, respiratory; 
peanut: anaphylaxis 
644 soybean: 17.8
*
; 
peanut: 100
*
 
716 soybean: symptoms not specified; 
peanut, no information 
nd soybean: 7.2
#
; 
peanut: 18
#
  
719 soybean and wheat: asthma  1406 soybean: 22
*
; peanut: 
23
*
 
721 soybean: no information; peanut: 
reported but symptoms not 
specified 
14725 soybean: 47
*
; peanut 
44
*
 
RG-LEG-103 soybean: no information; peanut: 
hives, throat swelling  
1032 soybean: 12.2
*
, 1.7
#
; 
peanut: 100
#
 
RG-LEG-105 soybean: oral itch, facial edema, 
breathing difficulty 
1023 soybean: 2.3
*
; 
peanut: 5
*
 
RG-LEG-118 soybean and peanut: hives and 
edema of face, throat and tongue 
915 soybean: 6.6
*
; 
peanut: 100
*
 
19392-CS Angioedema, vomit, EOS G; milk, 
egg, meat, fruit, peaches, pears, 
(?profilin?) 
nd soy: 68
#
; peanut: 15
#
 
 
*
 = Phadia ImmunoCAP® Total and specific IgE as kU/L 
#
 = Siemens IMMULITE® specific IgE as kU/L 
**
 = Total IgE = 644 kU/L (ImmunoCAP) 
 nd= not detected 
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APPENDIX B:  NON-SOYBEAN ALLERGIC CONTROL SERA USED FOR 
EVALUATING TRANSGENIC SOYBEAN LINE I 
Serum # 
Reported food allergies and 
symptoms of past reactions 
Total IgE 
kU/L 
Soy-specific IgE 
(ImmunoCAP or 
IMMULITE) kU/L 
RG-71  allergic to lupin, but no 
symptoms to soybean or peanut 
nd soybean: 1.5
*
; peanut: 1.5
*
 
RG-73 allergic to pea (no claim of 
allergy, but weak skin test 
positive to peanut and soy) 
nd Soybean: 0.7
*
; peanut: 15
*
 
RG-74 allergic to lupin, oral symptoms 
to peanut, no symptoms to 
soybean 
nd soybean: nd; peanut <0.35
*
 
SNP no known allergies nd Nd 
RS-ID-1 Asthma nd soybean: nd; German 
cockroach 31
*
 
RS-ID-3 Asthma nd soybean: nd; German 
cockroach 42
*
 
nd = not determined 
 
*
 = Phadia ImmunoCAP® Total and specific IgE as kU/L 
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APPENDIX C: SOYBEAN ALLERGIC HUMAN SERA USED FOR 
EVALUATING TRANSGENIC SOYBEAN LINE II 
Serum 
number 
Gender; 
Age 
(years) 
Reported food allergies 
and symptoms of past 
reactions 
Soybean-
specific IgE 
(ImmunoCAP
*
 
or 
IMMULITE
#
) 
kU/L 
Peanut-
specific IgE 
(ImmunoCAP
*
 or 
IMMULITE
#
) 
kU/L 
17006-RM Male; 48 Soybean: no information; 
peanut: no information 
7.8
*
 Nd 
22206-DL Female; 
29 
Nuts, beans and seeds 7.8
*
 Nd 
18534-LN Female; 
52 
Nuts, beans and seeds 17.3
* 
 
715 Male; 19 Soybean: oral, dermal, 
respiratory; peanut: 
anaphylaxis
**
 
17.8
*
  100
*
 
716 Male; 29 Soybean: symptoms not 
specified; peanut, no 
information 
7.2
#
  18
#
 
9735-RE Male: 58 Anaphylaxis to peanut, 
soybean, causes sore 
throat, itchy mouth, 
queasy stomach 
5
*
  58
*
 
20197-BH Male; 39 Itchy throat with nuts and 
raw veggies 
 3
*
  95
*
 
19392-CS Male; 40 Nuts, beans and seeds  71.6
*
 Nd 
22329-JE Male; 25 No recorded history  8.6
*
 Nd 
20770-MH Male; 26 Nuts, beans and seeds; 
soybean; peanut: causes 
throat closes 
 16.4
*
 Nd 
*
 = Phadia ImmunoCAP® Total and specific IgE as kU/L 
#
 = Siemens IMMULITE® specific IgE as kU/L 
**
 = Total IgE = 644 kU/L (ImmunoCAP) 
 nd= not detected 
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APPENDIX D: NON-SOYBEAN ALLERGIC CONTROL SERA USED FOR 
EVALUATING TRANSGENIC SOYBEAN LINE II 
Serum 
number 
Reported food allergies and 
symptoms of past reactions 
Soybean-
specific IgE 
(ImmunoCAP
*
) kU/L 
Peanut-specific 
IgE 
(ImmunoCAP
*
) 
kU/L 
RG-71 Allergic to lupin, but no 
symptoms to soybean or peanut 
1.5
*
 1.5
*
 
RG-73 Allergic to pea (no claim of 
allergy, but weak skin test positive 
to peanut and soy) 
0.7
*
  15
*
 
RG-74 Allergic to lupin, oral symptoms 
to peanut, no symptoms to 
soybean 
nd  <0.35
*
 
SNP No known allergies nd Nd 
 
nd = not determined 
 
*
 = Phadia ImmunoCAP® Total and specific IgE as kU/L 
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APPENDIX E: SOYBEAN ALLERGIC HUMAN SERA USED FOR 
EVALUATING TRANSGENIC SOYBEAN LINE III 
Serum 
number 
Gender; 
Age 
(years) 
Reported food allergies and 
symptoms 
Soybean-
specific IgE 
Immuno-
CAP
TM
 
kU/L 
Peanut-
specific 
IgE 
Immuno-
CAP
TM
 
kU/L 
9735-
RE 
Male: 58 Anaphylaxis to peanut, soybean, 
causes sore throat, itchy mouth, 
queasy stomach 
5 58 
20197-
BH 
Male; 39 Itchy throat with nuts and raw 
veggies 
3 95 
19392-
CS 
Male; 40 Nuts, beans and seeds 71.6 Nd 
CC 10 Female; 
44 
Peanut (a, b), Soybean (a,b,d), 
Milk (a,b,c), Almond (a), Walnut 
(a), Hazelnut (a,b,d), Celery root 
(a), Anaphylaxis with hazelnut.  
Food challenge positive to soybean 
hazelnut and celery. Positive skin 
prick test to soybean. 
6.7 18.9 
CC 03 Male; 45 Peanut (a,d), Soybean (a,d), Fish 
(a,d,b,c,e), Walnut (a,d), Hazelnut 
(a), Pepper(a,b), Anaphylaxis to 
fish. Food challenge positive to 
soybean and peanut. Skin prick test 
positive to soybean, birch pollen, 
grass and hazelnut. 
1.2 21.5 
CC 04 Female; 
44 
Peanut (a,b,c,d,e), Soybean (b,d,e), 
Almond (a,b,c,d), Walnut (a,b,c,d), 
Hazelnut (a,b,c,d,e), Celery root 
(a,b,c,d).  Food challenge positive 
to soybean.  Skin prick test 
0.6 1.9 
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positive to soybean, birch, 
housedust mite, grass. 
CC 08 Female; 
32 
Peanut (d), Soybean (a,c), almond, 
walnut, hazelnut (a,c), celery root 
(a,c).  Food challenge positive to 
soybean, negative to hazelnut and 
celery.  Skin prick test positive to 
soybean, peanut, hazelnut and 
celery. 
1.1 2.1 
CC 15 Male; 42 Lentil (a), Peanut (a,c), Soybean 
(a), Almond (a).  Food challenge 
positive to soybean and peanut.  
Skin prick test positive to soybean 
and peanut. 
1.1 84.6 
 
TM=Trademark of Phadia, Uppsala, Sweden 
nd = not done 
Symptoms:  a: Mouth (lip swelling, itching, swollen tongue, swelling of throat);  b: Skin 
(itching, hives, eczema);  c: Gastrointestinal tract (abdominal cramping, vomiting, 
diarrhea, flatulence); d: Lower respiratory tract (coughing, wheezing, severe chest 
tightening/difficulty breathing;  e: Systemic anaphylaxis, requiring epinephrine or 
emergency room care. 
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APPENDIX F: NON-SOYBEAN ALLERGIC CONTROL SERA USED FOR 
EVALUATING TRANSGENIC SOYBEAN LINE III 
Serum 
numbe
r 
 
Gender; 
Age 
(years) 
Reported food allergies and 
symptoms of past reactions 
Soybean-
specific IgE 
(Immuno 
CAP) kU/L 
Peanut-
specific IgE 
(Immuno 
CAP) kU/L 
CC 11 Female; 
27 
Green pea (a), carrot (a), 
almond(a), walnut (a), Hazelnut 
(a,b), peach, cherry, kiwi (a).  
Food challenge positive to 
hazelnut, celery and carrot.  Skin 
prick test positive to hazelnut, 
carrot and grass pollen. 
0.1 0.4 
CC 12 Female; 
58 
Peanut (a,b), carrot (a,d,b), 
almond (a,d,b), walnut and 
hazelnut (a,d,b), celery(a) , 
anaphylaxis (strawberry).  Food 
challenge positive to hazelnut 
and carrot.  Skin prick test 
positive to hazelnut, carrot, 
celery and birch pollen. 
0.1 0.6 
CC 16 Female; 
23 
Carrot (a,b), hazelnut (a,b), apple 
(a).  Food challenge positive to 
hazelnut.  Skin prick test positive 
to hazelnut, carrot and birch 
pollen. 
0.04 0.1 
SNP  No known allergies Nd  
 
Symptoms: a: Mouth (lip swelling, itching, swollen tongue, swelling of throat), b: Skin 
(itching, hives, eczema), c: Gastrointestinal tract (abdominal cramping, vomiting, 
diarrhea, flatulence), d: Lower respiratory tract (coughing, wheezing, severe chest 
tightening/difficulty breathing, e: Systemic anaphylaxis, requiring epinephrine or 
emergency room care. 
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CHAPTER 3: THE EFFECT OF HEAT PROCESSING ON SOYBEAN 
ALLERGENICITY 
 
 
INTRODUCTION 
 Processed fractions of soybean protein including soy flour, soy protein concentrate 
(SPC) and soy protein isolates (SPI) are widely used in processed foods because of their 
nutritional value and functionality. Processed soybean ingredients are used in various 
baked products, meat products and dairy products to provide specific functional 
properties such as improved texture, moisture and fat retention, foaming properties and 
emulsification (Klein et al., 1995; Lusas and Riaz, 1995; Singh et al., 2008). Thermal 
processing of soy based food ingredients is commonly used to inactivate anti-nutritional 
components including trypsin inhibitors, improve protein digestibility and impart 
characteristic flavors to products (Amigo-Benavent et al., 2008). Heat processing has also 
been used to improve or gain certain functional properties as well as to reduce the 
allergenic activity of soy-based food products (Anderson and Wolf, 1995; Lusas and 
Riaz, 1995; Sorgentini et al. 1995; L’Hocine and Boye, 2007). However, very few studies 
have systematically investigated the effect of heat processing on the allergenicity of soy 
flour or individual soy proteins (Burks et al., 1992; Shibasaki et al., 1980; Muller et al., 
1998). In these studies, the allergenicity of soybean proteins has been interpreted based 
on in vitro IgE binding using soy allergic sera. IgE binding against allergenic structures 
does not correlate well with the expression of clinical symptoms which may be due to the 
presence of cross-reactive carbohydrate determinants, which may be bound by IgE with 
low affinity binding, the presence of only one IgE binding epitope, or ineffective spatial 
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orientation of the IgE epitopes. Positive IgE binding detected by in vitro IgE binding tests 
should be evaluated further for clinical relevance (Ladics et al., 2008). The study 
conducted by Burks et al., (1992) has used a pool of sera to investigate changes in IgE 
binding after soybean processing. Using pooled sera may not be a proper method to 
investigate reduction in allergenicity as there is a chance that one highly sensitive allergic 
serum in the pool may dominate the others and the result seen may be representation of 
binding by that one dominant individual. Further a low levels of IgE against some 
epitopes found in one serum sample may get diluted by other sera in the pool. Heat 
treatment can cause unfolding of proteins, exposing hydrophobic and sulfhydryl groups 
located in the interior of the molecule, which can result in irreversible protein 
aggregation, thus leading to a decrease in solubility (Renkema et al., 2000). However, the 
extractability of soybean proteins following heat treatment has not been performed in 
studies claiming to evaluate potential reduction in allergenicity. The proteins of heat 
treated materials in most studies have only been measured by extraction under very mild 
conditions (e.g. phosphate buffered saline [PBS], pH 7.4, low salt). It is possible that 
most of the reduction of IgE binding previously reported following heat treatment of 
soybean ingredients is simply due to protein aggregation and insolubility. If so, soybean 
products that are heat treated may not have easily extractable and detectable allergens, 
but would still contain the insoluble allergens that could cause allergic reactions if the 
solid food is ingested. 
In this study, soybean samples heat treated under different conditions were 
evaluated for IgE binding by extracting the proteins using a variety of extraction buffers 
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for testing by immunoblotting to maximize protein solubilization for a more complete 
evaluation of potential allergenicity compared to extraction in simple PBS. The 
allergenicity was evaluated by IgE immunoblot using individual soybean allergic serum 
samples. In addition, a basophil mediator release assay was performed to further evaluate 
the potential biological relevance of any IgE binding detected by immunoblotting. The 
results of this study provide additional information on potential changes in the 
allergenicity of various heat treatments of soybean ingredients performed to alter their 
potential risk for soybean allergic consumers.  
MATERIALS AND METHODS 
Human sera 
Historical serum samples collected from consenting soybean allergic and non-soybean 
allergic human subjects collected under Institutional Review Board oversight at various 
clinical institutions were used in this study. Additional serum samples procured from 
PlasmaLab International, a U.S. FDA approved facility, were used in this study. The 
University of Nebraska Institutional Review Board approved the use of these samples in 
these and similar studies (reviewed and approved for Goodman laboratory). Samples 
from eight soybean allergic subjects and one control subject without soybean allergy 
were used in this study (Table 1). The allergic patients utilized in this study had soybean 
specific IgE level ranging from 3-68 kU/L as measured by ImmunoCAP® or 
IMMULITE® systems. Most of the soybean allergic subjects also had peanut specific 
allergic reactions and significant peanut specific IgE levels ranging from 15 to100 kU/L. 
The control subject used in this study has no reported food allergies. 
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Table 1. Soybean allergic and control sera used to evaluate heat treated soybean products 
nd- not detected 
 
Serum  Reported food allergies 
Soybean-specific 
IgE 
(ImmunoCAP 
Peanut-specific 
IgE 
(ImmunoCAP 
18534-LN Nuts, beans and seeds 17.30 nd 
9735-RE Anaphylaxis to peanut, 
soybean, causes sore throat, 
itchy mouth, queasy stomach 
5  58 
20197-BH Itchy throat with nuts and raw 
veggies 
 3  95 
19392-CS Angioedema, vomit, EOS G; 
milk, egg, meat, fruit, peaches, 
pears, (?profilin?) 
68 15 
20770-MH Throat swelling with peanut  38 43 
24033/20431 Peas, peanut, soy, lentil, sulfur 
drugs, garbanzo beans; 
anaphylactic shock from 
peanut, eczema, hives 
Nd nd 
23736-AM/20300 all trees, grass, peanuts, cats, 
rabbits 
15.3 >100 
20247-LA/20160 buckwheat, rice, rye, celery, 
lettuce, orange, crab, parsley, 
tomato, almond, coconut, 
peanut, pecan, sesame, corn, 
pea, whitebean, carrot, potato, 
wheat, oat, soybean 
14.9 15.6 
Control serum 
(RP) 
No known allergies Nd nd 
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Heat processing of soybean samples 
Three different heat treatment conditions were used in this study. Soybean flour dispersed 
in PBS was treated under various temperature and time combination; soybean seeds were 
dry roasted or oil roasted prior to extraction. Raw (unprocessed) Vinton 81 soybean seeds 
were used in the study. For heat processing of soybean flour, soybean seeds were ground 
to a fine powder in a SPEX CertiPrep 6850 freezer mill under liquid nitrogen, to make 
full fat flour. The soybean flour samples were dispersed in 0.01M PBS, pH 7.4 at 
concentrations of 5% and 50% w/v. The dispersed samples were incubated at 80
o
C and 
100
o
C in a water bath for 15, 30, 60 or 120 min. The samples were then cooled 
immediately and centrifuged using an Eppendorf centrifuge 5810R at 10,000 x g for 30 
min at 4
o
C to separate insoluble and aggregated material from soluble material. After 
centrifugation any supernatant (cooking water) obtained was stored at ¬20
o
C until further 
analysis. The pellets were thawed at room temperature and extracted (1:10 or 1:5 w/v) 
using different extraction buffers. Dry and oil roasting of soybean seeds were performed 
according to the method described by Boge et al. (2009). Raw Vinton 81 soybean seeds 
were soaked in distilled water (1:3 w/v) for 20 hours at 4
o
C. The water left from soaking 
of the soybeans (soaking water) was stored at -20
o
C for further analysis to measure 
leached proteins. The soaked soybean samples were then dry roasted in a conventional 
oven at 171
o
C (340
o
F) for 30, 60 or 90 min or they were roasted in canola oil at 171
o
C 
(340
o
F) for 2, 5 or 8 min. After dry or oil roasting, the soybean seed samples were ground 
in a freezer mill under liquid nitrogen and were then extracted with specific extraction 
buffers detailed below. 
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 Eight different extraction buffers were used to extract soybean proteins after 
processing. The extraction buffers used were, 1) 0.01M PBS, pH 7.4, 2) 0.01M PBS with 
0.5M NaCl, pH 7.4, 3) non-reducing Laemmli buffer, 4) reducing Laemmli buffer [2X 
buffer composition: 100mM Tris HCl, pH 6.8, 200mM DTT (not included under non-
reducing condition), 4% SDS and 10% glycerol] 5) 100 mM Tris HCl buffer, pH 6.8, 6) 
0.01M PBS with 0.2% Tween 20, pH 7.4, 7) 0.01M PBS with 2% CHAPS, pH 7.4, and 
8) borate buffer (0.1M H3BO3, 0.025N Na2 B4 O7, 0.075M NaCl, pH 8.45). Extraction 
was carried out at room temperature for 2 hours. After extraction the samples were 
centrifuged at 10,000 x g for 30 min at 4
o
C using an Eppendorf centrifuge 5810R. The 
soluble protein content of the extracts was estimated by the Lowry method (BioRad, 
Hercules, CA, USA, Cat # 500-0113, reagent A, Cat # 500-0114, reagent B) for all the 
extraction buffers except for the CHAPS containing buffer for which Bradford protein 
assay (BioRad, Hercules, CA, USA, Cat # 500-0205) was used. BSA (BioRad, Hercules, 
CA, USA, Cat # L9704881) was used as a standard in both the assays. The untreated 
soybean flour sample was also extracted with each of the extraction buffers. 
SDS-PAGE and IgE immunoblotting  
The protein profiles of the heat treated and control soybean samples were examined after 
separating the proteins by SDS-PAGE using XCell SureLock™ Mini-Cell (Invitrogen, 
Carlsbad, CA, USA). Samples were run under reducing conditions by diluting the high 
-
sample buffer (Boston Bio-products, Ashland, MA, Cat # BP-111NR), containing the 
reducing agent 2-mercaptoethanol (Bio-Rad, Hercules, CA, USA, Cat # 161-0710). 
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Samples were heated at 100
o
C for 5 min. Samples were also run under non-reducing 
-sample buffer (Boston 
Bio-products, Ashland, MA, Cat # BP-111NR), without mercaptoethanol and without 
heating prior to loading in the gel. Samples were loaded in wells of a 10-20% tris glycine 
gel (Invitrogen, Carlsbad, CA, USA, Cat # EC61355BOX) so that non-reducing samples 
were spaced at least one lane away from samples that included reducing agent. Protein 
sizes were estimated based on migration of known proteins from a 4 µl sample of 
Precision Plus protein standards (BioRad, Hercules, CA, USA, Cat # 161-0374) that were 
loaded in the same gel. Electrophoresis was carried out at a constant 125 V for 1.5 hours. 
The proteins separated in the gels were then fixed in a solution of 7% acetic acid and 
40% methanol in water and then stained with Brilliant Blue G-colloidal (Sigma, St Louis, 
MO, USA, Cat # B2025) for at least 2 hours. After staining, the gels were destained for 
one min in 10% acetic acid and 25% methanol in water and and then the gels were 
washed with multiple changes of 25% methanol until the background was clear of blue 
dye. 
   For immunoblotting, the separated proteins from unfixed, unstained gels were 
electro-transferred to polyvinylidene difluoride (PVDF) membranes (Invitrogen, Carlsbad, 
CA, USA, Cat. # LC3675) at 25 V for 90 minutes. The membranes were blocked with 5% 
non-fat dry milk (NFDM) in PBS containing 0.05% Tween 20 (PBST) for at least one 
hour. Individual human sera (eight individual soybean allergic and one control sera) were 
diluted 1:10, in 2.5% NFDM in PBST and allowed to block for 1 hour before incubating 
with the blocked membrane for overnight at room temperature. Unbound antibody was 
removed from the membranes by washing four times, 5 min each with PBST. Bound IgE 
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was detected using monoclonal horseradish peroxidase (HRP) conjugated anti-human IgE 
(SouthernBiotech, Birmingham, AL: clone B3102E8 Cat # 9160-05), diluted 1:1000 with 
2.5% NFDM in PBST. Unbound secondary antibodies were removed by washing the 
membranes four times with PBST. Detection was achieved using Supersignal West Dura 
Extended Duration substrate (Pierce, Rockford, IL, USA, Cat # 34076) and capturing 
emitted light by Kodak Gel Logic 440 image station with multiple exposures. A 
nitrocellulose membrane (Invitrogen, Carlsbad, CA, USA, Cat # 645239) was spotted with 
serially diluted purified IgE, air-dried, then blocked with 5% NFDM in PBST and 
incubated with the secondary antibody and substrate used to detect immunoblotsand 
exposed along with the immunoblots to evaluate signal strength between experimental 
blots.  
Mediator release assay 
Humanized rat basophilic leukemia (hRBL) cells (RBL-703/21) developed by 
transfecting an immortalized RBL with the alpha-chain of the human FcεRI gene to 
present the high-affinity receptor for human IgE (Vogel et al., 2005) were used for 
mediator release assays. The hRBL cells were maintained in 50 ml culture flasks in a 5% 
CO2 incubator at 37°C with minimal essential media (MEM) from Invitrogen (Carlsbad, 
CA, USA, Cat #10370), supplemented with 5% (v/v) fetal calf serum (Invitrogen, 
Carlsbad, CA, USA, Cat # 10100), and 1.0% L-glutamine-Penicillin-Streptomycin 
(Sigma, St Louis, MO, USA, Cat # G6784). A 20X Tyrode’s buffer (provides 
physiological condition in tissue culture) was prepared by adding 80.0 g of NaCl (JT 
Baker Cat #4058-05), 2.0 g KCl (Sigma, St Louis, MO, USA, Cat # P5405), 0.65 g of 
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NaH2PO4.2 H2O (Sigma, St Louis, MO, USA, Cat # 71505), 1.0 g MgCl2. 6H2O (Sigma, 
St Louis, MO, USA, Cat # M2393), 4.0 g CaCl2. 2 H2O (Sigma, St Louis, MO, USA, Cat 
# C7902) and 24.0 g HEPES (Sigma, St Louis, MO, USA, Cat # H3375) to water with a 
final volume of 500 ml. Tyrode’s wash buffer was prepared by adding 0.50 g D -(+)- 
Glucose (Sigma, St Louis, MO, USA, Cat # G7528) to 25 ml of the 20X Tyrode buffer 
and approximately 450 ml dH2O and the pH was adjusted to pH 7.15 using 3 M NaOH, 
followed by addition of 0.5 g of bovine serum albumin (BSA, Sigma, St Louis, MO, 
USA, Cat # A9647) before adjusting to a final volume of 500 ml. Antigen challenge 
buffer (ACB) was prepared by adding 0.50 g of glucose to 25 ml of 20X Tyrode’s buffer 
and 250 ml of deuterium oxide (Thermo Fisher scientific, Rockford, IL, USA, Cat# 
16630-1000), adjusting the pH to 7.45 with 3 M NaOH prior to adding 0.5 g BSA and 
adjusting to a final volume of 500 ml with dH2O. Lysis buffer was prepared fresh with 
1% by volume,Triton X-100 (Fisher Scientific, Rockford, IL, USA, Cat # 161-0407) in 
1X PBS. Substrate solution was prepared from 8.9 g of Na2HPO4. 2 H2O (Sigma, St 
Louis, MO, USA, Cat # 30412), 0.65 g of P-nitrophenyl N–acetyl-β-D-glucosaminide 
(Sigma, St Louis, MO, USA, Cat # N9376) in water and the pH adjusted to 4.5 with citric 
acid buffer before adjusting the final volume to 500 ml with dH2O. Stop solution (0.5M 
glycine, pH 10.7) was prepared with fresh glycine (Sigma, St Louis, MO, USA, Cat # 
G7126). 
Mediator (β-hexosaminidase) release assays were carried out according to the 
method of Kaul et al. (2007). Adherent cells in stationary phase were dislodged by 
application of 0.01 M EDTA in MEM for 30-45 minutes. Dislodged cells were washed 
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twice with fresh media and diluted to a cell density of 2.0 X 10
6
 cells/ml. Cells (50 µl) 
were seeded into wells of a 96 well micro titer plate (Fisher scientific, Rockford, IL, 
USA, Cat #167008) followed by the addition of 50 µl of serum or plasma (diluted 1:10 
with the MEM) to allow binding of IgE to the FcεRI during 12 hours of incubation at 5% 
CO2 and 37°C. Cells were then washed twice with Tyrode’s wash buffer before 
challenging replicate wells with one of five concentrations of soluble antigen (heat 
treated and control samples) diluted in allergen challenge buffer (10 µg/ml, 1 µg/ml, 0.1 
µg/ml, 0.01 µg/ml or 0.001 µg/ml) of soluble antigen. The plates were then incubated in a 
water bath (37°C) for 1 hour before transferring 30 µl of cell supernatant from each well 
to corresponding wells of an untreated polystyrene 96-well micro plate (Thermo 
Scientific, Rockford, IL, USA, Cat # 269620) which contained 50 µl per well of 
substrate.  Substrate conversion was allowed to proceed at 37°C in a water bath for one 
hour. Reactions were stopped by the addition of 100 µl of stop solution before reading 
absorbance values at 405 nm. Absorbance values of samples were adjusted to a baseline 
reference by subtracting readings from IgE sensitized cells that were not exposed to 
antigen (serum negative controls). Cells sensitized by the addition of purified human IgE 
(Fisher, scientific, Rockford, IL, USA, Cat #ab65866) and cross-linked by addition of 
anti-human IgE (Sigma, St Louis, MO, USA, Cat # I6284) were used as positive control. 
Additional wells with cells sensitized with the test serum and challenged by anti-IgE 
instead of the antigen extract were used as an individual subject control for total serum 
IgE release. Test sample readings were expressed as a percentage of total (complete) 
release as well as total serum IgE release. 
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RESULTS  
Heat treatment of 5% (w/v) and 50% (w/v) soybean flour samples dispersed in PBS 
Soluble protein concentrations of extracts were determined for all soybean sample 
treatments. As demonstrated from the soluble protein content of the supernatant of the 
5% soy flour heat treated and control samples (Figure 1), it is clear that the pellets 
retained proteins that were extractable by the more robust extraction buffers. Non-
reducing Laemmli buffer resulted in greater protein extraction from the heat treated 
sample pellets among all the extraction buffers followed by the Tween 20 containing 
buffer. The NaCl containing buffer resulted in the least amount of protein being extracted 
from the pellets. For the 50% soy flour samples (Figure 2), non-reducing Laemmli buffer 
resulted in more efficient protein extraction from the heat treated samples compared to 
the other two extraction buffers. However, the 0.5M NaCl buffer was better for extracting 
proteins from the control (unheated) sample. In order to investigate whether there was 
differential solubility, heat treated and control samples were separated by SDS-PAGE 
and compared. Figure 3 (A-D) shows the protein profile of the 5% w/v heat treated soy 
flour supernatant as well as the pellets extracted with the three extraction buffers. Figure 
4 shows the protein profiles of 50% w/v heat treated soy flour samples extracted with the 
same extraction buffers. Based on the stained gel patterns from SDS-PAGE, the 5% soy 
flour supernatants (Figure 3A) under reducing conditions demonstrated that the protein 
profiles of the heat treated samples (lane B-E and lane I-L) were similar to those of the 
control sample (lane A) except for few protein bands (bands 1, 2, 5, 6), whose intensity 
declined as the heat treatment was prolonged. These bands became almost invisible when 
the samples were heat treated at 100
o
C for 120 min (lane L). Under non-reducing 
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conditions a similar trend was observed. The intensity of protein bands 1, 3, 4, 5, 6, 9, 10 
and 13 declined as the heat treatment duration was increased. Additionally some new 
protein bands not present in the control sample become visible in the heat treated samples  
(bands 2, 7, 8, 11, 12 and 14). When pellets were extracted with non-reducing Laemmli 
buffer (Figure 3B), some new protein bands appeared in both the heat treated and control 
samples that were not observed in the supernatant (band 2 in the control sample (lane A) 
and band 16 in the heat treated samples (lane C-M) under non-reducing conditions. For 
pellets extracted with the higher salt buffer (Figure 3C), an additional band, 15 was 
observed under non-reducing conditions in the control sample (lane A). This band was 
not present in the supernatant nor in samples that were extracted with non-reducing 
Laemmli buffer. Other bands (3, 4, 7) different from supernatant were also observed 
under reducing conditions. Some differences were also observed when the pellets were 
extracted with buffer containing Tween 20 (Figure 3D; under reducing conditions, bands 
3, 4 not observed in the supernatant and band 8 not observed with any other extraction 
buffers). For the 50% soy flour samples (Figure 4), the intensity of most of the protein 
bands decreased as the heat treatment conditions increased. A similar protein profile was 
observed for samples extracted with Tween 20 containing buffer and salt containing 
buffer. With the non-reducing Laemmli buffer, some proteins in the heat treated samples 
were extracted more efficiently compared to the other two extraction buffers (e.g. bands 1 
and 2 under reducing conditions and bands 1 and 3 under non-reducing conditions). 
Similar to the 5% soy flour sample, some new protein bands also appeared in the 50% 
soy flour sample following heat treatment (band 6 under reducing conditions and bands 6, 
7 and 8 under non-reducing conditions).  
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 The soluble protein content as well as the SDS-PAGE profile of the pellets 
extracted with Laemmli buffer with reducing agent was comparable to that of Laemmli 
buffer without reducing agent. Additionally, the pattern from pellets extracted with Tris 
HCl, Borate buffer, 1X PBS and PBS with 2% CHAPS were similar to that produced 
from the pellet extracted from PBS with Tween 20 (not shown). Based on obvious 
protein extraction differences in the SDS-PAGE profile of proteins extracted with 
Laemmli buffer without reducing agent, PBS with Tween 20 and the PBS with 0.5M 
NaCl, these three extraction buffers were used for subsequent immunoblot analysis as 
well as in RBL assay to find out differences in the allergenicity of the heat treated 
samples compared to the control sample.  
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Figure 1. Soluble protein content (g/l) of the supernatants and pellets extracted 
with PBS containing salt, non-reducing Laemmli buffer and PBS containing Tween 
20 of 5% (w/v) soy flour dispersion control sample and samples heat treated at 80
o
C 
and 100
o
C for 15 and 120 min. Soluble protein content was determined using the 
Lowry method. 
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Figure 2. Soluble protein content (g/l) of the 50% (w/v) soy flour dispersion 
control sample and samples heat treated at 80
o
C and 100
o
C for 15 and 120 min 
extracted with PBS containing salt, non-reducing Laemmli buffer and PBS 
containing Tween 20. Soluble protein content was determined using the Lowry 
method. 
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Figure 3A. SDS-PAGE stained gel of the supernatants of the 5% w/v soy flour 
samples dispersed in PBS and heat treated under various temperature and time 
combinations compared to the control samples. Samples (10 g protein/lane) were run 
under both reducing and non-reducing conditions, then gels were fixed and stained with 
Brilliant Blue G-colloidal stain. Reduced gel lanes: A, unheated control; B- E, heat 
treatment at 80
o
C for 15, 30, 60 and 120 min respectively; F, empty; G, molecular weight 
marker; H, empty. I-L, heat treatments at 100
o
C for 15, 30, 60 or 120 min respectively. 
Non-reduced gel lanes: A, Unheated control; B, empty; C-F, heat treatments at 80C for 
15, 30, 60 or 120 min respectively; G, Empty; H, molecular weight marker; I, empty; J-
M, heat treatment at 100
o
C for 15, 30, 60 or 120 min respectively.  
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Figure 3B. SDS-PAGE stained gels with extracts of pellets from 5% w/v soy flour 
samples dispersed in PBS and heat treated under various temperature and time 
combinations compared to the control samples extracted with non-reducing 
Laemmli buffer. Lane designations are same as in Figure 3A for both reducing and non-
reducing conditions.  
 
Figure 3C. SDS-PAGE stained gels with extracts of pellets from 5% w/v soy flour 
samples dispersed in PBS and heat treated under various temperature and time 
combinations compared to the control samples extracted with NaCl containing 
buffer. Lane designations are same as in Figure 3A for both reducing and non-reducing 
conditions.  
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Figure 3D. SDS-PAGE stained gels with extracts of pellets from 5% w/v soy flour 
samples dispersed in PBS and heat treated under various temperature and time 
combinations compared to the control samples extracted with Tween 20 containing 
buffer. Lane designations are same as in Figure 3A for both reducing and non-reducing 
conditions. 
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Figure 4. SDS-PAGE stained gels of the 50% w/v soy flour samples dispersed in PBS 
and heat treated under various temperature and time combinations extracted with 
0.01M PBS containing 0.5M salt, 0.01M PBS containing 0.2% Tween 20 and non-
reducing Laemmli buffer. Samples (10 g protein/lane) was run under both reducing 
and non-reducing conditions, then gels were fixed and stained with Brilliant Blue G-
colloidal stain. Lanes: A, unheated control; B, heat treated at 80
o
C for 15 min; C, heat 
treated at 80
o
C for 120 min; D, heat treated at 100
o
C for 15 min; E, heat treated at 100
o
C 
for 120 min; F, empty; G, Molecular weight marker; H, empty; I, unheated control; J, 
heat treated at 80
o
C for 15 min; K, heat treated at 80
o
C for 120 min; L, heat treated at 
100
o
C for 15 min; M, heat treated at 100
o
C for 120 min. 
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The same sample extracts and conditions used for the SDS-PAGE stained gels were used 
for IgE immunoblotting experiments with serum samples from eight soybean allergic 
patients to evaluate potential differences in IgE binding patterns and possibly allergy to 
differentially processed soybean ingredients for a number of allergic subjects. Figure 5A 
shows the immunoblot of the 5% soy flour heat treated and control samples blotted with 
serum 19392-CS. For the supernatant under reducing conditions, strong IgE binding was 
observed to bands of 75 kDa, 50 kDa and 35 kDa (bands 1, 2 and 3) in the control sample 
(lane A) as well as the samples heat treated at 80
o
C for 15 or 120 min (B, C) or 100
o
C for 
15 min (D). The sample heat treated at 100
o
C for 120 min (E) showed very faint IgE 
binding to the 50 kDa band. However, when the pellets were extracted with non-reducing 
Laemmli buffer, strong IgE binding was also observed to the 50 kDa protein band in the 
same samples. With all other extraction buffers, very faint binding was seen to the three 
bands (1, 2 and 3) for the 100
o
C, 120 min heat treated sample. This indicates that non-
reducing Laemmli buffer is efficient in extracting proteins from the pellets that were 
insoluble and not present in the supernatant compared to the buffers containing 0.5 M 
NaCl or Tween 20. Under non-reducing conditions, strong IgE binding was observed to 
higher molecular weight protein bands ranging from 50 to 150 kDa for both the control 
and all of the heat treated samples in the supernatants, indicating that no apparent 
changes occurred in IgE binding epitopes of these proteins due to heat processing. Only a 
slight reduction in IgE binding was seen for sample heat treated at 100
o
C for 120 min. 
However, IgE binding was observed to a 25 kDa protein band (band 4) only in the control 
(unheated) supernatant indicating that this protein epitope is labile under all of the heat 
treatment conditions used in this study. Interestingly, a faint IgE binding band was 
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observed for supernatant samples at approximately 20 kDa (band 5) for all of the heat 
treatments, but not the control sample, indicating a new epitope may have been created 
under heat treatment, or alternatively that the protein was dissociated from other 
components in the soybean matrix. The second possibility seems plausible since 
extraction of the pellets with the salt containing buffer produced a faint IgE binding band 
at 20 kDa, which also became visible in the control sample indicating differential 
solubility of the protein rather than creation of a new epitope by heat treatment. 
  Immunoblots applying the same serum (19392-CS) to the extracts of the 50% soy 
flour samples (Figure 6A) showed high intensity IgE binding to the 35, 50 and75 kDa 
bands under reducing conditions for both the control (A) as well as the samples heat 
treated at 80
o
C for 15 (B) and 120 min (C). Although IgE binding to the 75 kDa and the 
50 kDa bands was reduced for the sample heated at 100
o
C for 15 min (D) and extracted 
with the NaCl and Tween 20 containing buffers, intense IgE binding was observed to 
both the bands when the sample was extracted with non-reducing Laemmli buffer. This 
observation again indicated better extraction efficiency for the non-reducing Laemmli 
buffer. For the sample heat treated at 100
o
C for 120 min (E), a reduction in IgE binding 
was observed to all of the three bands. Under the non-reducing condition, strong IgE 
binding to the larger protein bands (50 to 150 kDa) in the control samples were also 
drastically reduced when the sample was heat treated at 100
o
C for 120 min. 
 The immunoblotting results of serum 20247-LA with the 5% soy flour samples 
(Figure 5B) showed strong IgE binding to a 35 kDa protein band (band 1) under reducing 
conditions for both the control and heat treated samples in the supernatant as well as in all 
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of the three extraction buffer extracted pellets. The intensity of IgE binding to a protein 
band of 25 kDa (band 3) was reduced as the heat treatment times were increased. In the 
supernatants, strong IgE binding was observed to two protein bands of approximately 30 
and 22 kDa (band 2 and 4 respectively), which were visible only in the heat treated and 
not in the control samples. Pellets extracted with Tween 20 and salt containing buffers 
also showed intense IgE binding to the 30 kDa band (band 2) only in the heat treated 
sample. However, when the pellets were extracted with non-reducing Laemmli buffer IgE 
binding was seen to both band 2 and 4 in the control sample as well. Strong IgE binding 
was observed to band 4 in the control sample when pellets were extracted with salt 
containing buffer. These results again indicate that differential solubility of proteins in 
different extraction buffers is responsible for the apparent differences in IgE binding. 
Under non-reducing conditions, IgE binding to most protein bands observed in the 
control sample were reduced in samples with increased heat treatments. However, strong 
IgE binding to the 30 kDa band (band 5) was observed only in the sample heat treated at 
80
o
C for 15 mins (lane B). This may indicate creation of a potential new IgE binding 
epitope in that particular protein due to heat treatment. IgE binding to this band was 
observed in four out of eight sera.  
 The IgE binding pattern of serum 20247-LA with the 50% soy flour samples 
differed from that observed for the 5% heat treated samples (Figure 6B). Under reducing 
condition, intense IgE binding was observed to four bands of approximately150, 70, 30 
and 20 kDa (bands 1, 2, 3, 4 respectively) with both the control (lane A) and the 80
o
C 15 
min (B) heat treated sample for all of the three extraction buffers. For sample heat treated 
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at 80
o
C for 120 min (C) and for both the 100
o
C heat treated samples (D and E) extracted 
with the Tween 20 and NaCl containing buffer, IgE binding to band 1 and 2 was reduced 
drastically and IgE binding intensity to band 3 and 4 was lower compared to the control 
sample. However, when the samples were extracted with non-reducing Laemmli buffer, 
IgE binding to all of the four bands in the heat treated samples was comparable to the 
control sample except for the 100
o
C 120 min heat treated sample, which showed binding 
only to the 30 kDa band (band 3). Under non-reducing condition, intense IgE binding was 
seen to four protein bands of approximately 100, 70, 30 and 22 kDa (bands 5, 6, 7, 8 
respectively) for both control (A) and the 80
o
C 15 min (B) heat treated samples. 
Although IgE binding to these bands were reduced for all other heat treated samples 
extracted with salt and Tween 20 containing buffer, non-reducing Laemmli buffer 
extracted samples showed high intensity IgE binding to these bands for all samples 
except for the 100
o
C 120 min heat treated sample (E).  
Figure 5C shows the IgE immunoblot of serum 20431 with the 5% soy flour samples. 
With this serum strong IgE binding was observed to bands of molecular weights ranging 
from 50 to 100 kDa for both the control and heat treated supernatant as well as the pellets 
extracted with the three extraction buffers indicating the stability of these IgE binding 
proteins to the heat treatment conditions used. Additionally faint IgE binding bands (band 
circled in red) were observed only in the heat treated sample indicating creation of some 
new IgE binding epitopes in some proteins undergoing heat processing. For the 50% soy 
flour samples, immunoblot results with the same sera (Figure 6C) under reducing 
condition showed strong IgE binding to three protein bands of approximately 75, 50 and 
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25 kDa (bands 1, 2, 3) for the control sample (A) and comparable IgE binding to all of 
the three bands was observed for the 80
o
C heat treated samples (B and C). For the 
samples extracted with the Tween 20 and salt containing extraction buffers, IgE binding 
to these bands were reduced for the 100
o
C 15 min heat treated sample (D) and was 
completely abolished for the 100
o
C 120 min heat treated sample (E). However, with the 
non-reducing Laemmli buffer extracted samples, IgE binding to all three bands for all of 
the heat treated samples were comparable to the control sample. Under non-reducing 
conditions, the control sample extracted with NaCl and Tween 20 containing buffer 
showed strong IgE binding to three protein bands of approximately of 150, 100 and 45 
kDa (bands 4, 5, 6 respectively), which was reduced as the heat treatment temperature 
and time were increased. For the non-reducing Laemmli buffer extracted samples, 
although IgE binding to the 45 kDa band (band 6) was observed for the control as well as 
for all of the heat treated samples, strong IgE binding to the 150 and 100 kDa (bands 4, 5) 
bands was observed only for the 80
o
C heat treated samples (B and C). These differences 
in IgE binding patterns among the non-reducing Laemmli buffer and NaCl containing 
buffer again indicated the role of differential solubility of some proteins in salt containing 
buffer (better at extracting proteins from control samples) and non-reducing Laemmli 
buffer (better at extracting proteins from heat treated samples). 
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Figure 5A. IgE immunoblot of 5% w/v soy flour dispersed in PBS and heat treated 
at various temperature and time combinations compared to the unheated control 
soy flour sample using serum 19392-CS. Unstained proteins from both non-reducing 
and reducing SDS-PAGE gels loaded with 10 µg of each protein extract were transferred 
onto PVDF membranes. The membranes were blocked with 5% NFDM in PBST 
followed by incubation with 1:10 dilution of plasma and 1:1000 dilution of monoclonal 
anti-human IgE. Images were captured using a Kodak imaging system after adding 
chemiluminescent substrate to the membranes. Lanes: A, control soy flour sample 
dispersed in PBS; B, soy flour dispersion heat treated at 80
o
C for 15 min; C, soy flour 
dispersion heat treated at 80
o
C for 120 min; D, soy flour dispersion heat treated at 100
o
C 
for 15 min; E, soy flour dispersion heat treated at 100
o
C for 120 min. 
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Figure 5B. IgE immunoblot of 5% w/v soy flour dispersed in PBS and heat treated 
at various temperature and time combinations compared to the unheated control 
soy flour sample using serum 20247-LA. Unstained proteins from both non-reducing 
and reducing SDS-PAGE gel loaded with 10 µg of each protein extract were transferred 
onto PVDF membranes. The membranes were blocked with 5% NFDM in PBST 
followed by incubation with 1:10 dilution of plasma and 1:1000 dilution of monoclonal 
anti-human IgE. Images were captured using a Kodak imaging system after adding 
chemiluminescent substrate to the membranes. Lanes: A, control soy flour sample 
dispersed in PBS; B, soy flour dispersion heat treated at 80
o
C for 15 min; C, soy flour 
dispersion heat treated at 80
o
C for 120 min; D, soy flour dispersion heat treated at 100
o
C 
for 15 min; E, soy flour dispersion heat treated at 100
o
C for 120 min. 
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Figure 5C. IgE immunoblot of 5% w/v soy flour dispersed in PBS and heat treated 
at various temperature and time combinations compared to the unheated control 
soy flour sample using serum 20431. Unstained proteins from both non-reducing and 
reducing SDS-PAGE gel loaded with 10 µg of each protein extract were transferred onto 
PVDF membranes. The membranes were blocked with 5% NFDM in PBST followed by 
incubation with 1:10 dilution of plasma and 1:1000 dilution of monoclonal anti-human 
IgE. Image was captured using Kodak imaging system after adding chemiluminescent 
substrate to the membranes. Lanes: A, control soy flour sample dispersed in PBS; B, soy 
flour dispersion heat treated at 80
o
C for 15 min; C, soy flour dispersion heat treated at 
80
o
C for 120 min; D, soy flour dispersion heat treated at 100
o
C for 15 min; E, soy flour 
dispersion heat treated at 100
o
C for 120 min. 
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Figure 6A. IgE immunoblot of 50% w/v soy flour dispersed in PBS and heat treated 
at various temperature and time combinations compared to the unheated control 
soy flour sample using serum 19392-CS. Unstained proteins from both non-reducing 
and reducing SDS-PAGE gel loaded with 10 µg of each protein extract were transferred 
onto PVDF membranes. The membranes were blocked with 5% NFDM in PBST 
followed by incubation with 1:10 dilution of plasma and 1:1000 dilution of monoclonal 
anti-human IgE. Image was captured using Kodak imaging system after adding 
chemiluminescent substrate to the membranes. Lanes: A, control soy flour sample 
dispersed in PBS; B, soy flour dispersion heat treated at 80
o
C for 15 min; C, soy flour 
dispersion heat treated at 80
o
C for 120 min; Lane D, soy flour dispersion heat treated at 
100
o
C for 15 min; Lane E, soy flour dispersion heat treated at 100
o
C for 120 min.  
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Figure 6B. IgE immunoblot of 50% w/v soy flour dispersed in PBS and heat treated 
at various temperature and time combinations compared to the unheated control 
soy flour sample using serum 20247-LA. Unstained proteins from both non-reducing 
and reducing SDS-PAGE gel loaded with 10 µg of each protein extract were transferred 
onto PVDF membranes. The membranes were blocked with 5% NFDM in PBST 
followed by incubation with 1:10 dilution of plasma and 1:1000 dilution of monoclonal 
anti-human IgE. Images were captured using Kodak imaging system after adding 
chemiluminescent substrate to the membranes. Lanes: A, control soy flour sample 
dispersed in PBS; B, soy flour dispersion heat treated at 80
o
C for 15 min; C, soy flour 
dispersion heat treated at 80
o
C for 120 min; Lane D, soy flour dispersion heat treated at 
100
o
C for 15 min; Lane E, soy flour dispersion heat treated at 100
o
C for 120 min.  
 
 
 
 
 
PBS + 0.5M Salt
10
15
20
25
37
50
75
100
150
250
5
A B    C   D    E 
Reduced
102 101 1       10-1 10-2   10-3
1
3
2
4
Non-reduced
10
15
20
25
37
50
75
100
150
250
5
102 101 1       10-1 10-2   10-3
5
6
7
8
A B    C   D    E A B    C  D   E A B    C   D   E 
PBS + 0.2% Tween 20
10
15
20
25
37
50
75
100
150
250
5
102 101 1      10-1 10-2   10-3
Non-reduced
5
6
7
8
10
15
20
25
37
50
75
100
150
250
5
Reduced
102 101 1       10-1 10-2   10-3
1
2
3
4
ng IgE/spot
A B   C   D   E 
A B   C  D  E 
102 101 1       10-1 10-2   10-3
Non- reduced Laemmli buffer
Reduced
10
15
20
25
37
50
75
100
150
250
5
102 101 1       10-1 10-2   10-3
1
2
3
4
Non-reduced
10
15
20
25
37
50
75
100
150
250
5
5
6
7
8
ng IgE/spot
128 
 
 
Figure 6C. IgE immunoblot of 50% w/v soy flour dispersed in PBS and heat treated 
at various temperature and time combinations compared to the unheated control 
soy flour sample using serum 20431. Unstained proteins from both non-reducing and 
reducing SDS-PAGE gel loaded with 10 µg of each protein extract were transferred onto 
PVDF membranes. The membranes were blocked with 5% NFDM in PBST followed by 
incubation with 1:10 dilution of plasma and 1:1000 dilution of monoclonal anti-human 
IgE. Images were captured using Kodak imaging system after adding chemiluminescent 
substrate to the membranes. Lanes: A, control soy flour sample dispersed in PBS; B, soy 
flour dispersion heat treated at 80
o
C for 15 min; C, soy flour dispersion heat treated at 
80
o
C for 120 mins; Lane D, soy flour dispersion heat treated at 100
o
C for 15 min; Lane 
E, soy flour dispersion heat treated at 100
o
C for 120 min.  
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To evaluate the biological significance of the IgE binding differences visible in 
immunoblots among the heat treated and control soybean flour samples, a mediator 
release assay was performed with serum 19392-CS, the highest IgE binding human 
sample. The hRBL cells were sensitized with 1:10 dilution of serum 19392-CS followed 
by challenges with different concentrations of the antigen extracts diluted in the antigen 
challenge buffer. Figure 7 and 8 shows the β-hexosaminidase release as a percentage of 
total serum IgE release (obtained by sensitizing the cells with serum and challenging with 
anti-IgE) from the hRBL cells with the 5% and 50% heat treated and control soy flour 
samples respectively extracted with non-reducing Laemmli buffer and NaCl containing 
extraction buffer. For the 5% soy flour samples, comparing the mediator release at 0.1 
µg/ml of antigen concentration, it was observed that the control supernatant as well as the 
supernatant of samples heat treated at 80
o
C for 15 and 120 min showed a mediator 
release of approximately 60%. Both these heat treated sample pellets extracted with non-
reducing Laemmli buffer also showed a similar mediator release as the control pellet 
(approximately 60%) However, a reduced mediator release was observed for the 80
o
C 
heat treated sample pellets compared to the control sample pellets extracted with the 
NaCl containing buffer (approximately 25% vs 45%). For both the supernatant and the 
pellets extracted with NaCl containing buffer, the 100
o
C, 15 min heat treated sample gave 
a very low mediator release (≤ 20%); whereas the same sample extracted with non-
reducing Laemmli buffer resulted in a release of approximately 35%. These observations 
indicate that the samples heat treated at 80
o
C for 15 min and 120 min and the sample heat 
treated at 100
o
C for 15 min still retain IgE binding and apparent allergenicity. In 
accordance with the immunoblot results (Figure 5A), the 100
o
C 120 min heat treated 
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samples (both the supernatant and sample pellets extracted with NaCl containing buffer 
and non-reducing Laemmli buffer) resulted in a lower mediator release (< 10%) 
compared to the control sample. With the 50% soy flour, the control as well as all the 
heat treated samples except for the 100
o
C 120 min heat treated sample gave a mediator 
release ranging from 25-60% for both the NaCl containing buffer and non-reducing 
Laemmli buffer extracts. Although the 100
o
C 120 min heat treated sample showed a 
release of less than 10% when extracted with the NaCl containing buffer, release from the 
same sample extracted with non-reducing Laemmli buffer was comparable to the other 
samples (approximately 40%). These results indicate that the 100
o
C 120 min heat treated 
sample still retains allergenicity even though a lower IgE binding was observed with the 
same sample in immunoblot (Figure 6A).  
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Figure 7. β-hexosaminidase release from humanized RBL-703/21 cells, sensitized 
with IgE from serum 19392-CS and challenged with 5% w/v soy flour suspension 
control and heat treated samples. Humanized RBL-clone 703/21 were sensitized with 
IgE from serum 19392-CS (diluted 1: 10) and were challenged with 100 μl of 5% w/v soy 
flour suspension control samples as well as the sample heat treated at 80
o
C and 100
o
C for 
15 and 120 min. 0.001 μg/ml to 10 μg/ml of antigen was used to challenge the cells as 
shown in the graph. Absrobance values were measure at 405 nm and β-hexosaminidase 
release was expressed as percentage of total serum IgE release.  
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Figure 8. β-hexosaminidase release from humanized RBL-703/21 cells, sensitized 
with IgE from serum 19392-CS and challenged with 50% w/v soy flour suspension 
control and heat treated samples. Humanized RBL-clone 703/21 were sensitized with 
IgE from serum 19392-CS (diluted 1: 10) and were challenged with 100 μl of 50% w/v 
soy flour suspension control samples as well as the sample heat treated at 80
o
C and 
100
oC for 15 and 120 min. 0.001 μg/ml to 10 μg/ml of antigen was used to challenge the 
cells as shown in the graph. Absrobance values were measure at 405 nm and β-
hexosaminidase release was expressed as percentage of total serum IgE release.  
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Dry and oil roasting of soybean seeds 
Three different extraction buffers (PBS + 0.5M salt, non-reducing Laemmli buffer and 
PBS + 0.2% Tween 20) were used to extract proteins from the dry and oil roasted 
soybean seed samples. For both samples, as the heat treatment was prolonged the soluble 
protein content of the samples was reduced. Out of all of the three extraction buffers, the 
non-reducing Laemmli buffer resulted in a higher recovery of soluble proteins from the 
heat treated samples (Figure 9 and 10). The total protein content of the dry and oil roasted 
samples was determined by the Dumas method using a LECO instrument at University of 
Nebraska (Table 2 and 3). After adjusting for moisture loss during the baking process, the 
total protein content of all of the roasted soybean seed samples was found to be similar to 
the unheated control soybean sample. This observation indicates that the lower protein 
content observed in the Lowry assay for the roasted soybean samples is because of 
aggregation and denaturation of soybean proteins making them insoluble and thereby un-
extractable by the extraction buffers used.  
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Figure 9. Soluble protein content by Lowry (g/l) of dry roasted soybean seeds. 
Soaked soybean seeds were roasted in a conventional oven at 171
o
C for 30, 60 and 
90 min and were extracted with salt containing buffer, Tween 20 containing buffer 
and non-reducing Laemmli buffer. 
 
Figure 10. Soluble protein content by Lowry (g/l) of oil roasted soybean seeds. 
Soaked soybean seeds were roasted in canola oil at 171
o
C for 2, 5 and 8 min and 
were extracted with salt containing buffer, Tween 20 containing buffer and non-
reducing Laemmli buffer. 
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Table 2. Total protein content of dry roasted soybean samples by Dumas (LECO) method 
 
Table 3. Total protein content of oil roasted soybean samples by Dumas (LECO) method 
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The SDS-PAGE profile of the dry and oil roasted soybean samples showed a number of 
differences compared to the control sample (Figure 11 and 12). The collected soaking 
water collected was also separated by SDS-PAGE to find out whether there is any protein 
loss due to the soaking process. 10 µg of each protein was loaded unto gels under both 
reducing and non-reducing condition. From Figure 11 it can be observed that the soybean 
seeds that were dry roasted for 30 min (lanes D and M) showed a similar protein profile 
as the control (soaked soybean) sample (C and L) except for disappearance of a few high 
molecular weight protein bands. Although the seeds dry roasted for 60 min (E and N) 
showed considerable reduction in protein band intensity compared to the control samples 
when extracted with Tween 20 or NaCl containing buffer, non-reducing Laemmli buffer 
resulted in better protein extraction from the same sample. For the 90 min dry roasted 
sample (F and O), no protein bands were observed in SDS-PAGE with any of the three 
extraction buffers. With all three extraction buffers, some new protein bands (bands 5, 2, 
3) appeared in the heat treated sample. Although the overall protein extraction was better 
with the non-reducing Laemmli buffer, some protein bands were better extracted by the 
NaCl containing buffer compared to the non-reducing Laemmli buffer (e.g. band 5 and 3 
under non-reducing condition). The SDS-PAGE protein profile of the samples extracted 
with the Tween 20 containing buffer was found to be comparable to that of the NaCl 
containing buffer. A protein band of approximately 10 kDa (band 1) was observed in the 
soaking water (B) under reducing condition. A similar molecular weight band (band 6) 
was also observed in the 30 min dry roasted sample (D) when the gel was run under 
reducing condition. Under non-reducing condition a 12 kDa band (band 4) was observed 
only in the soaking water (K). 
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For the oil roasted soybean samples (Figure 12), again the non-reducing Laemmli 
buffer was found to be better at extracting proteins from the 2 min (lane C and K) and 
5 min (D and L) oil roasted samples compared to the other two extraction buffers. 
However, a reduction in band intensity was observed for the 8 min oil roasted sample 
(E and M). Similar to dry roasted soybean samples, new protein bands (bands 1, 2, 4, 
5) also appeared in the oil roasted samples.  
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Figure 11. SDS-PAGE stained gels of dry roasted soybean seed samples compared to 
the control samples extracted with 0.01M PBS containing 0.5M salt, 0.01M PBS 
containing 0.2% Tween 20 and non-reducing Laemmli buffer. Samples (10 g 
protein/lane) were run under both reducing and non-reducing conditions, then gels were 
fixed and stained with Brilliant Blue G-colloidal stain. .Lanes: A, whole soybean flour 
extract; B, soaking water; C, soaked soybean (control); D, dry roasted at 171
o
C for 30 
min; E, dry roasted at 171
o
C for 60 min; F, dry roasted at 171
o
C for 90 min; G, empty; H, 
molecular weight marker; I, empty; J, whole soybean flour extract; K, soaking water; L, 
soaked soybean (control); M, dry roasted at 171
o
C for 30 min; N, dry roasted at 171
o
C for 
60 min; O, dry roasted at 171
o
C for 90 min. 
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Figure 12. SDS-PAGE stained gels of oil roasted soybean seed samples compared to 
the control samples extracted with 0.01M PBS containing 0.5M salt, 0.01M PBS 
containing 0.2% Tween 20 and non-reducing Laemmli buffer. Samples (10 g 
protein/lane) were run under both reducing and non-reducing conditions, then gels were 
fixed and stained with Brilliant Blue G-colloidal stain. Lanes: A, soaking water; B, 
soaked soybean (control); C, oil roasted at 171
o
C for 2 min; D, oil roasted at 171
o
C for 5 
min; E, oil roasted at 171
o
C for 8 min; F, empty; G, molecular weight marker; H, empty; 
I, soaking water; J, soaked soybean; K, oil roasted at 171
o
C for 2 min; L, oil roasted at 
171
o
C for 5 min; M, oil roasted at 171
o
C for 8 min. 
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Since both the NaCl containing as well as Tween 20 containing buffer resulted in a 
similar protein profile in SDS-PAGE for both the dry and oil roasted soybeans seeds, 
immunoblot was performed only with the non-reducing Laemmli buffer and the NaCl 
containing extraction buffer to find out any differences in IgE binding due to the roasting 
process. Figure 13 shows the immunoblots of dry roasted soybean seeds with serum 
19392-CS (panel I) and serum 18534-LN (panel II). With serum 19392-CS, the 30 min 
dry roasted soybean seed (lane C) showed strong IgE binding comparable to the control 
sample (B) when the samples were extracted with either the NaCl containing or the non-
reducing Laemmli buffer. The 60 min dry roasted sample (D) also showed intense IgE 
binding to some protein bands when the sample was extracted with non-reducing 
Laemmli buffer. However, the 90 min dry roasted sample (E) did not show any IgE 
binding with both extraction buffers. This may indicate the destruction of IgE binding 
epitopes or an inability of either extraction buffer to extract proteins due to insoluble 
aggregate formation as a result of the prolonged roasting process. With serum 18534-LN 
although the 30 min dry roasted sample (C) extracted with non-reducing Laemmli buffer 
showed strong IgE binding comparable to the control sample (B), both the 60 min (D) 
and 90 min (E) roasted sample showed a significant reduction in IgE binding for either 
extraction buffers used.  
The immunoblot of the 2 min (C) and 5 min (D) oil roasted samples extracted 
with non-reducing Laemmli buffer showed strong IgE binding comparable to the control 
sample (B) with serum 19392-CS (Figure 14, panel I). The 8 min oil roasted soybean 
seeds (E) extracted with the same buffer showed an overall reduction in IgE binding 
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compared to the control sample (B); however, strong IgE binding was still observed to a 
band of approximately 50 kDa under non-reducing condition and two bands of 50 and 35 
kDa under reducing condition. With serum 20770-MH (Figure 14, panel II), the 2 min 
(C) and 5 min (D) oil roasted samples showed a drastic reduction in IgE binding when 
extracted with NaCl containing buffer whereas the non reducing Laemmli buffer 
extracted samples still retained IgE binding to a 24 kDa band under non-reducing 
condition and two bands of molecular weight of 30 and 25 kDa under reducing condition. 
IgE binding to the 8 min oil roasted sample (E) was reduced drastically compared to the 
control sample with both extraction buffers.  
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Figure 13. IgE immunoblot of dry roasted soybean seeds with serum 19392-CS 
(Panel I) and 18534-LN (Panel II). Unstained proteins from both non-reducing and 
reducing SDS-PAGE gel loaded with 10 µg of each protein extract were transferred onto 
PVDF membranes. The membranes were blocked with 5% NFDM in PBST followed by 
incubation with 1:10 dilution of plasma and 1:1000 dilution of monoclonal anti-human 
IgE. Image was captured using Kodak imaging system after adding chemiluminescent 
substrate to the membranes. Lanes: A, soaking water; B, soaked soybean seeds (control); 
C, soybean seeds dry roasted at 171
o
C for 30 min; D, soybean seeds dry roasted at 171
o
C 
for 60 min; E, soybean seeds dry roasted at 171
o
C for 90 min. 
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Figure 14. IgE immunoblot of oil roasted soybean seeds with serum 19392-CS (Panel 
I) and 20770-MH (Panel II). Unstained proteins from both non-reducing and reducing 
SDS-PAGE gel loaded with 10 µg of each protein extract were transferred onto PVDF 
membranes. The membranes were blocked with 5% NFDM in PBST followed by 
incubation with 1:10 dilution of plasma and 1:1000 dilution of monoclonal anti-human 
IgE. Image was captured using Kodak imaging system after adding chemiluminescent 
substrate to the membranes. Lanes: A, soaking water; B, soaked soybean seeds (control); 
C, soybean seeds oil roasted at 171
o
C for 2 min; D, soybean seeds oil roasted at 171
o
C 
for 5 min; E, soybean seeds oil roasted at 171
o
C for 8 min. 
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With six out of eight sera used in the immunoblots, intense IgE binding at approximately 
10 kDa was observed only for the soaking water (Figure 13 and 14, lane A, band 1). The 
identity of this IgE binding band in the soaking water was verified by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) by the analytical core facility, 
at the University of Nebraska. The Mascot (Matrix Sciences) output search for mass 
identity matches indicated a match to soybean hull allergen Gly m 1, GI: 123506, from 
the non-redundant NCBI database (sequence with identified peptide coverage (red) 
shown below). This indicates that soybean hull allergen Gly m 1 is leached out of 
soybean into the water that was used to soak the soybean seeds before they were dry or 
oil roasted.  
 
Band 1 (Soybean Gly m 1) GI: 123506 
ALITRPSCPD LSICLNILGG SLGTVDDCCA LIGGLGDIEA IVCLCIQLRA 
LGILNLNRNL QLILNSCGRS YPSNATCPRT 
 
The biological significance of the IgE binding observed by immunoblot analysis 
of the dry and oil roasted soybean seeds was evaluated by hRBL cell assay. Figure 15 
shows the β-hexosaminidase release compared to the total serum IgE release from the 
hRBL cell for the dry roasted soybean samples using serum 19392-CS. Considering the 
mediator release at 1µg/ml antigen concentration, the control samples (soaked soybean) 
extracted with both the non-reducing Laemmli buffer and the NaCl containing buffer 
showed a release of approximately 50%. The soybean samples that were dry roasted for 
30 min resulted in a β-hexosaminidase release comparable to or higher than the control 
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sample (approximately 50% when extracted with NaCl containing buffer and 70% with 
non-reducing Laemmli buffer). The β-hexosaminidase release from the 60 min dry 
roasted sample was lower (approximately 20%) than the control sample when extracted 
with the NaCl containing buffer.  However, when extracted with non-reducing Laemmli 
buffer the same sample showed a release comparable to the control sample 
(approximately 45%). The 90 min dry roasted sample resulted in a very low β-
hexosaminidase release (< 20%) with both extraction buffers. This result correlated with 
the IgE immunoblot finding where reduced IgE binding compared to the control sample 
was observed for the 90 min dry roasted sample with the same sera (Figure 13, Panel I). 
Figure 16 shows the β-hexosaminidase release compared to the total serum IgE release 
from the hRBL cell for the oil roasted soybean samples using serum 19392-CS. A high β-
hexosaminidase release (approximately 35-50%) was observed from the 2 min and 5 min 
oil roasted samples extracted with either the NaCl containing buffer or non-reducing 
Laemmli buffer, although the release was lower compared to the control sample 
(approximately 60%). For the 8 min oil roasted sample, while the NaCl containing 
extraction buffer showed a release of approximately 20%, the non-reducing Laemmli 
buffer showed a release of approximately 30%. This reduction in mediator release by the 
8 min oil roasted sample compared to other samples again correlated with the IgE 
immunoblot result with the same sera where IgE binding was observed only to one single 
protein band under the non-reducing condition and two bands under the reducing 
condition (Figure 14, panel I).  
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Figure 15. β-hexosaminidase release from humanized RBL-703/21 cells, sensitized 
with IgE from serum 19392-CS and challenged with dry roasted soybean seeds and 
control samples. Humanized RBL-clone 703/21 were sensitized with IgE from serum 
19392-CS (diluted 1: 10) and were challenged with 100 μl of individual samples. 0.001 
μg/ml to 10 μg/ml of antigen was used to challenge the cells as shown in the graph. 
Absorbance values were measure at 405 nm and β-hexosaminidase release was expressed 
as percentage of total serum IgE release.  
 
 
Figure 16. β-hexosaminidase release from humanized RBL-703/21 cells, sensitized 
with IgE from serum 19392-CS and challenged with oil roasted soybean seeds and 
control samples. Humanized RBL-clone 703/21 were sensitized with IgE from serum 
19392-CS (diluted 1: 10) and were challenged with 100 μl of individual samples. 0.001 
μg/ml to 10 μg/ml of antigen was used to challenge the cells as shown in the graph. 
Absorbance values were measure at 405 nm and β-hexosaminidase release was expressed 
as percentage of total serum IgE release.  
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DISCUSSION 
Soybean is an important source of dietary oil and protein that is gaining popularity in 
Asian as well as western countries. Soybean protein fractions in various processed forms 
are widely used in food because of their functional, nutritional properties and low cost. 
Some soybean ingredients are processed either by heat treatment or enzymatic hydrolysis 
to attain desirable functional properties or in some cases with the intent of reducing the 
allergenicity. Heat treatment by far is the most important process utilized during 
preparation of soybean food products. Heat treatment helps in removing anti-nutritional 
factors presents in soybean, imparts characteristic flavors to the product and improves a 
number of functional properties (gel forming, foaming and emulsification) of soybean 
proteins (Anderson and Wolf, 1995). Heat treatment is a common process involved in the 
preparation of soy products such as soy milk, tofu and texturized soybean products. 
Soybean protein products used as soy flour, soy protein isolates and concentrates are used 
in various baked products, yeast-leavened products, processed meat products and dairy 
products, have undergone various degrees of heat processing (Riaz, 1999; Singh et al., 
2008; Klein et al., 1995). Keeping in mind the wide range of heat processing conditions 
that are encountered during the manufacturing of soybean products, it is essential to have 
an understanding of the impact of various heat treatment conditions on the allergenicity 
of soybean proteins. This could help in managing the risk of allergy to sensitive 
individuals in the population. Although several studies have been done in the past to 
investigate the effect that heat processing could have on allergenicity of soybean products 
(Burks et al., 1992; Shibasaki et al., 1980; Muller et al., 1998), there are several 
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shortcomings in the methods used in evaluating the allergenicity, such as the use of 
pooled sera for in vitro IgE binding studies and lack of investigation of the extractability 
of proteins after heat processing. The most important shortcoming is that the 
interpretation of allergenicity is based only on in vitro IgE binding tests such as ELISA or 
immunoblotting. Since results of in vitro IgE binding assays often do not correlate with 
food allergic reactions and can either over or under-predict allergic activity, assays 
confirming the biological activity of IgE such as skin prick tests or basophil histamine 
release should be performed to answer very specific questions about the ability of 
proteins to cross-link IgE on basophils and mast cells and induce release of vasoactive 
mediators. In our study, the allergenicity of heat processed soybean products were 
evaluated after extracting proteins with eight different extraction buffers and the potential 
allergenicity was interpreted based on the results of in vitro IgE immunoblots using 
individual soybean allergic patient sera as well as by a functional assay (mediator release 
assay using hRBL cell lines). 
 Most of the in vitro methods utilized to assess the presence of food specific IgE 
rely on soluble or extractable forms of food proteins. Heat treatment can result in 
denaturation and unfolding of protein leading to surface exposure of hydrophobic groups 
and formation of covalent complexes. This leads to decreased protein 
solubility/extractability. Thermal induced unfolding and aggregation of β-conglycinin has 
been shown to occur at a temperature above 75
o
C and that of glycinin at a temperature 
above 60
o
C (Mills et al., 2001; Mills et al., 2003). Inter and intra molecular covalent 
cross linking among proteins can occur during heat processing due to chemical 
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modification of proteins by the Maillard reaction (involving reaction of reducing sugar 
with free amino groups of proteins) resulting in further reduction in solubility (Schmitt et 
al., 2010). The use of detergents and reducing agents has been shown to maximize 
protein extraction from insoluble pellets (Schmitt et al., 2010). In our study, reducing and 
non-reducing formulations of Laemmli buffer (with or without beta-mercaptoethanol) 
were used for protein extraction. Our results showed a large difference in protein 
extraction between Laemmli buffer (non-reducing) and all other extraction buffers. 
Laemmli buffer was able to extract the maximum amount of protein from heat treated 
soybean products compared to all other extraction buffers (figure 1, 2, 9, 10). Laemmli 
buffer extracted samples showed higher IgE binding by immunoblot compared to the 
other extraction buffers and were also able to provide a higher mediator release from the 
heat treated samples in hRBL cell assay. Although Laemmli buffer resulted in higher 
overall protein solubilization, it was also observed that some proteins were extracted 
more efficiently by NaCl containing buffer especially from the unheated soybean samples 
(Figures 3B, 3C, 11, 12). This difference led to different interpretations with regard to 
allergenicity of heat treated products. For example, considering the immunoblot of 50% 
soy flour PBS dispersion, heat treated at various temperature and time combinations and 
incubated with serum 20431 (figure 6C), the Laemmli buffer extract showed high 
intensity IgE binding to two high molecular weight protein bands (bands 4, 5) only for 
the 80
o
C heat treated samples. Considering this result alone, one could conclude that the 
heat treatment condition has augmented the allergenicity of the soybean proteins by 
creating new epitopes in those proteins. However, when the same samples were extracted 
with NaCl containing extraction buffers, IgE binding to those two high molecular weight 
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protein bands were also observed in the control sample. This indicates that the differential 
solubility of soybean proteins in the different extraction buffers is the cause of the 
differences in the IgE binding pattern observed in immunoblot (Figure 6C). Therefore it 
is essential to evaluate proteins extracted with different extraction buffers and not just a 
single buffer while making any interpretation on allergenicity since consumers will 
include both soluble and insoluble proteins. Evaluation of the more complex extracts is 
necessary to understand the protein mixture that the consumer is exposed to. 
 In general, in our study heat treatment of 5% and 50% soy flour dispersions at 
80
o
C showed IgE binding comparable to the control sample by immunoblot with eight 
soybean allergic sera (Figures 5, 6). The same samples also showed comparable mediator 
release in the hRBL assay as the control sample (Figures 7, 8). For the 50% soy flour 
sample heat treated at 100
o
C for 2 hours, although a reduction in IgE binding was 
observed in the immunoblot, a comparable mediator release was observed as the other 
samples indicating that the sample still retained essentially full allergenicity (Figure 8). 
With the dry and oil roasted samples, except for the soybean samples that were dry 
roasted for 90 min, all other samples retained allergenicity as shown by a strong IgE 
binding in immunoblots and by high mediator release (> 20% at 1 µg/ml antigen 
concentration) in the hRBL assay (Figures 13, 14, 15, 16). The low IgE binding and 
mediator release shown by the 90 min dry roasted sample could either be due to the 
destruction in allergenic epitopes under high temperature or possibly that some soybean 
proteins after heat treatment at such a high temperature were un-extractable even with the 
harsh Laemmli buffer. Since both the immunoblots and hRBL assay utilized in this study 
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rely on soluble antigens, whether the insoluble complexes formed after heat processing 
will retain residual allergenicity is still a question. Double blind placebo controlled food 
challenge (DBPCFC) with soybean sensitive patients using whole heat processed 
products could give a complete answer to this question. However, the availability of 
willing soybean allergic patients to undergo a challenge test and lack of proper medical 
facility and expertise to conduct a challenge test limited the utilization of this method in 
this study. Nevertheless, the relevance of soluble antigen in elicitation of an allergic 
reaction has been shown by several studies (Roth-Walter et al., 2008; Martos et al., 
2011). Although aggregated antigens are essential for allergic sensitization by their 
ability to enter into Peyer’s patches through M cells, they are poor elicitors since from 
Peyer’s patches they are transported into draining mesenteric lymph nodes and thereby 
bypass the lamina propria or fail to reach the systemic circulation, which limits their 
ability to contact tissue mast cells or blood basophils. It is the soluble antigens that are 
required for allergic provocation by their ability to transcytose across the epithelium more 
easily and come in contact with the sensitized lamina propria mast cells (Roth-Walter et 
al., 2008). Heat-induced aggregation of milk allergens has been shown to prevent their 
absorption through enterocytes and subsequent onset of anaphylactic reactions in mice 
(Roth-Walter et al., 2008). Heating of an egg allergen, ovalbumin, has also been shown to 
completely abrogate the transcytosis of immunologically intact forms of allergen across 
the epithelial monolayer due to aggregate formation (Martos et al., 2011). Therefore it is 
possible that dry roasting of soybean seeds for 90 min may reduce the elicitation capacity 
of the soybean proteins (due to an inability of the soluble portion to degranulate mast 
cells as shown by reduced mediator release in the hRBL assay in our study and the 
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probable inability of the insoluble complexes that should be formed due to heat treatment 
to transcytose through enterocytes to come in contact with sensitized lamina propria mast 
cells).  
In conclusion, the results from this study showed that most of the heat processing 
methods that soybean proteins encounter will not affect their allergenicity. Soaking 
soybean seeds before processing removes soybean hull allergen Gly m 1 from soybean. 
Dry roasting of soybean proteins for a longer period of time (90 min in our study) may 
reduce their elicitation capacity as shown by a lower IgE binding by immunoblot as well 
as a lower mediator release by hRBL assay in this study. However, clinical challenge 
tests with soybean allergic individual could provide a more confirmative result. Another 
important finding from our study is that choice of extraction buffer while making a 
soluble extract could make a difference in interpretation of results from in vitro assays 
that utilize soluble antigens.  
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CHAPTER 4: THE EFFECT OF ENZYME HYDROLYSIS ON SOYBEAN 
ALLERGENICITY 
 
INTRODUCTION 
Soybean proteins are modified by processing that may include heating, solvent 
extraction, pH adjustment, enzymatic hydrolysis or a combination of processes to 
produce ingredients such as soy flour and soy protein isolates (SPI) to improve their 
functionality as food ingredients (Singh et al., 2008; Lusas and Riaz, 1995). The 
concentration of allergenic proteins present in soybean and the ability to induce allergic 
reactions in sensitized individuals is likely to depend on the degree of processing (Kosma 
et al., 2010). Enzymatic hydrolysis of soybean proteins is a common process used by 
industry to improve functional properties and has been used to reduce allergenicity in 
making hypoallergenic soybean products (Host and Halken, 2004; Lusas and Riaz, 1995; 
L’Hocine and Boye, 2007). The reduced solubility of soybean proteins at acidic pH 
(close to the isoelectric point (4.5) of major seed storage protein glycinins and β-
conglycinins) limits their use as functional ingredients in moderately acidic foods such as 
citric beverages and salad dressings. Hydrolysis of soybean proteins with proteases can 
increase protein solubility thereby providing functional properties that depends on protein 
solubility such as foaming and emulsifying properties (Molina Ortiz and Wagner, 2002; 
Adler-Nissen, 1976). Several enzymes have been used by investigators to improve the 
functionality of SPI and soy flour. Calderon de la Barca, et al. (2000) treated defatted 
soybean flour with chymotrypsin to improve protein solubility, emulsifying and foaming 
properties. In another study, SPI was treated with enzymes such as Alcalase, α-
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chymotrypsin, trypsin, liquozyme and rennet to improve solubility, emulsifying capacity 
and the ability to undergo thermal aggregation (Kim et al., 1990). SPI has also been 
treated with enzymes such as papain, bromelain, and cucurbita to improve solubility and 
foaming properties (Molina Ortiz et al., 2000). Since enzyme hydrolysis of protein does 
not always lead to reduction in allergenicity and can result in an increase in allergenicity 
because of exposure of new antigenic epitopes due to protein breakdown, it is essential to 
evaluate the allergenicity of various hydrolyzed soybean products. However, there are 
only a few studies, where the allergenicity of a few soybean proteins (Gly m Bd 30K, Gly 
m Bd 28K, 11s globulin) have been investigated after enzymatic hydrolysis by in vitro 
IgE binding tests (Tsumura et al., 1999; Lee et al., 2007). Furthermore, the effect of 
hydrolysis with several other enzymes including Alcalase, papain and bromelain on the 
overall allergenicity of SPI or soybean flour that are commonly used to make functional 
soy protein products, has not been investigated. 
 In this study, the overall allergenicity of soybean flour and SPI treated with 
several enzymes commonly used to improve functionality or to make hypoallergenic 
products were evaluated by both IgE binding studies as well as by the basophil mediator 
release assay using soybean allergic patient sera. The results of this study may provide 
information on the efficacy of any of the enzymes in making hypoallergenic soy protein 
hydrolysate products. 
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MATERIALS AND METHODS 
Sample preparation 
Defatted soybean flour extract and solubilized SPI were used as starting material for 
enzyme hydrolysis. The soybean seeds were ground in a SPEX CertiPrep 6850 freezer 
mill under liquid nitrogen to make flour. The flour was then defatted using a hexane 
extraction method. A 1:20 (w/v) ratio of flour to hexane was placed in a shaking water 
bath at 50
o
C for 30 min and the process was repeated three more times to remove lipids. 
Following air-drying in a chemical fume hood, the defatted soy flour was extracted with 
0.01M PBS (1:10 w/v) at room temperature for 2 hours followed by clarification by 
centrifuging at 10,000 g for 30 min using a table top centrifuge. 
Preparation of SPI from defatted soybean flour was carried out according to the 
procedure by Molina Ortiz and Wagner, (2002) and Sorgentini et al. (1995). Defatted 
soybean flour was extracted with alkaline water (1:10 w/v) at room temperature for 2 
hours after adjusting the pH of water to 8.0 with 2N NaOH. After extraction the solution 
was centrifuged at 10,000 x g for 30 min at 4
o
C using a table top centrifuge. The pellet 
was discarded and the supernatant was adjusted to a pH of 4.5 using 2N HCl. In this 
condition an isoelectric precipitate was formed, which was separated by centrifuging at 
5000 x g for 10 min at 4
o
C. The precipitate was resuspended in 0.01M PBS (5% w/v) and 
the pH was adjusted to pH 8.0 using 2N NaOH. The precipitate was dissolved by 
vortexing and subsequently shaking at room temperature for 1 hour, and stored at -20
o
C. 
The protein content of the defatted soy flour extract and that of the SPI was determined 
by the Lowry method (BioRad, Hercules, CA, USA, Cat # 500-0113, reagent A, Cat # 
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500-0114, reagent B) using BSA (BioRad, Hercules, CA, USA, Cat # 500-0205) as a 
standard.   
Human sera 
 Soybean allergic and non-soybean allergic control serum samples collected by 
PlasmaLab International, an FDA licensed blood collection company, were used in this 
study (Table 1). Use of these serum samples has been approved by the UNL Institutional 
Review Board. The allergic patients utilized in this study have soybean specific IgE level 
ranging from 3-68 kU/L as measured by ImmunoCAP® (Phadia, now Thermo Scientific, 
Uppsala, Sweden) or IMMULITE® (Siemens Healthcare, Erlangen, Germany), allergen-
specific IgE test systems. Most of the soybean allergic subjects also reported peanut 
specific allergic reactions and have significant peanut specific IgE levels ranging from 15 
to100 kU/L. The control subject used in this study did not report any food allergies. 
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Table 1. Soybean allergic and control serum used to evaluate enzyme hydrolyzed 
soybean proteins 
 
nd- not detected 
 
Serum  Reported food allergies 
Soybean-specific 
IgE 
(ImmunoCAP 
Peanut-
specific IgE 
(ImmunoCAP 
18534-LN Nuts, beans and seeds 17.30 Nd 
9735-RE Anaphylaxis to peanut, 
soybean, causes sore throat, 
itchy mouth, queasy stomach 
5  58 
20197-BH Itchy throat with nuts and raw 
veggies 
 3  95 
19392-CS Angioedema, vomit, EOS G; 
milk, egg, meat, fruit, peaches, 
pears, (?profilin?) 
68 15 
20770-MH Throat swelling with peanut  38 43 
24033/20431 Peas, peanut, soy, lentil, sulfur 
drugs, garbanzo beans; 
anaphylactic shock from 
peanut, eczema, hives 
Nd Nd 
23736-
AM/20300 
all trees, grass, peanuts, cats, 
rabbits 
15.3 >100 
20247-LA/20160 buckwheat, rice, rye, celery, 
lettuce, orange, crab, parsley, 
tomato, almond, coconut, 
peanut, pecan, sesame, corn, 
pea, whitebean, carrot, potato, 
wheat, oat, soybean 
14.9 15.6 
Control serum 
(RP) 
No known allergies Nd Nd 
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Enzyme hydrolysis of soybean samples 
Five different enzymes including Alcalase® (Novozymes, Bagsvaerd, Denmark), papain, 
bromelain, trypsin and chymotrypsin were purchased from Sigma (Sigma-Aldrich, Saint 
Louis, MO) and were used to hydrolyze the SPI and defatted soy flour extract samples. 
The concentrations and hydrolysis conditions (pH and temperature) used for hydrolysis 
of SPI and soy flour extract with different enzymes are summarized in Table 2. These 
hydrolysis conditions were chosen based on previously published studies (Kim et al., 
1990; Oritz, 2000; Cabanillas et al., 2010). Hydrolysis was carried out for 5, 15, 30 or 60 
min with each enzyme and after hydrolysis the enzymes were inactivated by rapidly 
heating the samples at 95
o
C for 5 min. The samples after hydrolysis were aliquoted and 
stored at -20
o
C until further analysis. Two different types of control samples were used 
along with the hydrolyzed samples for analysis. Heat-controlled samples were prepared 
for SPI and soy flour extracts and incubated at the respective incubation temperatures for 
each enzyme along with the test samples, and then they were also heated at 95
o
C for 5 
min.  In addition, untreated extracts of SPI and soy flour were analyzed along with 
treated samples, as unheated controls. An enzyme only control was also analyzed along 
with the treated and control extracts. 
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Table 2. Hydrolysis conditions of SPI and defatted soy flour extracts with different 
enzymes 
Enzyme Concentration Hydrolysis condition 
Alcalase® (Protease 
from Bacillus 
licheniformis, Sigma # 
P4860), Activity = 
2.4U/g  
 
0.2U of enzyme/gm of protein  
 
50
o
C and pH 8.00 
Papain from papaya 
latex (Sigma # P4762, 
Activity ≥ 10 units/mg 
solid) 
4 parts of protein mixed with 
1 part of 0.168 mg/ml of 
enzyme solution (for SPI),  4 
parts of protein mixed with 1 
part of 0.197 mg/ml of 
enzyme solution (for soy 
flour) 
 
40
o
C and pH 8.00  
 
Bromelain from pine 
apple stem (Sigma # 
B4882), Activity= 3-
7 units/mg protein  
 
4 parts of protein mixed with 
1 part of 0.168 mg/ml of 
enzyme solution (for SPI),  4 
parts of protein mixed with 1 
part of 0.197 mg/ml of 
enzyme solution (for soy 
flour) 
 
40
o
C and pH 8.00  
 
Trypsin (Sigma, 
Trypsin  from bovine 
pancreas # T8003)  
 
2% of SPI or defatted soy 
flour extract (w/w)  
 
37
o
C and pH 8.00  
 
Chymotrypsin (Sigma, 
α-chymotrypsin from 
bovine pancreas # 
C4129) 
 
2% of SPI or defatted soy 
flour extract (w/w)  
 
37
o
C and pH 8.00  
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1D- and 2D-PAGE and IgE immunoblotting 
The hydrolyzed SPI and defatted soy flour extracts and control samples were diluted 
using Laemmli SDS-sample buffer (Boston BioProducts, Ashland, MA) to a allow 
loading 10 µg of soybean protein (10 µl /well) in SDS-PAGE gel. Samples were run 
under both reducing (2-mercaptoethanol and heating at ~ 95°C for 5 minutes) and non-
reducing conditions using a Novex 10-20% tris-glycine gels (Invitrogen, Carlsbad, CA). 
A pre-stained Precision Plus molecular weight marker protein sample (BioRad, Hercules, 
CA, USA) was run in a separate lane to estimate protein size. Electrophoresis was 
accomplished at a constant 125 V for 105 min. The proteins separated in the gels were 
then fixed in a solution of 7% acetic acid, 40% methanol in water and stained with 
Brilliant Blue G-colloidal (Sigma, St Louis, MO, USA, Cat # B2025) for at least 2 hours. 
After staining, the gels were destained for one min in 10% acetic acid, 25% methanol in 
water, and then multiple changes of 25% methanol until the background was clear of blue 
dye. 
  For two dimensional (2D) PAGE, a BioRad PROTEAN IEF Cell (BioRad 
Hercules, CA, USA, Cat # 165-4001) was used for the first dimensional separation of the 
proteins based on their iso-electric points. Sample consisting of 25 µg of heated control 
SPI or SPI digested with Alcalase, trypsin or chymotrypsin for 60 min were diluted to 125 
µl with IEF sample buffer [8M urea, 2% CHAPS, 50 mM DTT (Fisher Bioreagents, 
Pittsburg, PA, USA, Cat # BP172-5) and 0.5% ampholyte (BioRad, Hercules, CA, USA, 
Cat # 163-1112)] and then applied to individual troughs of the IEF focusing tray (BioRad, 
Hercules, CA, USA, Cat # 165-4030). Individual pI 3-10 linear IEF strips (BioRad, 
Hercules, CA, USA, Cat # 163-2000) were placed into the trough of each sample well and 
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focusing was carried out after covering the strip in each well with 4 ml of mineral oil 
(BioRad, Hercules, CA, USA, Cat # 163-2129). An active rehydration was performed at 
50 V for 12 hours followed by 250 V run for 15 min, 4000 V ramping for 2 hours and 
finally a 4000 V limit step was used until 34,000 integrated Vhr was reached. Proteins 
were then maintained in position with a constant application of 500 V until morning. The 
strips were then equilibrated for 15 min in 2.5 ml of DTT equilibration buffer (6 M urea, 
2% SDS, 0.375 M Tris-HCl, pH 8.8, 20% glycerol, 130 mM DTT) and then 15 min 2.5 ml 
iodoacetamide equilibration buffer (6 M urea, 2% SDS, 0.375 M Tris-HCl, pH 8.8, 20% 
glycerol, 135 mM iodoacetamide) for reduction and acetylation. Separation in the second 
dimension was carried out by placing the focused strips into the 7cm wide well and 4 µl of 
pre-stained Precision Plus molecular weight marker proteins into the small well of 
NuPAGE® Novex 4-12% Bis-Tris ZOOM® Gels (Invitrogen, Carlsbad, CA, USA, Cat # 
NP0330BOX).  The wells were sealed with molten 0.5% agarose (Invitrogen, Carlsbad, 
CA, USA, Cat # 15510-019). Electrophoresis was accomplished at a constant 150 V for 60 
min.  Staining of proteins in the gels after electrophoresis was performed using EZBlue
TM
 
gel stain (Sigma, St Louis, MO, USA, Cat # G1041). 
  For immunoblots, the separated proteins from unstained gels were electro-
transferred to polyvinylidene difluoride (PVDF) membranes (Invitrogen, Carlsbad, CA, 
USA, Cat. # LC3675) at 25 V for 90 min using Novex® transfer buffer (Invitrogen, 
Carlsbad, CA, USA, Cat # LC 3675). The protein transfer was verified by staining the 
membranes with Ponceau S stain (Sigma, St Louis, MO, USA, Cat# P7170). The 
membranes were then blocked with 5% non-fat dry milk (NFDM) in PBS containing 
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0.05% Tween 20 (PBST) for at least one hour. Individual human sera (eight individual 
soybean allergic and one control sera) were diluted 1:10, in 2.5% NFDM in PBST and 
allowed to bind to the NFDM for 1 hour before incubating with the blocked membrane for 
overnight at room temperature. Unbound antibody was removed from the membranes by 
washing four times 5 min each with PBST. Bound IgE was detected using monoclonal 
horse radish peroxidase (HRP) conjugated anti-human IgE (SouthernBiotech, 
Birmingham, AL: clone B3102E8 Cat # 9160-05), diluted 1:1000 with 2.5% NFDM in 
PBST. The unbound secondary antibodies were removed by washing the membranes four 
times with PBST. Detection was achieved using Supersignal West Dura Extended 
Duration substrate (Pierce, Rockford, IL, USA, Cat # 34076) and capturing emitted light 
with a Kodak Gel Logic 440 image station with multiple exposures. A nitrocellulose 
membrane (Invitrogen, Carlsbad, CA, USA, Cat # 645239) spotted with diluted purified 
IgE (Human IgE, monoclonal with kappa light chain, ABCAM, Inc., Cambridge, MA, Cat 
# AB65866-100) then blocked with 5% NFDM in PBST and incubated with the secondary 
antibody and substrate as immunoblots was exposed along with the immunoblots to help 
evaluate signal strength.  
Mediator release assay using a humanized rat basophilic leukemia (hRBL) cell line  
Humanized rat basophilic leukemia (hRBL) cells (RBL-703/21) were used for the 
mediator release assay. The procedure for maintenance of the cells and preparation of 
buffers for use in the assay were similar to as described in Chapter 3. For the assay, 
adhered cells in stationary phase were dislodged by application of 0.01 M EDTA in 
MEM for 30-45 min. The cells were washed twice with fresh media and diluted to a cell 
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density of 2.0 X 10
6
 cells/ml and 50 µl (1 X 10
5
 cells) was seeded into each well of a 96 
well micro titer plate followed by sensitization with 50 µl of individual human plasma 
(diluted 1:10 with the MEM). Sensitization was carried out by incubating the plates at 5% 
CO2 at 37°C for approximately 12 hours. After 12 hours incubation cells were washed 
with Tyrode’s wash buffer twice and challenged with five different concentrations (10 
µg/ml, 1 µg/ml, 0.1 µg/ml, 0.01 µg/ml and 0.001 µg/ml) of the hydrolyzed SPI and 
defatted soy flour extracts as well as the control extracts diluted in allergen challenge 
buffer. The plates were then incubated in a water bath (37°C) for 1 hour. After one hour 
incubation 30 µl of cell supernatant was added to 50 µl of substrate in untreated 
polystyrene 96-well micro plates (Thermo Scientific Nunc # 12-565-226) and the plates 
were incubated at 37°C in a water bath for one hour.  Reactions were stopped by adding 
100 µl stopping solution and the absorbance of samples was measured at 405 nm. 
Absorbance values of samples challenged with antigen were adjusted to a baseline 
reference by subtracting readings from IgE sensitized cells that were not exposed to 
antigen (serum negative controls). Cells sensitized by human IgE (#ab65866 from Abcam 
Inc., Cambridge, MA) and cross-linked by anti-human IgE (Sigma # I6284) were used as 
positive control. Further cells sensitized with the test serum and cross-linked by anti-IgE 
instead of the antigen extract were used as a positive control for total serum IgE release. 
Test sample readings were expressed as a percentage of total (complete) release as well 
as serum IgE release. 
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RESULTS 
Hydrolysis of SPI and soy flour extract with Alcalase 
Alcalase is a serine endopeptidase from Bacillus licheniformis. The enzyme used in this 
study had a specific activity of 2.4 Anson units (AU) per gram. Extracts of SPI and 
defatted soy flour were digested with this enzyme at a concentration of 0.2 AU/ gram of 
protein. After hydrolysis the samples were run under both reducing and non-reducing 
SDS-PAGE. Figure 1A shows the SDS-PAGE pattern of the hydrolyzed and control SPI 
and soy flour extracts. Both the unheated and heated control samples under reducing 
conditions showed multiple bands between molecular weight of 10 to 100 kDa. After 
hydrolysis most of the higher molecular weight bands disappeared and at the same time 
an increase in low molecular weight protein bands ranging from 6-10 kDa appeared in the 
stained gel. Intense staining to some protein bands (approximately 20 kDa and two bands 
at 12-13 kDa) remained in the hydrolyzed samples. The staining pattern for the proteins 
bands appearing in SDS-PAGE was similar for all the three time points of hydrolysis (5, 
30 and 60 min) except for a slight reduction in band intensity with increase in hydrolysis 
time. Under non-reducing conditions, the heated control sample showed some differences 
in SDS-PAGE band pattern compared to the unheated control (e.g. disappearance of a 
band of approximately 50 kDa). All hydrolyzed samples showed a reduction in band 
intensity compared to the control samples. Additionally, new protein bands of 
approximately 6-12 kDa appeared in all the hydrolyzed samples as was evident in 
samples analyzed under reducing conditions.  
  In order to find out whether there are differences in the IgE binding patterns of 
protease treated samples as might be expected from stained gel patterns, immunoblotting 
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was performed using eight individual soybean allergic patient sera and one non-soybean 
allergic control sera. Figure 1B shows the IgE binding pattern of Alcalase hydrolyzed and 
control SPI and defatted soy flour samples with serum 19392-CS. Both the heated and 
unheated control samples of 5% SPI and defatted soy flour extract showed a complex 
pattern of IgE binding ranging from 30 kDa to 75 kDa under reducing conditions. With the 
SPI sample IgE binding to most of the protein bands was reduced after treatment with 
Alcalase. However, IgE binding was still similar for two bands of approximately 50 and 
35 kDa in the sample hydrolyzed for 5 min. Furthermore, strong IgE binding to a band of 
approximately 20 kDa appeared following digestion. The defatted soy flour extract control 
samples also showed a complex pattern of IgE binding to protein bands ranging from 
approximately 30 to 75 kDa under reducing conditions and IgE binding to the hydrolyzed 
samples was reduced compared to the control samples. Similar to the 5% SPI samples, 
strong IgE binding also appeared to a protein at approximately 20 kDa in all hydrolyzed 
samples. However, unlike SPI, IgE binding to the 50 kDa band remained in all hydrolyzed 
samples and binding to the 35 kDa band remained in the 5 min and 30 min hydrolyzed 
samples. Under non-reducing conditions, for both the 5% SPI and defatted soy flour 
samples the intense IgE binding observed to the higher molecular weight protein bands 
ranging from 35 to 250 kDa in both the unheated and heated control samples was reduced 
when samples were treated with Alcalase, although faint IgE binding to a 50 kDa band 
still retained in the hydrolyzed soy flour extract (Figure 1B). 
 With serum 20431 (Figure 1C), under both reducing and non-reducing conditions, both 
the unheated and heated control SPI showed strong IgE binding to protein bands ranging 
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from 50- 250 kDa and to a lower molecular weight protein band of approximately 25 kDa. 
After treatment with Alcalase most of the IgE binding to the higher molecular weight 
protein bands was markedly reduced. However, IgE binding to the 25 kDa band remained 
in all hydrolyzed samples. For the defatted soy flour sample most of the IgE binding seen 
to the control samples was reduced with Alcalase treatment. IgE binding to two protein 
bands of 50 and 25 kDa still remained in all hydrolyzed samples and IgE binding to a band 
of 35 kDa appeared only in the sample hydrolyzed for 5 min, but not longer (Figure 1C). 
With all other sera used in the immunoblot analysis, IgE binding to both the 5% SPI and 
soy flour samples treated with Alcalase was markedly reduced compared to the control 
samples (not shown).  
  To evaluate whether these reductions in IgE binding as well as appearance of new 
IgE binding bands in the hydrolyzed samples as observed in the immunoblots have any 
biological significance, mediator release assays were performed using the hRBL cell line. 
Figure 1D shows the β-hexosaminidase release results expressed as a percent of total 
serum IgE (anti-IgE induced) release of the Alcalase hydrolyzed and control 5% SPI and 
defatted soy flour extract samples using serum 19392-CS. Results of the β- 
hexosaminidase release using 1µg/ml antigen concentration, it can be observed that the 
unheated control sample showed a release of approximately 20% for the SPI sample and 
30% for the defatted soy flour extract sample. The β-hexosaminidase release was 
markedly reduced for the heated control (8% release for SPI and 12% for defatted soy 
flour extract) even though both samples showed similar IgE binding in immunoblots with 
the same sera (Figure 1B). SPI samples treated with Alcalase resulted in a similar mediator 
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release as the heated control sample except for the 60 min hydrolyzed sample, which 
showed a slightly lower release compared to shorter digestion samples. Similar to the 
hydrolyzed SPI samples all hydrolyzed defatted soy flour samples also showed a mediator 
release (approximately 12%) similar to the heated control indicating no effect of 
hydrolysis on the release.  
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Figure 1A. SDS-PAGE stained gel of 5% SPI and defatted soy flour extracts 
hydrolyzed for 5, 30 or 60 min with Alcalase compared to the unheated and heated 
control samples. Samples (10 g/lane) were run under both reducing and non-reducing 
conditions.  Proteins in gels were then fixed and stained with Brilliant Blue G-colloidal 
stain. 
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Figure 1B. IgE immunoblots of 5% SPI and defatted soy flour extract treated for 5, 
30 or 60 min with Alcalase compared to the control samples, using serum 19392-CS. 
Samples (10 µg pre-treatment protein) were treated as indicated for each lane, then 
separated by SDS-PAGE in both non-reducing and reducing gels prior to transfer onto 
PVDF membranes. A 1:10 diluted sample of serum was incubated with each membrane 
and following washing, bound IgE was detected using monoclonal anti-human IgE-HRP 
conjugate with detection by ECL. Images of the light emissions were captured using a 
Kodak imaging system as described in the text.  
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Figure 1C. IgE immunoblots of 5% SPI and defatted soy flour extract treated for 5, 
30 or 60 min with Alcalase compared to the control samples, using serum 20431. 
Samples (10 µg pre-treatment protein) were treated as indicated for each lane, then 
separated by SDS-PAGE in both non-reducing and reducing gels prior to transfer onto 
PVDF membranes. A 1:10 diluted sample of serum was incubated with each membrane 
and following washing, bound IgE was detected using monoclonal anti-human IgE-HRP 
conjugate with detection by ECL. Images of the light emissions were captured using a 
Kodak imaging system as described in the text. 
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Figure 1D. β-hexosaminidase release from humanized RBL-703/21 cells, sensitized 
with IgE from serum 19392-CS and challenged with Alcalase hydrolyzed and control 
SPI and soy flour extract samples. Humanized RBL-clone 703/21 cells were sensitized 
with IgE from serum 19392-CS (diluted 1: 10) and were challenged with 100 μl of alcalse 
hydrolyzed and control SPI and defatted soy flour extract samples. The challenge  doses 
corresponding to 0.001 μg/ml to 10 μg/ml of undigested soybean  antigen was used to 
challenge the cells as shown in the graph. Absorbance values were measure at 405 nm and 
β-hexosaminidase release is expressed as a percentage of total serum IgE release (cells 
sensitized with serum and challenged with anti-IgE)  
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Hydrolysis of SPI and soy flour extract with papain 
Papain, a cysteine protease from papaya latex, was used to hydrolyze SPI and defatted soy 
flour extracts and the effect of hydrolysis on soybean protein allergenicity was evaluated. 
Figures 2A and 2B show the SDS-PAGE profiles of the papain digested SPI and soy flour 
extract samples respectively in addition to the unheated and heated control samples. Under 
both reducing and non-reducing conditions the unheated and heated SPI and soy flour 
extract control samples showed multiple protein bands ranging from 12 to 100 KDa, 
which were reduced in intensity and number of bands in the digested samples. Some 
protein bands (e.g. approximately 25 kDa and two bands at approximately 14 kDa under 
reducing condition) still remained visible in the digested samples and some new lower 
molecular weight protein bands of approximately 10 kDa appeared in all the digested 
samples. A slight difference in band intensity was observed among the samples digested 
for longer times. All samples were analyzed by IgE immunoblots using eight soybean 
allergic sera to evaluate differences in IgE binding patterns. Figure 2C shows the 
immunoblot patterns of the papain digested and control SPI and defatted soy flour extract 
samples with serum 19392-CS. With this serum the strong IgE binding observed to both 
the unheated and heated control SPI and soy flour extract samples was markedly reduced 
when the samples were digested with papain. Very faint binding to a 35 kDa band under 
reducing conditions and a 50 kDa band under non-reducing conditions remained in all 
hydrolyzed SPI samples. With the hydrolyzed soy flour extract, strong IgE binding was 
observed to the 50 kDa band under non-reducing conditions for samples that were digested 
with papain for 30 and 60 min and under reducing condition IgE binding to the 35 kDa 
band remained in all hydrolyzed samples. Figure 2D shows the IgE immunoblots of the 
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papain digested SPI and soy flour extract samples with serum 20431. All papain digested 
SPI samples showed a complete absence of IgE binding with this serum both under 
reducing and non-reducing conditions. However, IgE binding to a 50 kDa band remained 
in the digested defatted soy flour extracts. IgE immunoblots with all other sera showed a 
complete absence of IgE binding to the papain digested samples (not shown). A mediator 
release assay was used to evaluate the biological significance of IgE binding observed in 
blotting experiments with serum 19392-CS (Figure 2E). The β-hexosaminidase release 
assay with hRBL cells challenged with a dose of 1 µg/ml antigen concentration produced a 
release of approximately 45% using unheated control SPI and soy flour extract samples 
while the heated control resulted in a comparatively lower release of approximately 20%.  
All papain digested SPI and defatted soy flour extract samples showed β-hexosaminidase 
release comparable to the heated control samples in spite of showing a strong reduction in 
IgE binding by immunoblots (Figure 2C).  
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Figure 2A. SDS-PAGE stained gel of 5% SPI hydrolyzed for 5, 15, 30 or 60 min with 
papain compared to the unheated and heated control samples. Samples (10 g 
protein/lane) were run under both reducing and non-reducing conditions, then the gels 
were fixed and stained with Brilliant Blue G-colloidal stain. 
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Figure 2B. SDS-PAGE stained gel of defatted soy flour extract hydrolyzed for 5, 15, 
30 or 60 min with papain compared to the unheated and heated control samples. 
Samples (10 g protein/lane) were run under both reducing and non-reducing conditions, 
then gels were fixed and stained with Brilliant Blue G-colloidal stain. 
.   
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Figure 2C. IgE immunoblots of 5% SPI and defatted soy flour extract treated for 5, 
30 or 60 min with papain compared to the control samples, using serum 19392-CS. 
Samples (10 µg pre-treatment protein) were treated as indicated for each lane, then 
separated by SDS-PAGE in both non-reducing and reducing gels prior to transfer onto 
PVDF membranes. A 1:10 diluted sample of serum was incubated with each membrane 
and following washing, bound IgE was detected using monoclonal anti-human IgE-HRP 
conjugate with detection by ECL. Images of the light emissions were captured using a 
Kodak imaging system as described in the text. 
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Figure 2D. IgE immunoblots of 5% SPI and defatted soy flour extract treated for 5, 
30 or 60 min with papain compared to the control samples, using serum 20431. 
Samples (10 µg pre-treatment protein) were treated as indicated for each lane, then 
separated by SDS-PAGE in both non-reducing and reducing gels prior to transfer onto 
PVDF membranes. A 1:10 diluted sample of serum was incubated with each membrane 
and following washing, bound IgE was detected using monoclonal anti-human IgE-HRP 
conjugate with detection by ECL. Images of the light emissions were captured using a 
Kodak imaging system as described in the text. 
 
 
 
5% SPI Defatted Soy flour extract 
102 101 1        10-1 10-2  10-3
10
15
20
25
37
50
75
100
150
250
5
Reduced
10
15
20
25
37
50
75
100
150
250
5
Non-reduced
ng IgE/spot10
2 101 1        10-1 10-2  10-3
10
15
20
25
37
50
75
100
150
250
5
Reduced
10
15
20
25
37
50
75
100
150
250
5
Non-reduced
ng IgE/spot
Serum 20431
P
ap
ai
n
d
ig
. 3
0 
m
in
P
ap
ai
n
U
n
h
e
at
e
d
 c
o
n
tr
o
l
H
e
at
e
d
 c
o
n
tr
o
l
P
ap
ai
n
d
ig
. 5
 m
in
P
ap
ai
n
d
ig
. 6
0 
m
in
P
ap
ai
n
d
ig
. 3
0 
m
in
P
ap
ai
n
U
n
h
e
at
e
d
 c
o
n
tr
o
l
H
e
at
e
d
 c
o
n
tr
o
l
P
ap
ai
n
d
ig
. 5
 m
in
P
ap
ai
n
d
ig
. 6
0 
m
in
P
ap
ai
n
d
ig
. 3
0 
m
in
P
ap
ai
n
U
n
h
e
at
e
d
 c
o
n
tr
o
l
H
e
at
e
d
 c
o
n
tr
o
l
P
ap
ai
n
d
ig
. 5
 m
in
P
ap
ai
n
d
ig
. 6
0 
m
in
P
ap
ai
n
d
ig
. 3
0 
m
in
P
ap
ai
n
U
n
h
e
at
e
d
 c
o
n
tr
o
l
H
e
at
e
d
 c
o
n
tr
o
l
P
ap
ai
n
d
ig
. 5
 m
in
P
ap
ai
n
d
ig
. 6
0 
m
in
180 
 
 
Figure 2E. β-hexosaminidase release from humanized RBL-703/21 cells, sensitized 
with IgE from serum 19392-CS and challenged with papain hydrolyzed and control 
SPI and soy flour extract samples. Cells of humanized RBL-clone 703/21 were 
sensitized with IgE from serum 19392-CS (diluted 1: 10) and were challenged with 100 
μl of papain hydrolyzed and control SPI and defatted soy flour extract samples 
Representing original protein concentrations of 0.001 μg/ml to 10 μg/ml of antigen. 
Absrobance values were measure at 405 nm and β-hexosaminidase release was expressed 
as percentage of total serum IgE release (cells sensitized with serum and challenged with 
anti-IgE)  
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Hydrolysis of SPI and soy flour extract with bromelain 
Bromelain from pineapple stem was used to hydrolyze the SPI and defatted soy flour 
extract samples. The protein profile of hydrolyzed samples was evaluated by separating 
them by both reducing and non-reducing SDS-PAGE (Figure 3A and 3B). Additionally, 
IgE immunoblotting was performed using eight soybean allergic and one control patient 
sera following transfer of the proteins from unstained gels onto PVDF membranes as 
described previously. Digestion of both SPI and defatted soy flour extracts with bromelain 
resulted in the elimination of some higher molecular weight protein bands that are visible 
in both the unheated and heated control samples. However, some lower molecular weight 
protein bands are still visible in digested samples (approximately 12, 14, 20 and 35 kDa 
under reducing condition and 12, 14, 37 and 45 kDa under non-reducing condition). 
Additionally some new lower molecular weight protein bands of approximately 5-13 kDa, 
appeared in the stained gels of the digested samples under both reducing and non-reducing 
conditions. Figure 3C shows the immunoblot analysis of the bromelain hydrolyzed SPI 
and defatted soy flour samples with serum 19392-CS. Most of the IgE binding seen to the 
control samples with this serum was retained in the hydrolyzed samples under both 
reducing and non-reducing conditions. Additionally a complex pattern of new IgE binding 
bands appeared in the hydrolyzed samples mostly under reducing conditions including 
bands of approximately 30, 45 and 55 kDa in hydrolyzed SPI samples and 22. 30, 45 and 
55 kDa in hydrolyzed defatted soy flour extract samples. With serum 20431 (Figure 3D), 
IgE binding to a band of 75 kDa observed under reducing conditions and three bands of 
75, 100 and 150 kDa under non-reducing condition observed in the control samples were 
eliminated when both SPI and defatted soy flour extract samples were hydrolyzed with 
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bromelain. However, IgE binding to a protein band of 50 kDa remained in all hydrolyzed 
samples. Additionally two new IgE binding protein bands of 25 and 30 kDa appeared in 
all hydrolyzed samples. Out of six other soy allergic sera that were used in IgE 
immunoblot tests, only serum 9735-RE showed a complete absence of IgE binding to the 
bromelain hydrolyzed SPI and defatted soy flour extract (Figure 3E) whereas all other sera 
still retained most of the IgE binding. Furthermore, four out of eight sera showed strong 
IgE binding to a 12 kDa band that appeared only in the hydrolyzed SPI samples under 
reducing conditions (Figure 3F).  
  In accordance with the immunoblot results, mediator release from hRBL cells 
sensitized with serum 19392-CS and stimulated with samples that correspond to 1 µg/ml 
antigen concentration revealed no reduction in β-hexosaminidase release for hydrolyzed 
samples of SPI relative to the heated control sample whereas a slight reduction in release 
was obtained for hydrolyzed defatted soy flour samples compared to the heated control 
(Figure 3G). Interestingly both the SPI and defatted soy flour samples that were treated 
with bromelain for 30 min showed an increase in β-hexosaminidase release compared to 
the heated control (Approximately 50% vs 40% for defatted soy flour sample and 30% vs 
15% for the SPI sample).  
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Figure 3A. SDS-PAGE stained gel of 5% SPI hydrolyzed for 5, 15, 30 or 60 min with 
bromelain compared to the unheated and heated control samples. Identical samples 
(10 g protein/lane) were run under both reducing and non-reducing conditions, and then 
gels were fixed and stained with Brilliant Blue G-colloidal stain. 
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Figure 3B. SDS-PAGE stained gel of defatted soy flour extract hydrolyzed for 5, 15, 
30 or 60 min with bromelain compared to the unheated and heated control samples. 
Identical samples (10 g protein/lane) were run under both reducing and non-reducing 
conditions, and then gels were fixed and stained with Brilliant Blue G-colloidal stain. 
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Figure 3C. IgE immunoblots of 5% SPI and defatted soy flour extract treated for 5, 
30 or 60 min with bromelain compared to the control samples, using serum 19392-
CS. Samples (10 µg pre-treatment protein) were treated as indicated for each lane, then 
separated by SDS-PAGE in both non-reducing and reducing gels prior to transfer onto 
PVDF membranes. A 1:10 diluted sample of serum was incubated with each membrane 
and following washing, bound IgE was detected using monoclonal anti-human IgE-HRP 
conjugate with detection by ECL. Images of the light emissions were captured using a 
Kodak imaging system as described in the text. 
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Figure 3D. IgE immunoblots of 5% SPI and defatted soy flour extract treated for 5, 
30 or 60 min with bromelain compared to the control samples, using serum 20431. 
Samples (10 µg pre-treatment protein) were treated as indicated for each lane, then 
separated by SDS-PAGE in both non-reducing and reducing gels prior to transfer onto 
PVDF membranes. A 1:10 diluted sample of serum was incubated with each membrane 
and following washing, bound IgE was detected using monoclonal anti-human IgE-HRP 
conjugate with detection by ECL. Images of the light emissions were captured using a 
Kodak imaging system as described in the text. 
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Figure 3E. IgE immunoblots of 5% SPI and defatted soy flour extract treated for 5, 
30 or 60 min with bromelain compared to the control samples, using serum 9735-
RE. Samples (10 µg pre-treatment protein) were treated as indicated for each lane, then 
separated by SDS-PAGE in both non-reducing and reducing gels prior to transfer onto 
PVDF membranes. A 1:10 diluted sample of serum was incubated with each membrane 
and following washing, bound IgE was detected using monoclonal anti-human IgE-HRP 
conjugate with detection by ECL. Images of the light emissions were captured using a 
Kodak imaging system as described in the text. 
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Figure 3F. IgE immunoblots of 5% SPI and defatted soy flour extract treated for 5, 
30 or 60 min with bromelain compared to the control samples, using serum 20770-
MH. Samples (10 µg pre-treatment protein) were treated as indicated for each lane, then 
separated by SDS-PAGE in both non-reducing and reducing gels prior to transfer onto 
PVDF membranes. A 1:10 diluted sample of serum was incubated with each membrane 
and following washing, bound IgE was detected using monoclonal anti-human IgE-HRP 
conjugate with detection by ECL. Images of the light emissions were captured using a 
Kodak imaging system as described in the text. 
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Figure 3G. β-hexosaminidase release from humanized RBL-703/21 cells, sensitized 
with IgE from serum 19392-CS and challenged with bromelain hydrolyzed and 
control SPI and soy flour extract samples. Cells of humanized RBL-clone 703/21 were 
sensitized with IgE from serum 19392-CS (diluted 1: 10) and challenged with 100 μl of 
bromelain hydrolyzed and control SPI and defatted soy flour extract samples. Doses of 
0.001 μg/ml to 10 μg/ml of antigen were used to challenge the cells as shown in the 
graph. Absrobance values were measure at 405 nm and β-hexosaminidase release is 
expressed as a percentage of total serum IgE release (cells sensitized with serum and 
challenged with anti-IgE). 
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Hydrolysis of SPI and soy flour extracts with trypsin and chymotrypsin 
Trypsin and chymotrypsin from bovine pancreas were used to hydrolyze the SPI and 
defatted soy flour extract samples in separate digestion samples. Any changes in the 
apparent allergenicity of the hydrolyzed proteins were evaluated by IgE immunoblot as 
well as mediator release assay. Figures 4A and 4B show the SDS-PAGE protein profiles 
of the trypsin or chymotrypsin digested SPI and defatted soy flour extract samples 
respectively. Trypsin hydrolysis of SPI and defatted soy flour extracts resulted in the 
disappearance or reduction of most of the high molecular weight protein bands compared 
to the control samples. However, a number of protein bands remained constant throughout 
the hydrolysis by trypsin under reducing and non-reducing conditions (e.g. 18-20 kDa 
under reducing conditions and a 30 kDa band under non-reducing conditions) and were 
present in undigested controls. Additionally some new protein bands appeared at 5 min of 
hydrolysis and remained constant in both SPI and soy flour samples (e.g. 24 kDa band 
under reducing conditions and three adjacent bands ranging from 24-26 kDa under non-
reducing conditions). A similar result was obtained when both SPI and defatted soy flour 
samples were hydrolyzed with chymotrypsin. For example, a 20 kDa and a 50 kDa band 
remained resistant to hydrolysis and a new protein band of 25 kDa appeared in the 
hydrolyzed samples under reducing conditions.  
  The IgE immunoblots with serum 19392-CS for 5% samples of SPI and 
defatted soy flour extract samples digested with trypsin and chymotrypsin are shown in 
Figures 4C and 4D. A marked reduction in IgE binding to the trypsin digested SPI 
samples was observed compared to the control samples under both reducing and non-
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reducing condition although strong IgE binding to a 20 kDa band remained under 
reducing conditions (Figure 4C). The mediator release assay using the same sera 
however, did not result in any differences in β-hexosaminidase release for all the trypsin 
hydrolyzed SPI samples compared to the heated control sample (Figure 4E). Some 
differences in IgE immunoblotting patterns were observed for trypsin digested defatted 
soy flour extract compared to the trypsin digested SPI with serum 19392-CS (Figure 4D). 
Under reducing conditions, most of the IgE binding to protein bands ranging from 35 to 
75 kDa still remained after 5 min and 15 min of trypsin digestion followed by marked 
reduction at 30 min and 60 min for soy flour extract. Under non-reducing conditions IgE 
binding to a 50 kDa band remained in the 5 min and 15 min trypsin hydrolyzed extract, 
however binding was completely abolished when the extract was digested with trypsin at 
30 and 60 min. Additionally two new IgE binding bands (24 and 30 kDa) appeared in the 
trypsin digested soy flour extract when the gel was run under reducing conditions, and a 
minor band appeared with a similar profile under non-reducing conditions (Figure 4D). 
The mediator release assay of the trypsin hydrolyzed defatted soy flour sample with the 
same sera showed a slight reduction in β-hexosaminidase release compared to the control 
samples when stimulated with either 1 or 10 microgram equivalents of digested sample 
(Figure 4E).  
   Chymotrypsin digested SPI (Figure 4C) and defatted soy flour extract (Figure 4D) 
retained most of the IgE binding that was observed in case of the control samples with 
serum 19392-CS. An interesting observation was that IgE binding to a 20 kDa band was 
obviously stronger for chymotrypsin digested SPI compared to the control samples (Figure 
192 
 
4C). This increase was not observed in case of chymotrypsin digested defatted soy flour 
extract (Figure 4D). The mediator release assay with the serum 19392-CS also reflected 
this difference between the chymotrypsin digested SPI and defatted soy flour extract 
(Figure 4F). While all the chymotrypsin digested SPI samples showed a higher β-
hexosaminidase release compared to the heated control sample at 1 µg/ml antigen 
concentration, the release with the chymotrypsin hydrolyzed defatted soy flour samples 
was lower compared to the heated control (Figure 4F).  
  With serum 20431 (Figure 4G), IgE binding to the higher molecular weight 
protein bands ranging from 50-150 kDa that was observed for the control SPI samples was 
eliminated or markedly reduced when they were treated with trypsin. Relatively faint IgE 
binding to a 50 kDa band remained in the hydrolyzed samples (mostly under reducing 
conditions) and faint IgE binding to a 25 kDa band that was observed in the control 
sample was strongly augmented in all the trypsin hydrolyzed SPI samples. Additionally a 
new IgE binding protein band (15 kDa) was observed for all the trypsin hydrolyzed SPI 
samples (Figure 4G). In contrast to the SPI samples most of the IgE binding to high 
molecular weight protein bands still remained in all the trypsin hydrolyzed defatted soy 
flour extract samples except for the sample that was hydrolyzed for 60 min (Figure 4H). 
However, similar to the SPI samples IgE binding to a 25 kDa band was increased 
considerably compared to the control samples. Chymotrypsin digestion of SPI (Figure 4G) 
and defatted soy flour extract (Figure 4H), although results in a reduction in IgE binding to 
higher molecular weight protein bands compared to control samples, all hydrolyzed 
samples still retained IgE binding to a 50 kDa protein band. Similar to the trypsin digested 
193 
 
results, SPI and defatted soy four extract samples digested with chymotrypsin also showed 
stronger IgE binding to a 25 kDa band compared to the control samples. Additionally a 
new IgE binding band of 35 kDa appeared in all chymotrypsin digested SPI and defatted 
soy flour samples, which was stronger under non-reducing conditions. Immunoblots with 
other soybean allergic sera resulted in similar IgE binding to all the trypsin and 
chymotrypsin digested SPI and defatted soy flour samples as the control samples (not 
shown).  
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Figure 4A. SDS-PAGE stained gel of 5% SPI hydrolyzed for 5, 15, 30 or 60 min with 
trypsin or chymotrypsin compared to the unheated and heated control samples. 
Samples (10 g protein/lane) were run under both reducing and non-reducing conditions, 
then gels were fixed and stained with Brilliant Blue G-colloidal stain. 
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Figure 4B. SDS-PAGE stained gel of defatted soy flour extract hydrolyzed for 5, 15, 
30 or 60 min with trypsin or chymotrypsin compared to the unheated and heated 
control samples. Samples (10 g protein/lane) were run under both reducing and non-
reducing conditions, then gels were fixed and stained with Brilliant Blue G-colloidal 
stain. 
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 Figure 4C. IgE immunoblot of 5% SPI treated for 5, 15, 30 or 60 min with trypsin 
or chymotrypsin compared to the control samples, using serum 19392-CS. Samples 
(10 µg pre-treatment protein) were treated as indicated for each lane, then separated by 
SDS-PAGE in both non-reducing and reducing gels prior to transfer onto PVDF 
membranes. A 1:10 diluted sample of serum was incubated with each membrane and 
following washing, bound IgE was detected using monoclonal anti-human IgE-HRP 
conjugate with detection by ECL. Images of the light emissions were captured using a 
Kodak imaging system as described in the text. 
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Figure 4D. IgE immunoblot of defatted soy flour extract treated for 5, 15, 30 or 60 
min with trypsin or chymotrypsin compared to the control samples, using serum 
19392-CS. Samples (10 µg pre-treatment protein) were treated as indicated for each lane, 
then separated by SDS-PAGE in both non-reducing and reducing gels prior to transfer 
onto PVDF membranes. A 1:10 diluted sample of serum was incubated with each 
membrane and following washing, bound IgE was detected using monoclonal anti-human 
IgE-HRP conjugate with detection by ECL. Images of the light emissions were captured 
using a Kodak imaging system as described in the text. 
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Figure 4E. β-hexosaminidase release from humanized RBL-703/21 cells, sensitized 
with IgE from serum 19392-CS and challenged with trypsin hydrolyzed and control 
SPI and soy flour extract samples. Humanized RBL-clone 703/21 were sensitized with 
IgE from serum 19392-CS (diluted 1: 10) and were challenged with 100 μl of trypsin 
hydrolyzed and control SPI and defatted soy flour extract samples. 0.001 μg/ml to 10 
μg/ml of antigen was used to challenge the cells as shown in the graph. Absrobance values 
were measure at 405 nm and β-hexosaminidase release was expressed as percentage of 
total serum IgE release (cells sensitized with serum and challenged with anti-IgE). 
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Figure 4F. β-hexosaminidase release from humanized RBL-703/21 cells, sensitized 
with IgE from serum 19392-CS and challenged with chymotrypsin hydrolyzed and 
control SPI and soy flour extract samples. Humanized RBL-clone 703/21 were 
sensitized with IgE from serum 19392-CS (diluted 1: 10) and were challenged with 100 μl 
of chymotrypsin hydrolyzed and control SPI and defatted soy flour extract samples. 0.001 
μg/ml to 10 μg/ml of antigen was used to challenge the cells as shown in the graph. 
Absrobance values were measure at 405 nm and β-hexosaminidase release was expressed 
as percentage of total serum IgE release (cells sensitized with serum and challenged with 
anti-IgE). 
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Figure 4G. IgE immunoblot of 5% SPI treated for 5, 15, 30 or 60 min with trypsin 
or chymotrypsin compared to the control samples, using serum 20431. Samples (10 
µg pre-treatment protein) were treated as indicated for each lane, then separated by SDS-
PAGE in both non-reducing and reducing gels prior to transfer onto PVDF membranes. A 
1:10 diluted sample of serum was incubated with each membrane and following washing, 
bound IgE was detected using monoclonal anti-human IgE-HRP conjugate with detection 
by ECL. Images of the light emissions were captured using a Kodak imaging system as 
described in the text. 
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Figure 4H. IgE immunoblot of defatted soy flour extract treated for 5, 15, 30 or 60 
min with trypsin or chymotrypsin compared to the control samples, using serum 
20431. Samples (10 µg pre-treatment protein) were treated as indicated for each lane, 
then separated by SDS-PAGE in both non-reducing and reducing gels prior to transfer 
onto PVDF membranes. A 1:10 diluted sample of serum was incubated with each 
membrane and following washing, bound IgE was detected using monoclonal anti-human 
IgE-HRP conjugate with detection by ECL. Images of the light emissions were captured 
using a Kodak imaging system as described in the text. 
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Additional investigations were undertaken in an attempt to identify the proteins from 
bands that appeared after initial hydrolysis. The strong IgE binding observed at 
approximately 20-25 kDa in the Alcalase, trypsin or chymotrypsin hydrolyzed 5% SPI 
samples with serum 19392-CS (Figure 1B, 4C) and for the trypsin or chymotrypsin 
hydrolyzed samples with serum 20431 (Figure 4G) may either represent creation of a 
fragment from the higher molecular weight proteins or may represent uncovered epitopes 
that were masked in undigested samples. To answer the question 2D gel electrophoresis 
of samples was performed to more effectively isolate proteins, followed by 
immunoblotting with serum 19392-CS for the Alcalse, trypsin or chymotrypsin digested 
SPI and serum 20431 for the trypsin or chymotrypsin digested SPI. Samples included 
both the heated control SPI and the SPI samples hydrolyzed for 60 min. Figure 5A shows 
the stained gel after separating the proteins by 2D gel electrophoresis. From the stained 
gel it can be observed that most of the higher molecular weight protein spots from 
approximately 37 to 75 kDa (upper left pane) that are observed in the control SPI sample 
(upper left panel) were no longer visible when the samples were treated with the three 
enzymes (other three panels of Figure 5A). With the Alcalase treated SPI very faint 
protein spots were observed around 25 kDa and 12 kDa. A number of lower molecular 
weight protein spots ranging from 10-20 kDa were observed when the samples were 
treated with trypsin or chymotrypsin. A protein spot of approximately 25 kDa at a pI=4 
(Spot #1) and two spots of similar molecular weight and pI values (Spots # 2, 3) appeared 
in the trypsin and chymotrypsin digested samples respectively (right two panels, Figure 
5A). These spots do not appear to be present in the control SPI sample. Further spots of 
approximately 50 kDa appeared in both the control and the chymotrypsin hydrolyzed SPI 
203 
 
(# 10) indicating the resistance of these spots to digestion by chymotrypsin. Immunoblots 
with serum 19392-CS (Figure 5B) showed strong IgE binding to protein spots ranging 
from 37-150 kDa in the control SPI sample (upper left panel). These dominant IgE 
binding spots were completely absent when the samples were treated with Alcalase and 
trypsin (upper right and lower left panels).  However, there was a faintly visible spot at 
approximately 50 kDa (# 10) in the chymotrypsin hydrolyzed sample (lower right panel). 
With both trypsin and chymotrypsin hydrolyzed samples, relatively strong IgE binding 
was observed to the 25 kDa, pI= 4 spots (# 1, 2, 3) that seem to correspond to the 
similarly marked spots visible in the stained gels (Figure 5A). The Alcalase hydrolyzed 
sample also showed strong IgE binding to a spot of similar molecular weight (25 kDa) 
and pI=4 that is marked as spot # 9, which was not visible in the stained gel. 
Furthermore, the immunoblot of the trypsin hydrolyzed sample showed modest IgE 
binding to three spots of approximately 23 kDa, with pI values between 6-7 (spots # 4, 5, 
6).  IgE binding to those spots was very faint in the control SPI sample. With serum 
20431 (Figure 5C) again strong IgE binding was observed to the spots at 25 kDa, pI=4 
(#1, 2, 3) only in the trypsin and chymotrypsin hydrolyzed samples. Further similar to 
serum 19392-CS, IgE binding was observed at 50 kDa (Spot # 10) for chymotrypsin 
digested as well as the control samples indicating the resistance of these IgE binding 
spots to digestion by chymotrypsin. These results were consistent with the results 
obtained from 1D immunoblots with both the sera (Figures 1B, 4C, 4G).  
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Figure 5A. Two dimensional gel electrophoresis of heated control SPI and SPI 
treated with Alcalase, trypsin or chymotrypsin for 60 min. Samples representing 25 
µg of protein from the original undigested extracts were separated according to their 
isoelectric point using linear 3-10 IPG strips after dilution with rehydration buffer (8M 
urea, 2% CHAPS, 50mM DTT and 0.5% ampholyte). Separation in the second dimension 
was performed using SDS-PAGE. After protein separation the gels were fixed and then 
stained with Brilliant blue G colloidal and images were captured using Kodak gel logic 
440 imaging system with white light illumination. 
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Figure 5B. Immunoblot of heated control SPI, Alcalase, trypsin or chymotrypsin 
treated SPI separated by two dimensional gel electrophoresis using serum 19392-
CS. Samples representing 25 µg of protein from the original undigested extracts were 
separated according to their isoelectric point using linear 3-10 IPG strips after dilution 
with rehydration buffer (8M urea, 2% CHAPS, 50mM DTT and 0.5% ampholyte). 
Separation in the second dimension was performed using SDS-PAGE. The proteins from 
the gel were transferred onto a PVDF membrane. A 1:10 diluted sample of serum was 
incubated with each membrane and following washing, bound IgE was detected using 
monoclonal anti-human IgE-HRP conjugate with detection by ECL. Images of the light 
emissions were captured using a Kodak imaging system as described in the text. 
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Figure 5C. Immunoblot of heated control SPI, trypsin or chymotrypsin treated SPI 
separated by two dimensional gel electrophoresis using serum 20431. Samples 
representing 25 µg of protein from the original undigested extracts were separated 
according to their isoelectric point using linear 3-10 IPG strips after dilution with 
rehydration buffer (8M urea, 2% CHAPS, 50mM DTT and 0.5% ampholyte). Separation 
in the second dimension was performed using SDS-PAGE. The proteins from the gel 
were transferred onto a PVDF membrane. A 1:10 diluted sample of serum was incubated 
with each membrane and following washing, bound IgE was detected using monoclonal 
anti-human IgE-HRP conjugate with detection by ECL. Images of the light emissions 
were captured using a Kodak imaging system as described in the text. 
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The 25 kDa, pI=4 spots marked on the immunoblots of Figure 5C (spot #1, 2, 3) in the 
trypsin and chymotrypsin hydrolyzed samples were not visible in the control sample. The 
strong IgE binding to these spots with both sera used in immunoblotting indicates the 
creation of a protein fragment of high IgE binding capacity due to hydrolysis of some high 
molecular weight proteins in SPI. Furthermore, the three spots at 23 kDa, pI=6-7 (Figure 
5, spot # 4, 5, 6) showed stronger IgE binding for the trypsin hydrolyzed sample compared 
to the control sample with serum 19392-CS although the spots are visible in both the 
control and trypsin hydrolyzed sample stained gels. This indicates these proteins were 
likely modified to some extent by trypsin digestion, exposing hidden epitopes that resulted 
in stronger IgE binding. These strong IgE binding protein spots in Figure 5 (# 1, 2, 3, 4, 5, 
6) were excised from a Coomassie stained gel and identified by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) by the analytical core facility at the University of 
Nebraska (Dr. Nandakumar). The high molecular weight protein spots (# 7, 8) showing 
strong IgE binding in the control sample and the 50 kDa spot (# 10) showing IgE binding 
both in the control and chymotrypsin digested sample with both serum 19392-CS and 
20431 were also analyzed by LC- MS/MS. The highest scoring matches are shown here. 
The identified spots with peptide coverage (red) are indicated in the sequences below. The 
Mascot (Matrix Sciences) program output search for mass identity matches indicated 
matches to Glycinin G1 protein for spot # 4, 5, 6 from the non-redundant NCBI database 
showing coverage strictly in the basic chain of the protein (starting point shown by arrow). 
Spots # 1 and 3 showed a match with the alpha subunit of β-conglycinin whereas spot # 2 
showed a match with the alpha’ subunit of β-conglycinin indicating that these spots in the 
trypsin and chymotrypsin hydrolyzed samples are fragments of the alpha’ and alpha 
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subunits of β-conglycinin (Spot # 7 and 8 respectively) that were visible in the control SPI 
stained gel and showed intense IgE binding with both the serum used in immunoblot. Spot 
# 10, the 50 kDa spot that remained resistant to digestion by chymotrypsin was identified 
as beta subunit of β-conglycinin (Figure 5).   
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Spot 4 (Glycinin G1 protein) GI:255221  
 
MAKLVFSLCF LLFSGCCFAF SSREQPQQNE CQIQKLNALK PDNRIESEGG LIETWNPNNK 
PFQCAGVALS RCTLNRNALR RPSYTNGPQE IYIQQGKGIF GMIYPGCPST FEEPQQPQQR 
GQSSRPQDRH QKIYNFREGD LIAVPTGVAW WMYNNEDTPV VAVSIIDTNS LENQLDQMPR 
RFYLAGNQEQ EFLKYQQEQG GHQSQKGKHQ QEEENEGGSI LSGFTLEFLE HAFSVDKQIA 
KNLQGENEGE DKGAIVTVKG GLSVIKPPTD EQQQRPQEEE EEEEDEKPQC KGKDKHCQRP 
RGSQSKSRRN GIDETICTMR LRHNIGQTSS PDIYNPQAGS VTTATSLDFP ALSWLRLSAE 
FGSLRKNAMF VPHYNLNANS IIYALNGRAL IQVVNCNGER VFDGELQEGR VLIVPQNFVV 
AARSQSDNFE YVSFKTNDTP MIGTLAGANS LLNALPEEVI QHTFNLKSQQ ARQIKNNNPF 
KFLVPPQESQ KRAVA 
 
Spot 5 (Glycinin G1 protein) GI:255221 
 
MAKLVFSLCF LLFSGCCFAF SSREQPQQNE CQIQKLNALK PDNRIESEGG LIETWNPNNK 
PFQCAGVALS RCTLNRNALR RPSYTNGPQE IYIQQGKGIF GMIYPGCPST FEEPQQPQQR 
GQSSRPQDRH QKIYNFREGD LIAVPTGVAW WMYNNEDTPV VAVSIIDTNS LENQLDQMPR 
RFYLAGNQEQ EFLKYQQEQG GHQSQKGKHQ QEEENEGGSI LSGFTLEFLE HAFSVDKQIA 
KNLQGENEGE DKGAIVTVKG GLSVIKPPTD EQQQRPQEEE EEEEDEKPQC KGKDKHCQRP 
RGSQSKSRRN GIDETICTMR LRHNIGQTSS PDIYNPQAGS VTTATSLDFP ALSWLRLSAE 
FGSLRKNAMF VPHYNLNANS IIYALNGRAL IQVVNCNGER VFDGELQEGR VLIVPQNFVV 
AARSQSDNFE YVSFKTNDTP MIGTLAGANS LLNALPEEVI QHTFNLKSQQ ARQIKNNNPF 
KFLVPPQESQ KRAVA 
 
Spot 6 (Glycinin G1 protein) GI:255221 
 
MAKLVFSLCF LLFSGCCFAF SSREQPQQNE CQIQKLNALK PDNRIESEGG LIETWNPNNK 
PFQCAGVALS RCTLNRNALR RPSYTNGPQE IYIQQGKGIF GMIYPGCPST FEEPQQPQQR 
GQSSRPQDRH QKIYNFREGD LIAVPTGVAW WMYNNEDTPV VAVSIIDTNS LENQLDQMPR 
RFYLAGNQEQ EFLKYQQEQG GHQSQKGKHQ QEEENEGGSI LSGFTLEFLE HAFSVDKQIA 
KNLQGENEGE DKGAIVTVKG GLSVIKPPTD EQQQRPQEEE EEEEDEKPQC KGKDKHCQRP 
RGSQSKSRRN GIDETICTMR LRHNIGQTSS PDIYNPQAGS VTTATSLDFP ALSWLRLSAE 
FGSLRKNAMF VPHYNLNANS IIYALNGRAL IQVVNCNGER VFDGELQEGR VLIVPQNFVV 
AARSQSDNFE YVSFKTNDTP MIGTLAGANS LLNALPEEVI QHTFNLKSQQ ARQIKNNNPF 
KFLVPPQESQ KRAVA 
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Spot 1 (β-conglycinin alpha subunit) GI:15425633 
MRARFPLLLL GVVFLASVSV SFGIAYWEKQ NPKHNKCLQS CNSERDSYRN QACHARCNLL 
KVEKEEECEE GEIPRPRPRP QHPEREPQQP GEKEEDEDEQ PRPIPFPRPR QPRQEEEHEQ 
REEQEWPRKE EKRGEKGSEE EQDGREHPRP HQPHDEDEEQ DERQFPFPRP PHQKESEERK 
QEEDEDEEQQ RESEESESSE SQRELRRHKN KNPFHFGSNR FETLFKNQYG RIRVLQRFNQ 
RSPQLQNLRD YRILEFNSKP NTLLLPNHAD ADYLIAILNG TAILSLVNND DRDSYRLQSG 
DALRVPSGTT YYVVNPDNNE NLRLITLAIP VNKPGRFESF FLSSTEAQQS YLQGFSRNIL 
EASYDTKFEE INKVLFSREE GQQQGEQRLQ ESVIVEISKE QIRALSKRAK SSSRKTISSE 
DKPFNLRSRD PIYSNKLGKF FEITPEKNPQ LRDLDIFLSI VDMNEGALLL PHFNSKAIVI 
LVINEGDANI ELVGLKEQQQ EEQQEEQPLE VRKYRAELSE QDIFVIPAGY PVVVNATSNL 
NFFAIGINAE NNQRNFLAGS QDNVISQIPS QVQELAFLGS AQAVEKLLKN QRESYFVDAQ 
PKKKEEGNKG RKGPLSSILR AFY 
 
 
Spot 2 (β-conglycinin alpha'-subunit) GI:341603991 
MMRARFPLLL LGVVFLASVS VSFGIAYWEK QNPSHNKCLR SCNSEKDSYR NQACHARCNL 
LKVEEEEECE EGQIPRPRPQ HPERERQQHG EKEEDEGEQP RPFPFPRPRQ PHQEEEHEQK 
EEHEWHRKEE KHGGKGSEEE QDEREHPRPH QPHQKEEEKH EWQHKQEKHQ GKESEEEEED 
QDEDEEQDKE SQESEGSESQ REPRRHKNKN PFHFNSKRFQ TLFKNQYGHV RVLQRFNKRS 
QQLQNLRDYR ILEFNSKPNT LLLPHHADAD YLIVILNGTA ILTLVNNDDR DSYNLQSGDA 
LRVPAGTTYY VVNPDNDENL RMITLAIPVN KPGRFESFFL SSTQAQQSYL QGFSKNILEA 
SYDTKFEEIN KVLFGREEGQ QQGEERLQES VIVEISKKQI RELSKHAKSS SRKTISSEDK 
PFNLRSRDPI YSNKLGKLFE ITPEKNPQLR DLDVFLSVVD MNEGALFLPH FNSKAIVVLV 
INEGEANIEL VGIKEQQQRQ QQEEQPLEVR KYRAELSEQD IFVIPAGYPV VVNATSDLNF 
FAFGINAENN QRNFLAGSKD NVISQIPSQV QELAFPGSAK DIENLIKSQS ESYFVDAQPQ 
QKEEGNKGRK GPLSSILRAF Y 
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Spot 3 (β-conglycinin alpha subunit) GI:15425633 
MRARFPLLLL GVVFLASVSV SFGIAYWEKQ NPKHNKCLQS CNSERDSYRN QACHARCNLL 
KVEKEEECEE GEIPRPRPRP QHPEREPQQP GEKEEDEDEQ PRPIPFPRPR QPRQEEEHEQ 
REEQEWPRKE EKRGEKGSEE EQDGREHPRP HQPHDEDEEQ DERQFPFPRP PHQKESEERK 
QEEDEDEEQQ RESEESESSE SQRELRRHKN KNPFHFGSNR FETLFKNQYG RIRVLQRFNQ 
RSPQLQNLRD YRILEFNSKP NTLLLPNHAD ADYLIAILNG TAILSLVNND DRDSYRLQSG 
DALRVPSGTT YYVVNPDNNE NLRLITLAIP VNKPGRFESF FLSSTEAQQS YLQGFSRNIL 
EASYDTKFEE INKVLFSREE GQQQGEQRLQ ESVIVEISKE QIRALSKRAK SSSRKTISSE 
DKPFNLRSRD PIYSNKLGKF FEITPEKNPQ LRDLDIFLSI VDMNEGALLL PHFNSKAIVI 
LVINEGDANI ELVGLKEQQQ EEQQEEQPLE VRKYRAELSE QDIFVIPAGY PVVVNATSNL 
NFFAIGINAE NNQRNFLAGS QDNVISQIPS QVQELAFLGS AQAVEKLLKN QRESYFVDAQ 
PKKKEEGNKG RKGPLSSILR AFY 
 
 
 
Spot 7 (β-conglycinin alpha'-subunit) GI:341603991 
 
MMRARFPLLL LGVVFLASVS VSFGIAYWEK QNPSHNKCLR SCNSEKDSYR NQACHARCNL 
LKVEEEEECE EGQIPRPRPQ HPERERQQHG EKEEDEGEQP RPFPFPRPRQ PHQEEEHEQK 
EEHEWHRKEE KHGGKGSEEE QDEREHPRPH QPHQKEEEKH EWQHKQEKHQ GKESEEEEED 
QDEDEEQDKE SQESEGSESQ REPRRHKNKN PFHFNSKRFQ TLFKNQYGHV RVLQRFNKRS 
QQLQNLRDYR ILEFNSKPNT LLLPHHADAD YLIVILNGTA ILTLVNNDDR DSYNLQSGDA 
LRVPAGTTYY VVNPDNDENL RMITLAIPVN KPGRFESFFL SSTQAQQSYL QGFSKNILEA 
SYDTKFEEIN KVLFGREEGQ QQGEERLQES VIVEISKKQI RELSKHAKSS SRKTISSEDK 
PFNLRSRDPI YSNKLGKLFE ITPEKNPQLR DLDVFLSVVD MNEGALFLPH FNSKAIVVLV 
INEGEANIEL VGIKEQQQRQ QQEEQPLEVR KYRAELSEQD IFVIPAGYPV VVNATSDLNF 
FAFGINAENN QRNFLAGSKD NVISQIPSQV QELAFPGSAK DIENLIKSQS ESYFVDAQPQ 
QKEEGNKGRK GPLSSILRAF Y 
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Spot 8 (β-conglycinin alpha subunit) GI:15425633 
MRARFPLLLL GVVFLASVSV SFGIAYWEKQ NPKHNKCLQS CNSERDSYRN QACHARCNLL 
KVEKEEECEE GEIPRPRPRP QHPEREPQQP GEKEEDEDEQ PRPIPFPRPR QPRQEEEHEQ 
REEQEWPRKE EKRGEKGSEE EQDGREHPRP HQPHDEDEEQ DERQFPFPRP PHQKESEERK 
QEEDEDEEQQ RESEESESSE SQRELRRHKN KNPFHFGSNR FETLFKNQYG RIRVLQRFNQ 
RSPQLQNLRD YRILEFNSKP NTLLLPNHAD ADYLIAILNG TAILSLVNND DRDSYRLQSG 
DALRVPSGTT YYVVNPDNNE NLRLITLAIP VNKPGRFESF FLSSTEAQQS YLQGFSRNIL 
EASYDTKFEE INKVLFSREE GQQQGEQRLQ ESVIVEISKE QIRALSKRAK SSSRKTISSE 
DKPFNLRSRD PIYSNKLGKF FEITPEKNPQ LRDLDIFLSI VDMNEGALLL PHFNSKAIVI 
LVINEGDANI ELVGLKEQQQ EEQQEEQPLE VRKYRAELSE QDIFVIPAGY PVVVNATSNL 
NFFAIGINAE NNQRNFLAGS QDNVISQIPS QVQELAFLGS AQAVEKLLKN QRESYFVDAQ 
PKKKEEGNKG RKGPLSSILR AFY 
 
 
Spot 10 (-conglycinin beta subunit) GI: 341603993  
 
MMRVRFPLLV LLGTVFLASV CVSLKVREDE NNPFYFRSSN SFQTLFENQN GRIRLLQRFN  
KRSPQLENLR DYRIVQFQSK PNTILLPHHA DADFLLFVLS GRAILTLVNN DDRDSYNLHP          
GDAQRIPAGT TYYLVNPHDH QNLKIIKLAI PVNKPGRYDD FFLSSTQAQQ SYLQGFSHNI       
LETSFHEINR VLFGEEEEQR QQEGVIVELS KEQIRQLSRR AKSSSRKTIS SEDEPFNLRS       
RNPIYSNNFG KFFEITPEKN PQLRDLDIFL SSVDINEGAL LLPHFNSKAI VILVINEGDA       
NIELVGIKEQ QQKQKQEEEP LEVQRYRAEL SEDDVFVIPA AYPFVVNATS NLNFLAFGIN       
AENNQRNFLA GEKDNVVRQI ERQVQELAFP GSAQDVERLL KKQRESYFVD AQPQQKEEGS       
KGRKGPFPSI LGALY 
  
 
 
 
 
 
 
 
213 
 
DISCUSSION 
Soybean is a popular and widely used food protein source that is often processed by 
hydrolysates prior to addition to foods since hydrolysis has been shown to increase 
nutritional quality, flavor and functionality of soybean proteins (Sun, 2011). Among the 
two commonly used methods to obtain protein hydrolysates (acid and enzymatic), 
enzymatic hydrolysis is mostly preferred to hydrolyze soybean proteins since it prevents 
formation of undesirable side products. Further functionality of the final product can be 
controlled by selection of specific enzymes and reaction conditions (Sun, 2011). Several 
enzymes derived from plant, bacteria or fungal sources have been utilized to hydrolyzed 
soybean proteins in order to improve their functionality (Calderon de la barca, et al. 2000; 
Kim et al., 1990; Molina Ortiz et al. 2000). Protein hydrolysate formulas have also been 
developed with the aim to produce hypoallergenic foods that have reduced sensitizing or 
elicitating capacity. Enzymatic hydrolysis of food proteins can lead to alteration of 
epitope structure thereby reducing allergenicity (Paschke and Besler, 2002). Sequential 
hydrolysis of chickpea protein isolate and lentil protein extract with enzymes Alcalase 
and flavourzyme has been shown to reduce IgE binding to lentil and chickpea protein 
hydrolysates (Cabanillas et al., 2010; Clemente et al., 1999). Enzymes such as Alcalase, 
pepsin and trypsin has been used to hydrolyze and reduce immunoreactivity of pea 
protein extract (Szymkiewicz and  Jedrychowski, 2005). Furthermore, enzymes such as 
protease, elastase and trypsin have been shown to eliminate IgE binding to hazelnut 
proteins (Wigotzki et al., 2000). In case of soybeans several enzymes such as Bacillus sp. 
Protease porleather FG-F, pepsin and chymotrypsin has been shown to reduce IgE 
binding to hydrolyzed soybean proteins using soybean sensitive patient sera. However, 
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one of the major drawbacks in these studies has been the interpretation that allergenicity 
is only based on in vitro IgE binding as measured by ELISA or immunoblotting 
procedures. Yet, IgE binding does not always correlate with expression of clinical 
symptoms as IgE binding may be to poorly reactive cross-reactive carbohydrate 
determinants, low affinity binding, the occurrence of individual isolated IgE binding 
epitopes or ineffective binding due to very close or distant location of epitopes (Ladics et 
al., 2008). Therefore the final confirmation of reduced allergenicity should be from the 
results of functional assays such as basophil histamine release assay, skin prick test or 
double blind placebo controlled food challenge (DBPCFC). 
 In this study, soybean proteins in the form of defatted soy flour and SPI were 
hydrolyzed by five different enzymes (Alcalase, papain, bromelain, trypsin and 
chymotrypsin) that are commonly used to improve the functionality of soybean proteins 
as well as in making hypoallergenic protein formulas. The allergenicity of soybean 
proteins after hydrolysis was evaluated by in vitro IgE binding by immunoblot as well as 
a functional assay, which measured the release of β-hexosaminidase from hRBL cell 
lines. From the IgE immunoblot results with eight soybean allergic patient sera, an 
overall reduction in IgE binding to protein bands was observed for the soybean samples 
hydrolyzed with Alcalase, papain and trypsin. However, IgE binding was still retained for 
a few soybean proteins in the hydrolyzed samples. These proteins are probably more 
resistant to digestion than other immunoreactive proteins. With bromelain and 
chymotrypsin, most of the IgE binding seen with the control sample was retained in the 
hydrolyzed samples (observed with six out of eight soybean allergic sera used in 
immunoblot) indicating that digestion with these enzymes has little impact on the 
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immunoreactivity of soybean proteins. Furthermore, with two of the sera (19392-CS and 
20431) new IgE binding bands appeared in the samples hydrolyzed with Alcalase, 
bromelain, trypsin and chymotrypsin. This increase in IgE binding observed compared to 
control sample could represent an increase in immunoreactivity and possibly 
allergenicity, either due to creation of some new protein epitopes due to protein 
hydrolysis or exposure of some already present hidden epitopes making them more 
accessible to IgE antibodies. From the 2D immunoblot results of this study it was 
concluded that both of these processes resulted in increased IgE binding. With the 
samples used in this study, three spots at approximately 25 kDa, pI=4 (# 1, 2, 3) were 
identified as fragments of alpha’ and alpha subunits of β-conglycinin by LC-MS/MS.  
These spots were only in the trypsin and chymotrypsin digested samples in 2D gels 
(Figure 5A). These spots showed strong IgE binding in immunoblot with two sera (Figure 
5B and 5C) indicating creation of new protein epitopes by enzyme hydrolysis of the β-
conglycinin protein. Further with trypsin hydrolyzed sample, with one serum, increased 
IgE binding compared to the control sample was observed with three spots at 
approximately 23 kDa, pI 6-7, which was already present in the control sample (Spot # 4, 
5, 6, Figure 5A, 5B, identified as glycinin basic chain in LC-MS/MS) indicating exposure 
of some hidden epitopes in the glycinin protein by treatment with trypsin. 
 Despite the overall reduction in IgE binding to protein bands observed in case of 
soybean samples hydrolyzed with papain, Alcalase and trypsin, all of them showed a 
similar or slightly reduced mediator release as the control sample in hRBL assay. This 
indicates that the protein fragments remaining after hydrolysis with these enzymes can 
still cross-link IgE antibodies on basophils or mast cells and lead to elicitation of an 
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allergic reaction even if they were not detected by IgE immunoblot. Furthermore, 
bromelain hydrolysis of defatted soy flour and SPI and chymotrypsin hydrolysis of SPI 
lead to an increase in mediator release compared to the control sample indicating that 
digestion of soybean proteins with these enzymes can increase elicitation capacity of 
soybean proteins. 
 Another important finding from this study was that the form of soy protein 
product subjected to hydrolysis condition is important in determining the effect of 
hydrolysis on protein allergenicity. For example, with serum 19392-CS, chymotrypsin 
hydrolysis of SPI resulted in a strong increase in IgE binding at approximately 20-25 kDa 
compared to the control sample, whereas the IgE binding at the same molecular weight 
when defatted soy flour extract was digested with chymotrypsin was moderately increase 
(Figure 4C, 4D). These new strong IgE binding bands in the chymotrypsin digested SPI 
was identified as fragments of the alpha and alpha’ subunits of β-conglycinin by 2D gel 
electrophoresis followed by LC-MS/MS analysis. This observation was also reflected in 
the mediator release assay results where chymotrypsin digested SPI resulted in a higher 
mediator release compared to the control sample whereas a reduction in mediator release 
was observed with chymotrypsin digested defatted soy flour extract (Figure 4F). Since 
SPI is composed mostly of glycinin and β-conglycinin proteins (~90% of the total 
protein), which are the two major allergenic proteins of soybeans (Holzhauser et al., 
2009), it is possible that preparation of SPI resulted in concentration of these two allergic 
proteins in the SPI preparation and its subsequent digestion with chymotrypsin resulted in 
creation of fragments with strong IgE binding as well as higher mediator release capacity 
compared to undigested SPI.  
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 In conclusion, the finding from this study indicated that none of the enzymes that 
are used in making functional soybean protein products or hypoallergenic soybean 
protein hydrolysate are effective in reducing the allergenicity of soybean proteins. In fact 
some of the hydrolysates (bromelain and chymotrypsin hydrolyzed soybean proteins) 
have a potential to increase the allergenicity of soybean proteins. Hydrolysis of different 
forms of protein preparations may have different effect on allergenicity as demonstrated 
by an increase in allergenicity of chymotrypsin digested SPI and not defatted soy flour in 
our study. Most importantly our study demonstrated that in vitro IgE binding tests alone 
cannot be confirmatory methods to conclude on allergenicity of protein hydrolysates and 
function assays such as mediator release assay (used in this study) are essential for 
confirmation of allergenicity.  
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